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Abstract 
It is now understood that CD4+ T cells play a central role in antitumour immunity; they 
are important in the priming of CTL and can augment cytotoxicity; they are also 
responsible for enhancing antitumour responses via indirect mechanisms such as 
recruitment of accessory cells to the tumour site and they are crucial in the formation of 
memory T cells. CD4+ T cells recognise antigen in the context of peptide presented on 
MHC class II molecules, therefore recent research has focused on the identification of 
these peptides in order to formulate more effective immunotherapeutic strategies. As 
such, the aim of this study was to identify novel MHC class II HLA-DR1 and HLA-
DR4 restricted immunogenic peptides derived from the MART-1 and Tyrosinase 
tumour antigens. A computer algorithm (SYFPEITHI; available on the World Wide 
Web) was used to predict immunogenic peptides from the two tumour antigens; these 
peptides were then used to immunise HLA-DR1 and HLA-DR4 transgenic mice in 
order to assess their immunogenicity. At the same time efforts were made to optimise 
the screening process by fully characterising the BM-DC used in proliferation assays 
and employing antioxidants in conjunction with T cell culture. A second aspect of the 
project utilised p53 peptides in order to investigate the effects of protein specific T cell 
help on the generation of effector and memory CTL. 
Efforts were made to maximise the efficiency of the MHC class II peptide screening 
method by optimising expression of co-stimulatory molecules and cytokine production 
by BM-DC. Testing of BM-DC derived from FVB/N-DR1, C57bl/6-DR4 and C57bl/6 
HHD II HLA-A2 transgenic mice revealed that differing maturation protocols were 
required to generate BM-DC with the optimal T cell stimulatory capacity, depending 
upon the strain of transgenic mice employed. The screening process was further 
optimised by the use of Vitamin E in conjunction with T cell culture; this antioxidant 
was found to increase peptide specific proliferative responses against the immunised 
peptide. Using the optimised screening protocols, immunisation of transgenic mice with 
predicted epitopes led to the discovery of the novel HLA-DR1 restricted MART-129-43 
and the HLA-DR1/DR4 restricted Tyrosinase147-161 peptides. Further experiments also 
indicated that the Tyrosinase protein was processed by murine dendritic cells to produce 
the Tyrosinase147-161 peptide. This study demonstrated that HLA-DR restricted 
responses to novel peptide can be obtained in HLA-DR1 and HLA-DR4 transgenic 
mice. 
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In order to determine the most effective type of T cell help (protein specific/non-
specific) for augmentation of a CTL response a number of experiments were performed 
using p53 class I peptides in conjunction with either a Hep B or p53 class II helper 
peptide. Results showed that in short term, in vitro, experiments the p53 helper peptide 
augmented cytotoxicity more than a Hep B helper peptide; however in long term 
experiments involving recall by memory CTL, the Hep B helper peptide out-performed 
the p53 epitope; further investigation is required into these phenomena. 
Collectively these data demonstrate that the use of transgenic mice allows for rapid 
screening of novel MHC class II peptide epitopes that could be useful in the formulation 
of future cancer vaccines. It also highlights the requirement for further investigation into 
the precise nature of the T cell help required to maximise antitumour effects and the 
generation of memory CTL.       
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1 Chapter 1: Introduction 
1.1 Cancer, what is it and what are the common treatments? 
1.1.1 Cancer is a multi-factorial disease 
Cancer is not a single disease but a group of maladies characterised by uncontrolled cell 
growth. In normal tissues there exist two types of signals that govern cell behaviour: 
growth promoting signals and growth inhibiting signals. However in the case of tumour 
cells these signals have been circumvented leading to uncoupling from downstream 
regulatory mechanisms. These transformed cells thus become resistant to programmed 
cell death, cell-cell contact inhibition and/or growth factor removal and develop infinite 
proliferative capacity (Bertram, 2000). 
Subsequent research revealed that there were many factors that could elicit the onset of 
cancer in an individual. However it is generally agreed that these can be sub categorised 
into three main types of causative agent: 
1. Exposure to either chemical or physical carcinogens e.g. drugs or radiation 
respectively 
2. Exposure to microbial carcinogens e.g. viruses 
3. Inherited chromosomal defects e.g. multiple endocrine neoplasia type 2 
(Peczkowska & Januszewicz, 2005) 
Having been exposed to one or more of the above, cells may incur genetic damage. If 
this damage occurs to a gene responsible for regulation of the cell cycle then the cell 
may become capable of avoiding normal homeostatic mechanisms. However, because 
of checkpoints incorporated in the cell cycle, a single mutation is not sufficient to 
initiate cancer. It is necessary for damaged cells to proliferate to approximately 106 cells 
before it is statistically likely that further mutation would occur (Bertram, 2000). In fact 
it has been shown that human cells are required to accumulate at least five mutations 
before cancer will arise where each successive mutation allows the damaged cell to 
become more adapted to its surrounding environment and thus undergo unlimited 
growth (Cahill et al., 1999). The mutations produced can vary depending upon the 
cancer type, however the following requirements for human cell transformation have 
been proposed: the maintenance of telomere sequences, the inactivation of Rb and p53 
pathways, the activation of protein phosphatase 2A and the expression of activated Ras 
(Akagi, 2004). By mutating these particular genes the cell becomes more resistant to 
apoptosis and uncoupled from proliferative control mechanisms. The telomere is at the 
end of the chromosome and shortens in length each time a cell divides. After a certain 
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number of divisions the telomere gets “too short” and cell death is triggered. The 
enzyme that controls telomere length, telomerase, is often mutated in cancer leading to 
maintenance of telomere length and no triggering of apoptosis (Binz et al., 2005). Rb 
and p53 act to monitor cellular stress and can also initiate cell death if irreparable cell 
damage is incurred. As a result these genes are also mutated in cancer as they confer a 
survival advantage (Bertram, 2000). Protein phosphatase 2A is involved in regulating 
the function of the Rb protein so it is commonly mutated in cancer for the same reason 
(Akagi, 2004). Ras is a signalling molecule regulated by the binding of GTP. Mutations 
in this protein lead to uncoupling from the GTP dependant regulatory processes and 
downstream signal molecules are constitutively activated (Minamoto et al., 2000). This 
can lead to uncontrolled cell proliferation, the hallmark of tumour formation. 
1.1.2 Oncogenes and tumour suppressor genes 
Analysis of DNA damage in human tumours has highlighted two genetic subclasses of 
mutation required for carcinogenesis: oncogenes and tumour suppressor genes. An 
oncogene can be defined as a mutated and/or over expressed version of a normal gene, 
found within animal cells, that in a dominant fashion can release the cell from normal 
restraints on growth and thus alone or in concert with other changes, convert a cell into 
a tumour cell. Oncogenes originate from normal genes (Jakobisiak et al., 2003), which 
then undergo mutation and become constitutively or aberrantly activated. Most 
oncogenes are involved in signalling pathways that stimulate cell proliferation. A 
tumour suppressor gene can be defined as a gene that encodes a product that normally 
negatively regulates the cell cycle and that must be mutated or otherwise inactivated 
before a cell can proceed to rapid division. Thus tumour suppressor genes function at 
the opposite end of the spectrum and are involved in the regulation of cell cycle 
checkpoints and cell death. These tumour suppressors undergo mutations that result in 
loss of function, thereby allowing genetically damaged cells to proliferate and accrue 
further genetic damage. Thus it is entirely logical that mutations in both oncogenes and 
tumour suppressors are required for generation of the neoplastic phenotype (Gumus et 
al., 2002). 
Proto-oncogenic signalling pathways control cellular homeostatic processes such as 
gene up or down regulation, cytoskeletal rearrangements, protein synthesis and 
degradation, cell-cell contact inhibition and metabolism. It is mutations in proto-
oncogenes that lead to uncoupling from external regulatory signals. The ramifications of 
this are clear; factors produced by other cells are no longer capable of mediating the 
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growth of those cells harbouring oncogenes (Lucas et al., 2002), (Bertram, 2000). There 
are several modes of action for oncogenes: 
1. Inappropriate expression of growth factors or growth factor receptors such as 
PDGF or Erb-b respectively 
2. Activation of downstream signal transduction pathways by proteins such as Ras 
3. Inappropriate activation of nuclear transcription factors such as c-myc, fos and 
jun 
Early experiments investigating the transforming capabilities of oncogenes utilised 
immortalised mouse cell lines. However as work progressed it became apparent that the 
concept of oncogenes alone initiating carcinogenesis was too simplistic and that there 
existed other genes that could prevent transformation. For example when oncogenic Ras 
was transfected into hamster cells that had not been previously immortalised, 
transformation did not occur. In contrast, after spontaneous immortalisation of cells in 
culture, Ras was capable of inducing transformation indicating that it did not act alone 
but in concert with other genes (Scholl et al., 2005). These experiments coupled with 
the fact that fusion of normal cells with malignant cells resulted in a loss of 
tumourigenicity in the hybrids meant that further investigation was required. It was 
observed that transfer of certain chromosomes derived from normal cells could effect 
suppression of the neoplastic phenotype (Anderson & Stanbridge, 1993). These and 
subsequent experiments lead to the discovery of tumour suppressor genes as we 
understand them today.  
There are a number of crucial differences in how mutations in tumour suppressor genes 
exert their effects compared to those of oncogenes. As mentioned previously, mutations 
in tumour suppressor genes result in loss of function. However in most cases the normal 
suppressor allele can function alongside the mutated allele, therefore it is necessary for 
both genes to be inactivated before loss of function is seen. A further consequence of 
the differing mode of mutagenic action is that defects in tumour suppressor genes can 
be inherited. Oncogene expression exerts a dominant effect and normally prevents 
development of a viable embryo, whereas loss of a single tumour suppressor allele is 
generally sub-critical in embryonic development (Bertram, 2000). Individuals who have 
inherited one genetically mutated tumour suppressor gene are known as heterozygous; 
thus when the second gene becomes mutated it is known as loss of heterozygosity 
(LOH) and a tumour can form. This familial inheritance of suppressor gene knockouts 
leads to the development of early onset cancer in such individuals (Bamne et al., 2005; 
Fearnhead et al., 2004). 
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There are a number of tumour suppressors but two of the most important are RB and 
p53. Mutations in the RB gene lead to childhood onset of retinoblastoma, the most 
common ocular malignancy. The RB protein functions as a checkpoint for cells to entry 
into S-phase (see Fig 1.1). The p53 tumour suppressor gene monitors cellular stresses 
such as anoxia, lack of nucleotides for DNA synthesis, inappropriate activation of 
oncogenes, DNA lesions such as single strand breaks and covalent adducts (Graeber et 
al., 1996; Guidos et al., 1996; Linke et al., 1996). There is also evidence for the 
involvement of p53 in the monitoring of telomere length and therefore cell senescence 
(Bertram, 2000). Thus it is unsurprising that p53 is often termed “the guardian of the 
genome”. Mutation of p53 is so critical to the process of carcinogenesis that over 70% 
of all tumours have defects in this gene and almost all have mutations in genes 
immediately upstream or downstream of p53 (Levine, 1997). 
 
 
Figure  1.1: Mammalian cell cycle checkpoints. Cells possess a number of mechanisms to 
prevent improper progress from one stage of the cell cycle to the next (Taken from Bertram, 
2000). 
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In studying the mechanism of action of p53 it becomes clear why it is so often mutated 
in tumours. It forms the centre of a complex regulatory system involving both the cell 
cycle and control of apoptosis and functions in close collaboration with the Rb tumour 
suppressor (Levine, 1997). P53 functions via modulating expression levels of the 
protein p21; by increasing p21 expression the cyclin D/CDK4 complex is not 
phosphorylated leading to a block in cell cycle progression (el-Deiry et al., 1993). P53 
itself is negatively regulated by MDM2, which acts to reverse checkpoint control and 
allow cell cycle progression. Therefore mutations in p53, which allow uncoupling from 
this cell cycle regulation, would likely be selected for in a growing dysplasia thus 
allowing full transformation to the malignant state. Studies to identify mutational hot 
spots within p53 have borne this idea out (Fig 1.2) (Cho et al., 1994). 
 
 
Figure  1.2: A shows the localisation of mutations within p53 isolated from a wide range 
of tumours. The large majority of these mutations are localised within the DNA binding 
region of the gene. This is visualised in B which shows a number of the more common 
mutations 
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More than 90% of all mutations recorded fall within the DNA binding domain, the large 
majority of these being missense mutations leading to an amino acid substitution. Such 
alteration in amino acid sequence leads to disruption of the hydrogen bonds between 
p53 and the DNA, preventing gene transcription and thus allowing the cell cycle to 
progress or prevent apoptosis (Cho et al., 1994). Mutations also occur within the 
transactivation zone, which disrupts the formation of the transcription complex 
preventing downstream gene expression. The last major form of mutation is found 
within the tetramerisation zone of p53; amino acid substitutions prevent the formation 
of the p53 tetramers required for downstream gene activation, leading to uncoupling 
from regulatory pathways (Bertram, 2000).  
In summary, uncontrolled cell proliferation resulting in the formation of tumours is a 
direct consequence of mutations in key regulatory proteins involved in cell growth and 
survival. 
1.1.3 Cancer is a multi step disease 
The vast majority of cancers are not established as a result of a single mutation, it is 
necessary for a group of genes to become damaged. The probability of a single cell 
acquiring all these mutations at once is regarded as infinitesimally small, thus the multi-
step hypothesis was formulated. It is reasoned that a cell undergoes a mutation and then 
clonally expands until it is statistically likely that another mutation will occur. As the 
cells continue to expand further genetic damage is incurred with each subsequent 
mutation allowing the cells to become better adapted to their surrounding environment. 
Finally, as the disease progresses to the later stages the cells acquire the ability to 
invade surrounding tissues and metastasise (Figure 1.3).  
 
 
 
Figure  1.3: The stages of tumour progression from a single cell to eventual metastasis in 
prostate cancer (taken from http://faculty.umdnj.edu/cabm/faculty_abate_shen.asp) 
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1.1.4 Current treatments and limitations 
There are three common treatments for cancer: 
1. Surgery; removal of the tumour from the patient is attempted wherever possible 
2. Radiotherapy; radiation is applied to the tumour site(s) because tumour cells are 
more sensitive to radiation than normal cells. It is inherently necessary for 
tumour cells to have defective DNA repair mechanisms. Therefore when their 
DNA is badly damaged by radiation the tumour cells die as it is impossible to 
effect the required repairs as normal cells would. 
3. Chemotherapy; this consists of delivery of a single drug or a combination 
therapy which targets rapidly dividing cells. 
Unfortunately there are problems associated with each of these treatments. Surgery 
although quite radical is effective provided the tumour is localised and has not invaded 
surrounding tissues. However such therapy is useless to a patient who has metastases. 
The remaining two therapies both target rapidly dividing cells. However it is not only 
tumour cells that rapidly proliferate in the human body, therefore significant toxicity is 
usually associated with both radiotherapy and chemotherapy. These traditional 
treatments are not specific enough for tumour cells and five year survival rates vary a 
great deal depending upon the cancer type (Fig 1.4). Therefore it is necessary to develop 
new treatment modalities that can both increase survival and reduce toxicity by 
targeting tumour cells in a more specific manner. Immunotherapy is one possibility as 
the immune system is highly directed and has multiple levels of control ensuring low 
toxicity. 
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Figure  1.4: five year survival rates for selected cancers; for adults diagnosed during 
1998-2001, England (taken from http://www.statistics.gov.uk/cci/nugget.asp?id=861) 
1.1.5 Strategies for immunotherapy and definitions of type 
If immunotherapy is to be used in cancer patients then some sort of treatment regimen 
must be compiled; what circumstances should they be used under, how many doses 
should be given and at what intervals etc? The number of doses and the intervals 
between administrations would be different depending on the vaccine; however when 
they would be administered is up for debate. There are a number of possibilities: 
1. Individuals with a familial risk of a certain cancer type could be immunised in 
order to reduce the risk of disease 
2. Immunisation of patients before commencing traditional treatment. If a patient 
were to be immunised while on the waiting list for chemotherapy or 
radiotherapy then it might be possible to generate a CD4+ memory response 
resistant to both chemo/radiotherapy 
3. Immunisation of patients with minimal residual disease in order to achieve long 
lasting disease remission 
4. Immunotherapy of solid tumour masses 
At present it would seem most sensible to utilise immunotherapy on patients who have 
minimal residual disease. It may be possible to use the immune system to monitor for 
the presence of low numbers of tumour cells that were not eliminated by previous 
treatments. 
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There are a number of types of immunotherapy that could be exploited so a decision 
must be made as to which would be used:  
1. Active immunotherapy relies on specific stimulation of a patient’s immune 
system with vaccines and/or non-specific stimulation using adjuvants. 
2. Passive immunotherapy involves treatment of a patient with exogenously 
produced therapeutics such as antibodies  
3. Adoptive immunotherapy is based upon the transfer of lymphocytes and/or 
cytokines 
4. Restorative immunotherapy is designed to restore any deficiencies in a patients 
immune response 
5. Cytomodulatory immunotherapy is designed to enhance the expression of MHC 
molecules on the surface of tumour cells 
Cancer vaccines usually fall under active specific immunotherapy and are often 
combined with adjuvants in order to boost immune responses (Minev et al., 1999). The 
aim is to augment any one or several types of immune response against a tumour mass 
(Fig 1.5) 
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Figure  1.5: Positive and negative regulation of anti-tumour immunity. Active specific immunotherapy aims to push the balance towards tumour 
rejection. Activating pathways are red arrows; inhibitory pathways are black arrows. Effector points are the yellow areas (taken from(Mocellin et al., 
2004). 
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1.2 The immune system 
1.2.1 The immune system and its components 
The cells that comprise the immune system originate in the bone marrow. All the 
cellular components of immunity are derived from a population of bone marrow 
progenitor cells known as the haemopoietic stem cells. It is this population of stem cells 
that give rise to both the myeloid and lymphoid progenitor cells (Akashi et al., 2000; 
Kondo et al., 1997). 
Upon encounter with any pathogen or aberrant cell the immune system must react in 
two ways, it must first recognise the threat and then react in order to eliminate it. The 
responses to threat are made up of two immune components namely the innate and 
adaptive responses. These responses differ in that the adaptive immune response is 
highly specific for a certain antigen and is customised depending upon the nature of the 
threat. Adaptive immunity also allows for the generation of a “memory” response 
thereby allowing efficient antigen clearance on re-encounter (Janssen et al., 2005). The 
innate immune response however is based upon non-variable pathogen receptors and 
only generates a short lived response (Heine & Ulmer, 2005). 
The myeloid progenitor cells give rise to cells such as macrophages, dendritic cells, 
mast cells, eosinophils and basophils that comprise the innate immune system, the first 
line of defence. The recognition system of innate immunity is based upon the 
expression of a number of germline-encoded pathogen receptors, such as the toll like 
receptors, which bind to a plethora of microbial products allowing rapid threat detection 
and response without the delay of clonal expansion (Blach-Olszewska, 2005). It is the 
macrophages and in particular the dendritic cells (DC’s) that are of the most interest as 
these are the cells that present antigen to the adaptive immune system. Immature 
dendritic cells continuously sample antigen from surrounding tissues and are capable of 
ingesting large quantities of protein, which is then processed into small peptides and 
displayed on the cell surface. Upon encounter with a pathogen or aberrant cell DC’s 
rapidly mature, up regulate expression of costimulatory molecules and migrate to the 
lymph nodes to facilitate peptide presentation to T lymphocytes (Clark & Kupper, 
2005). 
The common lymphoid progenitor (CLP) cells give rise to lymphocytes and natural 
killer cells (NK cells). In this case it is the lymphocytes which comprise the adaptive 
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immune system that are of greatest interest as these are the cells targeted by active 
vaccination strategies (Dermime et al., 2004; Emens, 2005; Mosolits et al., 2005). 
The CLP generates two types of lymphocyte: B lymphocytes which when activated 
differentiate into plasma cells that secrete large quantities of antibodies; and T 
lymphocytes of which there are a number of sub types: 
1. Cytotoxic T-lymphocytes (CD8+ CTL’s) are capable of recognising virus 
infected cells, tumour cells etc and killing them directly 
2. T-helper-1 cells (CD4+ Th1) interact with phagocytic cells from the innate 
system and aid in pathogen clearance. They also play a crucial role in the 
development of CTL responses 
3. T-helper-2 cells (CD4+ Th2) mediate the development of B cell responses 
Precursor T-lymphocytes migrate from the bone marrow to the thymus where they 
undergo maturation into T-cells which can be fully activated upon correct contextual 
antigen encounter (Misslitz et al., 2004). 
The lymphocytic component of the immune system differs from the other immune cells 
in one very important way; lymphocytes are able to mount an antigen specific adaptive 
immune response. This is achieved via the ability of T-cells to recombine gene 
segments encoding an antigen binding molecule known as the T-cell receptor 
(Sleckman, 2005). It is this T-cell receptor that mediates antigen recognition/binding 
and allows T-cell activation to begin. This is achieved in conjunction with a number of 
co-stimulatory molecules such as CD28, CD40L and CD3. These co-stimulatory 
molecules on the T-cells are bound by the corresponding ligands on dendritic cells 
CD80/86 and CD40 respectively leading to co-conditioning of both cell types (Ridge et 
al., 1998). This area will be discussed in further detail later on in section 1.7. 
Such interaction between the innate and adaptive components of the immune system is 
crucial to mounting a competent immune response capable of dealing with an immune 
threat. Phagocytes internalise antigens, process them and then present them to T-
lymphocytes in a format they can recognise. This procedure is known as antigen 
presentation and is an absolute requirement for the development of an adaptive immune 
response. Those T-lymphocytes stimulated by antigen encounter in turn produce soluble 
factors known as cytokines, such as Interleukin 2 (IL-2) and 12, which act to stimulate 
phagocytes further in a feed back loop (Clark & Kupper, 2005; Watanabe et al., 2004). 
This stimulation leads to enhancement of antigen presentation by phagocytes resulting 
in the destruction of the antigen internalised. Therefore in the early stages of infection 
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innate responses dominate and antigen presentation initiates the adaptive immune 
responses. However after ~96 hours the activated T-lymphocytes have begun to clonally 
expand and dominate the process of antigen clearance. These cells then further 
differentiate into memory cells, upon secretion of IL-7 and IL-15 by dendritic cells, 
allowing rapid antigen clearance upon re-encounter with a specific antigen (Franco et 
al., 2000; Huster et al., 2004). 
This discussion will focus mainly on the adaptive immune system as immunotherapy 
aims to modulate those components of the immune system that can generate specific 
recognition of a threat. 
1.2.2 The adaptive immune response 
As stated above, initiation of adaptive immunity depends upon the innate immune 
system to present antigen by a specific group of phagocytic cells known as antigen 
presenting cells (APC’s). One of the most efficient antigen presenting cells is the 
dendritic cell (DC) that appears critical for the activation of CD4+ T helper (Th) cells 
via surface molecule costimulation and production of cytokines as described in section 
1.2.1 (Clark & Kupper, 2005; Ridge et al., 1998; Watanabe et al., 2004). Antigens are 
phagocytosed by DC’s and processed into peptides that are presented to the Th cells on 
major histocompatibility complex (MHC) class II molecules (Fig 1.6a) (Marsman et al., 
2005). Th cell recognition of MHC bound peptide presented by APC’s is achieved via 
the T cell receptor (TCR), which is composed of an αβ dimer that specifically 
recognises one peptide antigen presented on an MHC class II molecule. Upon 
MHC/TCR interaction, APC’s deliver costimulatory signals that induce Th cell 
activation (Fig 1.6a). In response to stimulation the Th cells then begin to proliferate 
and secrete cytokines, such as IL-2, which boosts their activation status in an autocrine 
manner. This results in differentiation into Th1 and Th2 cells that regulate both cell 
mediated and humoral immunity respectively whilst controlling the production of 
memory cell phenotypes (Dubey & Croft, 1996; Holzer et al., 2003).  
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Figure  1.6: Collaboration between innate and adaptive immunity. (a) APC’s take up 
antigen, process and present it to CD4+ T helper cells that become activated via 
costimulation. Activated Th cells then produce large amounts of IL-2 resulting in T-cell 
proliferation and differentiation into Th1, Th2 and memory T cells. (b) Th2 cells 
stimulate B cell differentiation into plasma cells and memory cells. (c) Th1 cells 
orchestrate maturation of CTL’s and the formation of memory CTL. 
 
Interaction between the TCR of Th2 cells and antigen loaded MHC class II molecules of 
B cells induces B cell proliferation and differentiation into memory B cells and antibody 
secreting plasma cells. During MHC/TCR interaction, binding of costimulatory 
molecules expressed by Th2 cells (CD28, BRP-1) to their respective ligands on 
immature B cells (CD86, ICOS) in conjunction with Th2 cell mediated secretion of IL-
2, 4, 6, 7 and 10 are necessary events for B cell survival/function and the initiation of B 
cell maturation and differentiation (Fig 1.6b) (Woodland & Schmidt, 2005).  
The Th1 cells aid in the maturation and expansion of CD8+ CTL’s via conditioning of 
dendritic cells along with the secretion of IL-2 (Fig 1.6a+c). The costimulatory process 
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that occurs between dendritic cells and CD4+ Th cells matures both cell types; therefore 
allowing DC’s to activate naïve CD8+ T cells (Ridge et al., 1998). This 
activation/maturation of the Th cells by DC’s induces the production of IL-2, which in 
turn induces proliferation and differentiation of CD8+ T cells into effector and memory 
phenotypes (Rocha & Tanchot, 2004).  
Th1 and Th2 responses are mutually inhibitory to one another; therefore modulation of 
the balance between the Th subtypes plays a central role in the regulation of cell 
mediated and humoral immunity by generating the required type of immune response to 
meet a pathogenic/altered self threat (Kidd, 2003). Since tumour cells are regarded as 
altered self it is generally believed that the initiation of a Th1 and CTL based, cell 
mediated response, rather than a Th2 regulated humoral response would be most useful 
for the elimination of cancer cells (Knutson & Disis, 2005b). 
1.3 The major histocompatibility complex and antigen recognition by T 
cells 
 
The major histocompatibility complex (MHC) is a large group of genes that were 
identified as a result of their effects on transplanted tissues. MHC genes are found on 
chromosome 6 in humans (Fig 1.7) and the equivalent H2 genes on chromosome 17 in 
mice. Within these regions are also multiple genes involved in the regulation/production 
of MHC: peptide complexes (Shiina et al., 2004). 
The role of MHC is to present antigenic peptides to T-cells in order to stimulate 
immunity. Early experiments showed that cells presenting antigen must share the same 
MHC alleles as the target T-cells in order for activation to occur (Saito & Germain, 
1988). This MHC genotype dependant restriction of T-cell antigen specificity became 
known as MHC restriction. MHC molecules are composed of α subunits or α and β 
subunits arranged in different combinations to form MHC class I or MHC class II 
molecules respectively (Bjorkman et al., 1987; Brown et al., 1995; Gao et al., 1997). 
These combinations generate a binding groove that allows for both stable peptide 
binding and heterologous peptide presentation by the same MHC allele (Fig 1.8). As 
many individuals are heterozygous at MHC loci further enhancement of the peptide 
binding repertoire is achieved via polymorphisms within the MHC genes. Thus a 
potentially huge range of antigenic peptides can be presented to T-cells (Reche & 
Reinherz, 2003). 
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Figure  1.7: The human major histocompatibility complex (MHC) locus is located on the 
short arm of the chromosome 6 at 6p21.3. The chromosome 6 is estimated to be 150-
180 Mb in size. The MHC locus spans about 4 mega base pairs. From HLA-F 
(telomeric in the MHC locus) to TABP (TAPASIN) (centromeric in the MHC locus), 
the MHC locus contains at least 121 functional genes and, among them, all the MHC 
class I (classical I and non-classical Ib), the MHC class III and MHC class II genes, 
MHC class I like genes, genes involved in the antigen processing and cytokines. Taken 
from 
http://imgt.cines.fr/textes/IMGTrepertoireMHC/LocusGenes/chromosomes/human/Hu_
MHCchrom6.html
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 A1            HLA - A 
C2            HLA - DR B2           HLA - DQ A2            HLA - DP 
C1           HLA - C B1           HLA - B 
 
Figure  1.8: Allelic variation results in specific amino acid changes within MHC molecules (Taken from Reche et al, 2003). A1, B1 and C1 show variability in MHC 
class I molecules and A2, B2 and C2 show variability in MHC class II molecules with red being non-variable and blue being highly variable.
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Peptide epitopes presented on MHC molecules are recognised by T cells via the T cell 
receptor (TCR), which is comprised of an α chain and a β chain and resembles a 
membrane bound Fab fragment. On both the α and β chains there are hypervariable 
regions which allow each TCR to be totally unique and specifically recognise one 
peptide on a given MHC molecule (Fig 1.9). T cell receptor genes are very similar to 
immunoglobulin genes in their organisation. The TCR beta locus contains V, D and J 
segments like the IgH locus and the TCR alpha locus contains V and J segments like the 
Ig light chain loci. In fact the mechanism of gene rearrangement for T cell receptors is 
essentially identical to Ig gene rearrangement and utilises a number of recombinases. 
Mutations, which lead to a failure of rearrangement, affect both Ig and TCR; such 
mutations produce a lack of both T and B cells and therefore a complete lack of 
adaptive immunity and a severe immunodeficiency (SCID), which is naturally fatal. 
(Chlewicki et al., 2005).  
TCR binding to the appropriate peptide loaded MHC molecule in conjunction with 
either CD4 or CD8 binding (MHC class II and MHC class I binding respectively) 
accompanied by co-expression with the multimeric CD3 complex leads to initiation of 
cell signalling cascades involved in T-cell activation. Ligation of other T cell surface 
molecules such as CD40 and CD28 is then required to elicit full T-cell activation. Thus 
MHC/TCR interaction is critical to antigen presentation and T-cell activation (Saito & 
Yamasaki, 2003). 
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Figure  1.9: Gene rearrangement to form the T cell receptor. First the beta chain is 
formed and paired with a germline “temporary” alpha chain. Successful pairing with 
this germline subunit induces cessation of beta chain rearrangement and leads to T cell 
survival. The alpha chain is then produced and the T cell must undergo further selective 
processes before entering general circulation (Adapted from http://www-
immuno.path.cam.ac.uk/~immuno/part1/lec08/lec8_97.html). 
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1.3.1 MHC class I 
The MHC class I gene loci code for the α chain and the β2 microglobulin (β2-m), which 
together comprise the MHC class I molecule. The transmembrane α chain is made up of 
three external domains α1, α2, and α3 and the β2-m is non-covalently associated with 
these three domains. The particular manner in which the α1 and α2 domains conform 
leads to the formation of a groove. It is this groove that binds peptides of between 8-10 
amino acids in length (Fig 1.10) (Bjorkman et al., 1987; Gao et al., 1997).  
MHC class I is expressed on all lymphoid tissues and nucleated cells. However, thymic 
epithelia, hepatocytes, kidney and brain only express MHC class I at relatively low 
levels and red blood cells not at all. The function of MHC class I is to present peptides 
of predominantly intracellular origin to CD8+ T cells. Under normal circumstances these 
molecules would be loaded with self-peptides, which are recognised as “normal” by the 
immune system; however if a cell were virally infected then a panel of non-self, virus 
derived, peptides would be displayed. This leads to recognition of a threat by the 
immune system and the infected cells are destroyed (Shastri et al., 2005). 
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Figure  1.10: Side view of the crystal structure of the MHC class I molecule. The α 
subunits are shown in red and the β2-m subunit is shown in blue. Bound peptide sitting 
in the cleft formed by the α1 and α2 subunits is shown in yellow (modified from 
http://nfs.unipv.it/nfs/minf/dispense/immunology/mhcstr.html). 
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1.3.2 MHC class II 
The MHC class II gene loci is much more complex than the MHC class I gene locus due 
to the MHC class II molecule being made up of two external transmembrane domains. 
The expression of these genes is regulated in conjunction with the expression of the 
invariant chain and HLA-DM by a conserved group of transcription factors; RFX, 
CREB, NF-Y and CIITA (Class II transactivator) (Boss & Jensen, 2003). 
The MHC class II molecule is a heterodimer consisting of a 33kDa α chain and a 28kDa 
β chain, which associate via non covalent interaction. Each of these transmembrane 
proteins is made up of two domains; α1, α2, β1 and β2 respectively. In humans there 
are three types of MHC class II molecules; HLA-DR, DP and DQ, each of which have 
their own particular α and β subunits. However further variation in the MHC repertoire 
is produced by multiple types of α and β chain for each type of class II molecule; there 
are five α chains (1 DRα, 2 DPα, 2DQα) and eight β chains (3 to 4 DRβ, 2 DPβ, 2 
DQβ) (Campbell & Trowsdale, 1993; Newell et al.). If a particular individual is 
heterozygous for the MHC genes, not only are parental MHC molecules expressed on 
the cell surface, combinations of the different parental α and β chains can be produced 
giving rise to a huge peptide binding repertoire. Therefore MHC heterozygosity is 
advantageous in that an individual would be capable of presenting a wider range of 
antigens to T cells than a homozygous individual (Lipsitch et al., 2003). 
In the case of MHC class II it is the non-covalent bonding between the α and β chains 
creates the peptide binding cleft from the α1 and β1 subunits (Fig 1.11) (Brown et al., 
1995). Unlike MHC class I, which has a peptide binding groove that is closed at both 
ends, the MHC class II cleft is open ended. The nature of the binding groove means that 
the peptides that are MHC class II restricted can be variable in length; between 13-18 
amino acids long but they can be much larger (Rudensky et al., 1991). 
It has been shown that the MHC class II molecule is capable of forming a dimer of two 
MHC molecules, (αβ)2 or superdimer. These dimers, which associate in a non covalent 
manner, are oriented so that the peptide binding clefts are diametrically opposite one 
another (Schafer et al., 1995). The formation of such superdimers is simultaneous with 
the formation of stable MHC class II peptide complexes demonstrating that peptide-
MHC binding can initiate superdimer formation (Schafer et al., 1998). Class II 
superdimer formation may be important in T cell responses to low affinity peptides as 
antibody blocking experiments showed that disruption of superdimer assembly was able 
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to inhibit responses to low affinity peptides but not to high affinity peptides (Schafer et 
al., 1995). 
Another role for these superdimers could be to stabilise the interaction of the MHC 
molecules with CD4. This interaction could be important in allowing “cross-talk” 
between a T cell and an APC such as a dendritic cell. The dimer could also act to cross 
link CD4 and therefore influence TCR signalling (Sakihama et al., 1995).      
MHC class II expression is limited to lymphoid tissues and activated T-cells with 
constitutive, high level, expression seen on professional antigen presenting cells such as 
dendritic cells. All other nucleated cells and red blood cells do not naturally express 
class II antigens but can when exposed to cytokines such as TNFα or interferons 
(Schartner et al., 2005), also aberrant class II expression is seen on tumour cells 
(Muhlethaler-Mottet et al., 1997). The function of MHC class II is to present peptides of 
predominantly exogenous origin to CD4+ T-cells. Peptides presented in such a manner 
are likely to play a significant role in the initiation of an adaptive immune response as 
CD4+ T helper cells help orchestrate immune regulation (Knutson & Disis, 2005a). 
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Figure  1.11: Side view of the crystal structure of the MHC class II molecule. The α 
subunits are shown in yellow and the β subunits are shown in magenta. Bound peptide 
sitting in the cleft formed by the α1 and β1 subunits is shown in blue (modified from 
http://nfs.unipv.it/nfs/minf/dispense/immunology/mhcstr.html). 
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1.3.3 Antigen presentation and processing 
As previously discussed, it is necessary for antigen to be presented to T cells as peptide 
epitopes on MHC molecules in order to generate an adaptive immune response. 
Therefore antigen degradation and presentation forms the basis for much of the body’s 
immunity. Antigens are processed and presented via one of two pathways; the MHC 
class II pathway is only in operation in professional APC’s where exogenous 
endocytosed material is the source of antigen. In contrast, the MHC class I pathway 
operates in all nucleated cells of the body and continuously displays intracellular 
peptides derived from old or incorrectly synthesised new proteins (Griekspoor et al., 
2005). 
By constantly presenting the intracellular peptide repertoire, the MHC class I pathway 
allows the immune system to monitor cellular protein content. Thus when viral infection 
or aberrant protein expression occurs it is recognised via a change in the presented 
peptide repertoire and CD8+ T cells then kill the abnormal cells.  
Peptide loading onto MHC class I molecules occurs during synthesis. They are 
assembled in the endoplasmic reticulum (ER) with assistance from the chaperones 
calnexin, calreticulin and ERp57. MHC molecules then dock with the peptide 
transporter associated with antigen processing (TAP). TAP is a member of the large 
family of ABC transporters that translocate a wide variety of substrates across 
membranes. TAP is a heterodimeric protein complex consisting of two subunits; the 
70kDa TAP1 and the 72kDa TAP2 (Ortmann et al., 1997). A specialised protein known 
as tapasin facilitates the MHC-TAP docking process. TAP then “pumps”, in an active 
ATP dependant manner, virally derived or cellular antigenic peptides produced by the 
proteasome and other peptidases into the ER lumen (Reits et al., 2000). It was found 
that TAP exhibits some specificity regarding the length of the peptides transported with 
7-13 amino acids being optimal (Shepherd et al., 1993), which corresponds to the 
approximate binding range of the MHC class I peptide binding groove (~8-12aa). Once 
in the ER lumen, these peptides bind to the MHC class I molecules that are then 
released from the TAP-tapasin loading complex. This binding of peptide to the MHC 
class I molecule stabilises the whole complex. The loaded class I molecules then leave 
the ER and are transported to the cell surface where they interact with the TCR of CD8+ 
T cells (Fig 1.12) (Griekspoor et al., 2005; Inaba & Inaba, 2005; Marsman et al., 2005). 
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Figure  1.12: MHC class I peptide loading. A) Partially folded MHC class I α chains bind to 
calnexin until β2-microglobulin binds. B) MHC class I αβ2-m complex is released from 
calnexin, binds a complex of chaperones (Erp57, calreticulin) and binds TAP via tapasin. C) 
Cytosolic proteins are degraded into peptide fragments by the proteasome, a large multicatalytic 
protease. D) TAP delivers a peptide that binds to the MHC class I molecule and completes its 
folding. The fully folded MHC class I molecule is released from the TAP complex and 
exported.  
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MHC class I and MHC class II are very similar in structure and both bind and present 
peptide fragments, however they differ in almost every other aspect. The primary 
difference between the two is the source of the antigens presented. MHC class I presents 
antigen fragments derived from either the cytoplasm or the nucleus (Griekspoor et al., 
2005; Marsman et al., 2005). MHC class II molecules present peptides derived from 
exogenous proteins degraded in the endocytic pathway (Cresswell, 2000; Wubbolts & 
Neefjes, 1999). Therefore it would seem likely that many steps in the process required 
for peptide loading of MHC class II molecules would be different from those for MHC 
class I. As previously mentioned MHC class II molecules are comprised of an α and a β 
chain which assemble in the endoplasmic reticulum (ER) to form an αβ heterodimer 
(Marsman et al., 2005). 
Post heterodimer formation, a third chain known as the invariant chain (Ii) interacts with 
the αβ subunits to form a heterotrimer. In fact a trimer of this heterotrimer is formed, 
resulting in a nonameric complex (Cresswell, 1994). Ii acts as a mock peptide antigen 
by allowing a small segment of itself (called CLIP, for Class II associated Ii peptide) to 
associate with the MHC class II peptide binding groove. It has also been shown that Ii is 
required for MHC transport out of the ER, as mice with and Ii deletion show a reduced 
surface expression of MHC class II (Bikoff et al., 1993). 
Most proteins, including MHC class I, are transported via the Golgi directly to the 
plasma membrane, whereas Ii targets MHC class II molecules from the trans-golgi 
network to late endosomal structures called MIIC for “MHC class II containing 
compartments” (Neefjes et al., 1990). The MIIC contains all the required components 
for efficient loading of peptide onto MC class II: first, proteases degrade Ii until only the 
CLIP fragment is left in the peptide binding groove (Neefjes & Ploegh, 1992). Second, 
proteases, reductases and unfoldases process antigenic fragments which have entered 
the cell by receptor mediated or fluid phase endocytosis (Lennon-Dumenil et al., 2002). 
Finally, a chaperone known as HLA-DM mediates the exchange of CLIP for a peptide 
fragment (~13-25aa long) generated from the enzyme digested endocytosed antigens 
(Sanderson et al., 1994). The activity of HLA-DM can be controlled by a chaperone of 
chaperones called HLA-DO (Denzin et al., 1997). Thus, within these specialised MIIC, 
the unique combination of endosomal chaperones and proteolytic activity facilitates the 
proper peptide loading of MHC class II molecules. These are then transported to the cell 
surface for antigen presentation to CD4+ T cells (Germain & Rinker, 1993; Neefjes & 
Ploegh, 1992) (Fig 1.13). 
  
Chapter 1: Introduction 
 40 
 
Endoplasmic reticulum
Cytosol
HLA-DM
MIIC
A B
CD
 
 
Figure  1.13: MHC class II peptide loading. A) Invariant chain (Ii) forms a complex with MHC 
class II blocking the binding of peptides and misfolded proteins. B) Ii is cleaved in an acidified 
endosome, leaving a short peptide fragment, CLIP, still bound to the MHC class II molecule. C) 
Endocytosed antigens are degraded to peptides in endosomes but CLIP blocks the binding of 
peptides to the MHC class II molecules. D) HLA-DM binds to the MHC class II molecule in the 
MHC class II compartment (MIIC), releasing CLIP and allowing other peptides to bind. The 
MHC class II molecule then travels to the cell surface. 
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The above mechanisms described are often referred to as the classical antigen 
presentation pathways. However it is becoming more apparent that MHC class I and 
MHC class II molecules do not strictly adhere to their prescribed roles of presenting 
endogenous and exogenous antigen respectively. MHC class I molecules are capable of 
presenting exogenous antigen in a phenomenon known as cross-presentation (Decker et 
al., 2006). This is particularly the case for dendritic cells where it is thought that fusion 
between the ER and phagosomes leads to class I loading with exogenous antigen 
(Ackerman et al., 2003; Guermonprez et al., 2003; Houde et al., 2003). This would 
mean that DC’s could directly induce CTL priming against tumour antigens without 
direct CTL-tumour cell interaction. Similarly it is accepted that MHC class II is capable 
of presenting endogenous antigen although the precise mechanisms for endogenous 
peptide loading onto MHC class II molecules is less well understood. Such cross 
presentation is thought to be important in the thymus where MHC class II molecules 
presenting endogenous peptides are involved in T cell selection (Yang et al., 2006). The 
ability of MHC class II molecules to present endogenous antigen to T-helper cells 
should be harnessed for possible use in clinical trials, as this would theoretically enable 
a pre-existing CTL response to be boosted. 
1.4 The definitions of tumour associated antigens 
1.4.1 The molecular definition 
In the 1950’s Baldwin et al pioneered the field of tumour immunology and developed 
the idea of tumour associated antigens and the interaction with the host immune system 
by utilising a chemically induced tumour model in rats (Baldwin, 1955a; Baldwin, 
1955b; Baldwin, 1971; Baldwin et al., 1971). In later years these ideas were taken and 
developed further to give rise to a sophisticated concept of immunosurveillance and the 
tumour host interaction (Dunn et al., 2004). In order to develop an effective cancer 
vaccine it is necessary to understand the mechanisms of antigen processing and 
presentation in conjunction with defining tumour associated antigens (TAA) that can 
provoke an immune response. In the last decade a great deal of progress has been made 
in the identification of tumour antigens that could be targeted for the purposes of 
immunotherapy. The first human TAA to be identified in humans, MAGE-1, was 
isolated by genomic DNA expression cloning using melanoma-reactive CTL generated 
from PBMC of a patient (van der Bruggen et al., 1991). cDNA expression cloning then 
became a primary technique for the identification of tumour antigens recognised by 
CD8+ T cells (Kawakami et al., 2004). However using this method makes it difficult to 
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determine the MHC restriction of antigens unless blocking antibodies or MHC tumour 
loss variants are available. In order to focus on those tumour antigens most relevant to 
in vivo tumour rejection, cultured tumour infiltrating lymphocytes able to elicit tumour 
regression in conjunction with high dose IL-2 were used. However, such tumour 
specific CTL clones are both difficult to obtain and maintain in vitro. These limitations 
led to the development of other techniques to identify viable tumour antigens 
(Kawakami et al., 2004). 
Many cancers do not seem to generate readily detectable levels of tumour-reactive T 
cells, with the exception of melanoma, therefore another approach was deemed 
necessary. This led to the development of serological analysis of recombinant cDNA 
expression libraries (SEREX) (Li et al., 2004; Sahin et al., 1995). The principle of the 
technique relies upon cancer patients eliciting a CD4+ T-helper response and B-cell 
activation leading to production of anti-TAA antibodies. The cDNA libraries are 
screened using these serum IgG antibodies produced in cancer patients, thus specific 
antigens in the library can be associated with an anti-tumour response. SEREX has also 
been found capable of isolating tumour-associated antigens recognised by CD8+ CTL 
(Old & Chen, 1998) and represents a powerful technique which is continuously being 
used to identify further tumour antigens in a wide range of cancers (Kawakami et al., 
2004). 
It is now feasible to identify possible tumour antigen candidates by systematic gene 
analysis. Mutation searches performed by DNA sequencing, coupled with the use of 
DNA databases allow the identification of tumour specific mutated antigens. There is a 
wide range of techniques used such as single nucleotide polymorphism (SNP) searches; 
gene amplification can be identified by comparative genomic hybridisation (CGH); 
mRNA/cDNA subtraction methods; DNA chip/microarray analysis and expressed 
sequence tag (EST) database searches. Using reverse immunology, any candidate 
antigens identified can then be evaluated to determine if they are capable of eliciting an 
immune response in cancer patients. 
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Group Antigen Cancer 
Mutated peptides β-catenin, CDK4, MART-2, MUM3, Melanoma 
Fusion proteins bcr-abl, TEL-AML1 Leukaemia 
Tissue-specific proteins Gp100, MART-1, Tyrosinase, 
PSA, PAP, PSM, PSMA, 
Proteinase 3 
Melanoma 
Prostate cancer 
Myelogenous leukaemia 
Cancer testis antigen MAGE, NY-ESO-1 Various cancers 
Molecules related to 
tumourigenesis 
Her2/neu, WT1, survivin, hTERT Various cancers 
Oncofetal antigens CEA, AFP Various cancers, hepatoma 
Mucin MUC-1 Breast, ovarian, pancreas cancers 
Viral proteins EBV-EBNA, HTLV-1 tax, HPV-16-E7 Lymphoma, ATL, cervical cancer 
Idiotype Antibody B cell lymphoma, Myeloma 
MHC mutation Mutated HLA-A2 Renal cell cancer 
mHa HA1 Various leukaemia/lymphoma 
Others SART-3, GnT-V Various cancers 
 
Table  1.1: Examples of the human tumour antigens recognised by T cells (adapted from 
Kawakami et al, 2004).  
1.4.2 Tumour antigens and their use in immunotherapy 
The techniques described in the above section have been used to identify a number of 
antigens with potential application for immunotherapy. The ideal immunotherapeutic 
target antigen would be exclusively expressed within the tumour tissue but not in 
normal tissues in order to minimise the risk of an autoimmune reaction. However this is 
not necessarily the case for all tumour-associated antigens, which can be sub divided 
into a number of classes. These classes will be discussed below with regard to the 
definition and possible usefulness within immunotherapy. 
The first class of TAA is known as the cancer testis (CT) antigens, so called because of 
their expression in various human tumours and in spermatocytes/spermatogonia of the 
testis and occasionally placenta. CT antigens are produced as a result of reactivation 
genes that are normally silent in adult tissues, but become transcriptionally activated in 
various tumours. The first member of this family to be discovered was MAGE-1, which 
was cloned in 1991 and one year later the first T cell epitope for this protein was 
defined. Other members of this group of antigens include further MAGE antigens, 
BAGE and GAGE families, NY-ESO1 and its alternative open reading frame products 
LAGE and CAMEL (Aarnoudse et al., 1999; Boel et al., 1995; De Backer et al., 1999; 
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Jager et al., 1998; Traversari et al., 1992; Van den Eynde et al., 1995; van der Bruggen 
et al., 1991). The reason these genes are grouped into families becomes apparent when 
sequence comparison is performed; all the proteins share certain regions of homology 
although it is still not clear what role the proteins play in the cell (Xiao & Chen, 2004). 
More genes from this group are being identified as research continues so further class I 
and class II epitopes are certain to follow. Expression of these genes can be found in a 
variety of solid tumours such as melanoma, liver cancer, ocular melanoma, gastric 
cancer and testicular cancer. These particular antigens make excellent targets for 
immunotherapy because their expression is restricted to tumour tissue and the immune 
privileged testis. Therefore CT antigen expression in testis does not lead to 
autoimmunity because the cells of the testis do not express class I and class II HLA 
molecules (Novellino et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 45 
Gene  HLA  
HLA 
Frequency 
(%) 
Peptide  
A1 26 EADPTGHSY161-169 
A3 22 SLFRAVITK96-104 
A24 20 NYKHCFPEI135-143 
DR13 19 LLKYRAREPVTKAE114-127 
MAGE-1 
DR15 20 EYVIKVSARVRF281-292 
A1 26 EVDPIGHLY168-176 
A2 44 FLWGPRALV271-279 KVAELVHFL112-120 
A24 20 IMPKAGLLI195-203 TFPDLESEF97-105 
DP4 75 TQHFVQENYLEY247-258 
DR1 18 ACYEFLWGPRALVETS267-282 
DR4 24 VIFSKASSSLQL149-160 
DR7 25 VIFSKASSSLQL149-160 
DR11 25 TSYVKVLHHMVKISG281-295 GDNQIMPKAGLLIIV191-205 
MAGE-3 
DR13 19 AELVHFLLLKYRAR114-127 LLKYRAREPVTKAE121-134 
A2 44 SLLMWITQC157-165, MLMAQEALAFLORF2 
A31 5 ASGPGGGAPR53-62 LAAQERRVPRORF2 
DP4 75 SLLMWITQCFLPVF157-170 
DR4 24 
VLLKEFTVSG121-130 PGVLLKEFTVSGNILTIRLT119-138 
AADHRQLQLSISSCLQQL139-156 
NY-ESO 1 
DR7 25 PGVLLKEFTVSGNILTIRLTAADHR119-143 
 
Table  1.2: Table showing a list of class I and class II restricted cancer testes antigen 
derived peptides recognised by T cells, which are endogenously processed. T cells were 
stimulated with protein, peptide, dendritic cells or autologous tumour cells. Peptide 
epitopes have also been developed for HLA-B, C, DP and DQ alleles. Figures in 
subscript = residue no’s (Taken from http://www.cancerimmunity.org/peptidedatabase).  
 
The second class, known as the differentiation antigens is shared between the tumour 
and the normal tissue from which they arose. Many of these are found in melanomas 
and normal melanocytes and are involved in the biosynthesis of melanin, for example 
MART-1 and Tyrosinase (Kawakami et al., 1994; Wolfel et al., 1994). The function of 
the tyrosinase enzyme has been defined; it is a copper containing oxidase involved in 
the production of pigment and catalyses the rate limiting step in the formation of various 
DOPA compounds from tyrosine. Production of tyrosinase is increased on exposure to 
UV-B radiation (Riley, 1993). Other differentiation antigens are also being discovered 
in epithelial tissues (CEA), tumours such as prostate (PSA) and breast carcinomas 
(mammaglobin-A) enabling specific immunotherapeutic targeting of such solid tumours 
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(Correale et al., 1997; Jaramillo et al., 2002; Tsang et al., 1995). Although this group of 
antigens are not exclusively expressed in the tumour they are regarded as legitimate 
immunotherapeutic targets provided that the antigen is not expressed in critical tissues 
such as the brain, lung and liver etc. 
 
Gene HLA 
HLA 
Frequency 
(%) 
Peptide 
A2 44 (E)AAGIGILTV26(27)-35 ILTVILGVL32-40 Melan-A / MART-1  
DR4 24 RNGYRALMDKSLHVGTQCALTRR51-73 
A1 26 KCDICTDEY243-251 SSDYVIPIGTY146-156 
A2 44 MLLAVLYCL1-9 YMDGTMSQV369-377 
A24 20 AFLPWHRLF206-214 
DR4 24 QNILLSNAPLGPQFP56-70 SYLQDSDPDSFQD450-462 
Tyrosinase  
DR15 20 FLLHHAFVDSIFEQWLQRHRP386-406 
PSA A2 44 FLTPKKLQCV165-174 VISNDVCAQV178-187 
Mammaglobin-A A3 22 PLLENVISK23-31 
A2 44 YLSGANLNL606-613 IMIGVLVGV691-699 
A3 22 HLFGYSWYK61-69 
DR9 3 YACFVSNLAGRNNS653-657 
DR11 25 LWWVNNQSLPVSP177-189 and 355-367 
DR13 19 LWWVNNQSLPVSP177-189 and 355-367 
CEA 
DR14 6 LWWVNNQSLPVSP177-189 and 355-367 
 
Table  1.3:Table showing a list of class I and class II restricted differentiation antigen 
derived peptides recognised by T cells, which are endogenously processed. T cells were 
stimulated with protein, peptide, dendritic cells or autologous tumour cells. Peptide 
epitopes have also been developed for HLA-B, C, DP and DQ alleles. Figures in 
subscript = residue no’s (Taken from http://www.cancerimmunity.org/peptidedatabase).  
 
A third class is referred to as widely occurring, overexpressed TAA’s. These antigens 
are not restricted to a specific tumour type and are often present in normal tissue at 
lower expression levels. It is thought that these antigens do not evoke a T cell response 
in normal tissues because the quantity of epitope processed and presented on the cell 
surface is below the threshold level for T cell recognition. However overexpression in 
tumour cells leads to increased surface epitopic representation, which triggers an anti-
cancer response by breaking previously established tolerance (Novellino et al., 2005). 
This phenomenon makes this particular group of antigens reasonable targets for 
immunotherapy provided care is taken to avoid possible autoimmunity. This can be 
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achieved by carefully checking the level of overexpression by either quantitative PCR 
or DNA microarrays when comparing tumour cells with normal tissues (Page et al., 
2006; Weinschenk et al., 2002). Statistical analysis can then be applied to expression 
data in order to determine if there is a significant difference in expression between the 
normal and tumour tissue; for example the percentage fold increase between normal and 
cancer tissue could be compared using Mann Whitney U. If this is the case then further 
study of the antigen would be deemed necessary. It is worthy of mention that some of 
these overexpressed TAA were discovered by DNA microarrays coupled with newer 
technologies such as reverse immunology and tetramer staining (Weinschenk et al., 
2002). Examples of antigens within this group are the anti-apoptotic proteins livin, 
survivin, hTERT and the tumour suppressor p53.  
 
Gene 
Normal 
tissue 
expression 
HLAa 
HLA 
Frequencyb 
(%) 
Peptide 
A2 44 LLGRNSFEV264-272 p53 ubiquitous 
(low level) A2 44 RMPEAAPPV65-73 
survivin  ubiquitous A2 44 ELTLGEFLKL95-104 
 
Table  1.4: Table showing a list of class I and class II restricted peptides derived from 
overexpressed TAA recognised by T cells, which are endogenously processed. T cells 
were stimulated with protein, peptide, dendritic cells or autologous tumour cells. 
Peptide epitopes have also been developed for HLA-B, C, DP and DQ alleles. Figures 
in subscript correspond to protein amino acid residue number (Taken from 
http://www.cancerimmunity.org/peptidedatabase). 
 
The fourth class is known as the unique and altered shared, tumour specific antigens. 
The unique TAA’s arise due to mutations in normal genes such as β-catenin, CDK4 and 
N-ras etc. Many of these molecular changes are associated with transformation or 
progression and in humans a T cell response against such antigens is associated with a 
good patient prognosis. However a major problem with this group of antigens is that 
they are rarely expressed outside of the tumour in which they were first identified. 
Therefore, although these antigens represent an excellent tumour specific 
immunotherapy target they are unsuitable for use in the clinic because of they do not 
represent a widely applicable therapeutic (Novellino et al., 2005). The altered shared 
antigens are generated by processes that occur in the tumour cells but not in normal 
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cells, such as splicing errors and point mutations (Gjertsen et al., 1997; Khong & 
Restifo, 2002). Again these alterations are normally required for disease progression, 
thus generation of antigen loss variants is relatively unlikely under selective pressure 
from immunotherapeutic strategies (Novellino et al., 2005). Such TAA’s would be 
useful in the therapy of a wide range of cancers and could generate a truly tumour 
specific response. Unfortunately only a narrow range of these antigens has been 
identified so far.  
 
Gene/protein Tumour HLA 
HLA 
Frequency 
(%) 
Peptide 
beta-catenin melanoma A24 20 SYLDSGIHF29-37 
CDK4 melanoma A2 44 ACDPHSGHFV23-32 
N-ras melanoma A1 26 ILDTAGREEY55-64 
 
Table  1.5: Table showing a list of class I and class II restricted peptides derived from 
unique and altered shared tumour specific antigens recognised by T cells, which are 
endogenously processed. T cells were stimulated with protein, peptide, dendritic cells or 
autologous tumour cells. Peptide epitopes have also been developed for HLA-B, C, DP 
and DQ alleles. Figures in subscript correspond to protein amino acid residue number 
(Taken from http://www.cancerimmunity.org/peptidedatabase). Amino acids in red 
correspond to altered residues due to mutation. 
 
The fifth class is the fusion proteins. Several cancers, particularly the leukaemias, can 
be characterised by chromosomal translocations leading to production of fusion proteins 
such as BCR-ABL in CML (Clark et al., 2001). The Philadelphia translocation that 
occurs in CML joins the ABL gene on chromosome 9q34 to BCR on chromosome 
22q11. The resulting BCR-ABL messenger RNA comprises a BCR derived portion 
ending in exon 3 fused to ABL exon 2 which generates a 210kDa protein. This protein 
possesses an improperly regulated tyrosine kinase activity leading to constitutive 
activation of phosphoinositide 3-kinase (PI3K). Consequently downstream PI3K 
effectors become permanently activated resulting in propagation of signals promoting 
myeloid and lymphoid transformation resulting in leukaemogenesis (Kharas & Fruman, 
2005). The region of novel protein sequence spanning the fusion junction has great 
immunotherapeutic potential as it generates new CD4+ and CD8+ T cell epitopes that 
could be employed in a wide range of patients and tumour types (Parmiani et al., 2002). 
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The risk of therapeutically induced autoimmunity is also minimal because normal cells 
would not contain the targeted fusion protein region.  
 
Gene/protein HLA 
HLA 
Frequency 
(%) 
Peptide 
A2 44 SSKALQRPV926-934 
A3 22 KQSSKALQR924-932 
DR4 24 ATGFKQSSKALQRPVAS920-936 
BCR-ABL fusion protein (b3a2) 
DR9 3 ATGFKQSSKALQRPVAS920-936 
 
Table  1.6: Table showing a list of class I and class II restricted peptides derived from 
fusion proteins recognised by T cells, which are endogenously processed. T cells were 
stimulated with protein, peptide, dendritic cells or autologous tumour cells. Figures in 
subscript correspond to protein amino acid residue number (Taken from 
http://www.cancerimmunity.org/peptidedatabase). 
 
The sixth and final category comprises the virally derived antigens. These arise as a 
result of viral transformation initiating tumourigenesis in cells. The transformed cells 
often express/shed viral proteins which can lead to T-cell responses against virally 
derived epitopes. These viral proteins represent excellent immunotherapeutic targets and 
can elicit strong immune responses as the immune system has often “seen” such 
antigens before. One application of viral antigen derived anti-tumour therapeutics can 
be seen in the treatment of cervical cancer. Over 90% of cervical cancers contain HPV, 
the most common oncogenic forms of which are HPV16 and HPV18. Although the 
whole HPV genome is not contained within tumour cells, the E6 and E7 genes which 
are essential for the transformation process are commonly retained and expressed 
(Boursnell et al., 1996). These two proteins form the basis for immunotherapeutic 
targeting of cervical cancer with a number of CTL epitopes and viral vaccines being 
developed (Boursnell et al., 1996; Garcia-Hernandez et al., 2006; Ressing et al., 1995). 
However in the case of cervical cancer prophylactic vaccines as well as therapeutic 
vaccines have been developed (Mahdavi & Monk, 2005). These prophylactic vaccines 
are based upon the HPV-16 L1 capsid protein, which when expressed in a recombinant 
system will form virus like particles (VLP) that resemble native virions. These VLPs 
have been proven to be highly antigenic and injection of these can elicit high titres of 
neutralising antibodies as well as conferring protection against viral challenge (Zhou et 
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al., 1991). Since then this work has progressed into the clinic with a number of notable 
clinical trials (see Table 1.7) 
 
Study Koutsky et al, 2002  
(Merck study) 
Harper et al, 2004  
(GlaxoSmithKline study) 
Design Randomised double-blind controlled 
trial 
Randomised double-blind controlled 
trial 
Age (years) 16-25 15-25 
No. of enrolees 2392 1113 
Location 16 sites in the US 32 sites in North America and Brazil 
Antigen 40µg HPV-16 L1 VLP 20µg HPV-16 L1 VLP 
20µg HPV-18 L1 VLP 
Adjuvant 225µg aluminium hydroxyphosphate 
sulphate 
500µg aluminium hydroxide and 50µg 
3-deacylatedmonophosphoryl lipid 
(ASO4) 
Vaccination 
schedule 
0, 2 and 6 months 0, 1 and 6 months 
Follow up Mean of 17.4 months Up to 27 months 
Specific titres 
compared to 
natural infection 
60 times greater 50 times greater for HPV-16 
80 times greater for HPV-18 
Clinical outcome 100% efficacy in preventing persistent 
HPV-16 infection 
No cytologic or histologic 
abnormalities 
100% efficacy in preventing persistent  
HPV-16/18 infection 
93% efficacy in preventing cytological 
abnormalities 
Adverse effects Non-significant Non-significant 
 
Table  1.7: Shows a comparison of two prophylactic HPV vaccination trials based upon 
VLP L1 designed to prevent infection (Adapted from Mahdavi et al, 2005). 
 
There are a number of other viruses that are implicated in the induction of cancer. 
Epstein-Barr virus (EBV) is a human herpesvirus that is linked to three B-cell 
malignancies; post transplant lymphoma, Hodgkins disease, and all endemic (African) 
plus some sporadic cases of Burkitts Lymphoma (Bell & Rickinson, 2003). Human T-
cell leukaemia virus (HTLV) is associated with T cell leukaemia (Greaves et al., 1984), 
Herpes type II is associated with Kaposi’s sarcoma (Zmonarski et al., 2005) and 
Hepatitis B is associated with liver cancer (Gish, 2005). Immunotherapies against these 
varied virally induced cancers are currently in their infancy but the viral proteins within 
these tumours represent excellent candidate antigens. Other work investigating the 
efficacy of viral antigens as tumour therapeutics is in process using gp70 as a model 
antigen (Ahmad et al., 2005). This work paves the way for developing further T cell 
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based therapeutics against viral antigens that are endogenously expressed by tumour 
tissue. 
 
Gene/protein HLA 
HLA 
Frequency 
(%) 
Peptide 
HPV16 E7 A2 44 YMLDLQPETT11-20 LLMGTLGIV82-90TLGIVCPI86-93 
gp70 H2-Kd 44 SPSYVHQF138-147 
 
Table  1.8: Table showing a list of class I restricted peptides derived from viral proteins 
recognised by T cells. T cells were stimulated with protein or peptide. Figures in 
subscript correspond to protein amino acid residue number (Adapted from Ressing et al, 
1995 and Ahmad et al, 2005) 
 
The above information begs a simple question; with such a wide range of antigens for 
the immune system to target why is it that an adequate anti-tumour response is rarely 
developed? A reason for this phenomenon is that the tumour itself has mechanisms 
capable of engendering immune evasion. 
1.5 Tumour evasion 
1.5.1 Mechanisms of tumour evasion 
In order to grasp the underlying mechanisms of tumour escape it is necessary to 
highlight some of the basic assumptions and principles of immunosurveillance and its 
potential role in tumour development. The tumour escape hypothesis assumes that if left 
unchecked the immune system would spontaneously eradicate a tumour. In other words 
the very idea of immune escape implies attack in the first place. 
Murine models designed to test the immunosurveillance hypothesis and discover its 
underlying mechanisms have been developed, for example Robert Schreiber’s group has 
shown that an IFNγ dependant tumour suppressor system exists in mice (Kaplan et al., 
1998). However the relevance of this finding with regard to the immunosurveillance of 
human tumours is unclear because only a minority of human tumour cell lines tested in 
this study showed a permanent IFNγ insensitivity (Kaplan et al., 1998). When 
examining the mechanisms of tumour development, care must be taken when drawing 
conclusions from these murine studies and it is entirely possible that there could be 
fundamental differences between the development of tumours injected into mice or 
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induced by chemical carcinogens when compared to the naturally occurring 
spontaneous tumours in humans that arise over many years (Khong & Restifo, 2002). 
IFNγ, perforin and tumour necrosis factor (TNF)-related apoptosis inducing ligand 
(TRAIL) act as immune effectors for the prevention of tumour development. Mice that 
are deficient in T cells and/or in IFNγ signalling pathways have a much higher 
incidence of spontaneous sarcoma, lymphoma and epithelial tumours (Shankaran et al., 
2001; Street et al., 2002). Other studies demonstrated that in perforin deficient mice 
there was a higher rate of spontaneous lymphoma and lung adenocarcinoma (Smyth et 
al., 2000). When these lymphoma cells were transplanted into syngeneic wild type mice 
they were rejected by CTL mediated activity. Thus evidence exists, that under certain 
circumstances immunosurveillance can play a role in growth suppression of early 
tumours. In this respect, when tumours arise, they are regarded as having escaped from 
immunosurveillance (Khong & Restifo, 2002). Another model proposes that tumours 
are seen as immunologically normal tissue. It is reasoned that tumour cells appear as 
normal healthy growing cells because they do not produce any danger signals to activate 
the immune system (Restifo et al., 2002). Thus tumour histology and phenotype could 
influence early tumour growth as a result of stealth and non-recognition or as the result 
of immune sculpting. 
Later in tumour development, during progressive growth, tumours may activate the 
immune system due to the disruption of surrounding tissue, production of reactive 
oxygen species, up regulation of heat shock proteins and death by apoptosis or necrosis. 
At the same time continual genetic dysregulation leads to the production and expression 
of large numbers of neoantigens. All these factors may contribute to the activation of 
local innate immunity resulting in development of a T cell mediated adaptive immune 
response against the tumour (Khong & Restifo, 2002). 
However, whatever mechanisms exist it is certain that when a tumour becomes 
clinically detectable spontaneous regression rarely occurs. Once a solid tumour has 
become established it is not known if immune escape is required because it is unclear 
whether or not these tumours are even capable of generating an immune response that 
could lead to regression (Restifo et al., 2002).  
Although the concept of immunosurveillance remains to be proven beyond doubt there 
are a number of mechanisms present within the tumour environment that could, and 
probably do, influence the course of tumour progression. For example tumour cells can 
be looked at in a Darwinian manner; one of the most important factors that influence the 
survival of an organism is genetic diversity. Genomic instability is an inherent property 
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shared by all tumours and results in a genetically heterogeneous cell population. This 
means that in any given tumour natural selection is at work when certain cells 
possessing traits beneficial to their survival and/or proliferation outgrow other tumour 
cells (Cahill et al., 1999). The same process would apply to tumour growth in the face 
of an effective immunotherapy. 
The loss or down regulation of HLA molecules on the tumour cell surface is another 
possible escape mechanism. Once again though there is conflicting evidence in the 
literature (Rees et al., 1988; Rodriguez et al., 2005; van Hall et al., 2006), it would be 
expected that loss of H2 expression in TAP-1 or LMP-2 deficient mice would increase 
the onset and variety of spontaneous tumours; however it does not (Johnsen et al., 
2001). In contrast some recurring tumours lose cell surface MHC class I in mice 
immunised with B7-1 transfected tumour cells and in humans after partial responses to 
immunotherapy (Restifo et al., 1996; Zheng et al., 1999). Decreased or absent HLA 
class I expression is associated with invasive and metastatic lesions. Total loss of HLA 
class I expression is not uncommon in many tumours including melanoma, colorectal 
carcinoma and prostate adenocarcinoma. In breast carcinoma the frequency of total 
HLA class I loss is >50% (Khong & Restifo, 2002). Thus it is entirely possible that in 
HLA-loss and MHC class I processing defective tumour cells the loss of HLA class I 
antigens occurs as a result of the immunoediting of early tumours (Dunn et al., 2002). 
Genetic mutation of the tumour genome can lead to total HLA loss or selective loss of a 
particular HLA class I haplotype due to mutations within chromosome 6 (Ramal et al., 
2000). 
Loss of tumour antigens and immunodominance can lead to tumour escape. Loss of 
antigen expression on the cell surface can occur independently of HLA loss or down 
regulation. It has been shown that tumour antigen expression even within a single 
tumour is heterogeneous and that decreased expression of melanoma differentiation 
antigens such as gp100, MART-1 and tyrosinase is associated with disease progression 
(de Vries et al., 1997). In one study there was a 25% decrease in MART-1 expression 
when patients with stage IV disease were compared with patients at stage I; such 
decreased antigen expression has also been observed in residual tumour mass post 
peptide vaccination (Hofbauer et al., 1998; Jager et al., 1996; Lee et al., 1998).  
The precise mechanisms underlying the phenomenon of tumour antigen loss or down 
regulation are as yet largely undefined; however the production of such antigen loss 
variants could be due to epitope immunodominance. In theory an immunodominant 
epitope acts as a focal point for the immune system to attack, thus allowing other 
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antigen loss variants to develop in the absence of attention from the immune system. 
Once these immunogenic parent cells have been destroyed a new hierarchy is 
established amongst the remaining tumour cell subpopulations and a new epitope 
becomes dominant (Schreiber et al., 2002). 
Defective death receptor signalling is another potential cause of tumour escape. Two 
death receptor ligands that have been shown to be important for immunosurveillance of 
tumours are Fas ligand (FasL) and TRAIL. If signalling pathways from these molecules 
are disrupted then a survival advantage is conferred to the tumour cells allowing 
continued proliferation and growth (Khong & Restifo, 2002). For example when Fas is 
engaged by its ligand a complex is formed on its cytoplasmic tail allowing the activation 
of an enzyme known as caspase-8, this enzyme then activates further caspases, which 
can induce cell death. The caspase-8 inhibitor, cellular FLICE-inhibitory protein 
(cFLIP), is expressed in a number of tumours and renders these cells resistant to death 
receptor mediated apoptosis as well as contributing to T cell immunoresistance in vivo 
(Irmler et al., 1997; Medema et al., 1999). Down regulation or loss of Fas expression in 
tumour tissue due to total gene deletion or missense mutation has also been shown to 
contribute to tumour escape in both myeloma and melanoma. Mutations in the pathways 
downstream of Fas signalling have also been identified (Khong & Restifo, 2002). 
With regard to TRAIL mediated apoptosis, loss of expression of TRAIL receptors 
occurs by one of the following mechanisms: chromosomal loss; chromosomal loss of 
caspase-8; lack of signalling from the death inducing signalling complex; inhibition of 
caspase-3 and low expression of death receptors due to post-transcriptional regulation 
are all hallmarks of tumour resistance to TRAIL mediated apoptosis (Hersey & Zhang, 
2001). Thus it can be seen that there could be defects at multiple sites in the death 
receptor signalling pathways contributing to tumour escape. 
A major factor in the escape of tumours from the immune system is a simple lack of co-
stimulation. This is because most tumours grow in a non-inflammatory environment 
that is sub-optimal for the generation of an immune response. A number of clinical trials 
have shown that tumour specific T cells can be generated; unfortunately these cells are 
not necessarily functional. However, when removed from the tumour environment and 
restimulated with antigen and specific cytokines they can be reactivated (Greenberg, 
2001). Therefore anti-tumour T cells generated are not dysfunctional but merely 
rendered anergic in some way (Pardoll & Topalian, 1998; Ridge et al., 1998). It seems 
likely that the dendritic cells encountering tumour antigen presented under the non-
inflammatory conditions found in the tumour microenvironment would not become 
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activated; such dendritic cells would not express the full repertoire of costimulatory 
molecules and would render tumour antigen specific T cells anergic (Fig 1.14). Tumour 
cells themselves can also cause anergy when T cells encountering antigen upon the 
tumour cell surface do not receive the appropriate costimulation (Khong & Restifo, 
2002). 
 
 
Figure  1.14: Induction of T cell tolerance by tumours and non-activated APCs. The 
figure also shows the normal activation route for T cells where the co-stimulatory 
molecules are present (taken from Pardoll, 1998). 
 
Immune escape does not necessarily have to be mediated by cell-cell contact; the 
presence of immunosuppressive cytokines in the tumour microenvironment also 
influences the outcome of tumour growth. Tumour cells can produce a variety of 
cytokines that are capable of down regulating an immune response such as VEGF, IL-
10, PGE2 and TGFβ. VEGF acts to inhibit the differentiation and maturation of 
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haematopoietic stem cells into DC by suppression of the transcription factor NF-κB. In 
patients with lung, head and neck and breast cancers there were decreases in both the 
number and the function of DC associated with increased plasma concentrations of 
VEGF (Almand et al., 2000). Increased concentrations of IL-10 are regularly detected in 
cancer patient sera, which can affect DC differentiation from stem cell precursors as 
well as compromising the maturation and functional status of DC. IL-10 is capable of 
inhibiting antigen presentation, IL-12 production and induction of Th1 type helper 
responses in vivo (De Smedt et al., 1997; Sharma et al., 1999). IL-10 also protects the 
tumour from the immune system via enhancement of DC autolysis, down regulation of 
HLA class I and class II molecules and ICAM-I. Such loss of HLA class I expression 
could be due to IL-10 mediated down regulation of TAP1 and TAP2 molecules within 
tumour cells (Khong & Restifo, 2002). PGE2 is a proinflammatory cytokine that is 
expressed in multiple human tumours; it acts to increase the production of IL-10 by 
lymphocytes and macrophages and inhibits IL-12 production by macrophages (Huang et 
al., 1998). Elevated TGFβ levels are seen in many cancer patients and are associated 
with disease progression and poor response to immunotherapy. TGFβ acts to inhibit the 
activation, proliferation and activity of lymphocytes in vivo (Fontana et al., 1989). 
However despite the effects of the various cytokines mentioned above, it must be borne 
in mind that these may not necessarily be escape mechanisms per se but merely side 
effects of the angiogenic and growth factor functions of these proteins. 
It has been proposed that tumour cells might be capable of inducing apoptosis of 
activated T cells via the expression of death receptor ligands on the tumour cell surface. 
Currently there is contrasting evidence in the literature on this subject (Khong & 
Restifo, 2002). However an additional mechanism that is likely to occur pertains to 
activation induced cell death (AICD) of antitumour T cells. Once T cells have become 
activated by tumour antigen recognition they express high levels of FasL, which induces 
both apoptosis of these T cells (suicide) and between T cells (fratricide). Such AICD 
can be reduced by the addition of vitamin E in vitro or by administration of a high oral 
dose of vitamin E in vivo (Malmberg et al., 2001). 
In recent years the role of “suppressor” or “regulatory” T cells has become more 
apparent with regard to tumour escape. These immunoregulatory CD4+ CD25+ T cells 
control immunological tolerance to self-antigens; removal of these cells, which 
comprise 5-10% of all CD4+ T cells in humans and rodents, induces autoimmune 
disease in a wide variety of tissues. Depletion of these regulatory cells in conjunction 
with injection of a CTLA-4 blocking antibody was able to enhance reactivity against a 
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known tumour associated antigen (Sutmuller et al., 2001). However simply blocking or 
removing regulatory T cells in order to overcome immune suppression and elicit 
regression of established tumours is unlikely to be successful as there would be 
autoimmune complications (Assudani et al., 2006).  
1.5.2 T-cell selection and tumour immunology 
As discussed in the previous section T cells can be rendered tolerant to tumour antigens 
due to lack of costimulation etc. However tolerance, both central and peripheral, is a 
natural mechanism employed by the body to protect an individual against 
autoimmunity. A more fundamental level of control of T cell auto-reactivity is 
employed during the process of T cell production; T cell progenitors (thymocytes) are 
actively selected against during their development if they are auto-reactive. During their 
early life, thymocytes begin rearrangement of their T cell receptors in a random manner 
(see Fig 1.8). During this process of rearrangement a T cell could produce a T cell 
receptor that is specific for a self antigen, which could lead to autoreactivity or a T cell 
receptor that is specific for a foreign antigen, which could be beneficial to the host. 
Therefore it is necessary for a mechanism to exist which is capable of selecting those T 
cells that recognise non-self antigens and deleting those that recognise self antigen and 
could cause autoimmunity (Goldrath & Bevan, 1999). This process of repertoire 
selection occurs at the CD4+8+ stage of T cell development in the thymus and involves 
positive selection, leading to T cell maturation to the CD4+8- and CD4-8+ stages and 
negative selection which induces cell death in potentially autoreactive thymocytes 
(Anderson et al., 1998). 
The driving factor in determining whether a CD4+8+ thymocyte undergoes positive or 
negative selection is the avidity of its TCR mediated interaction with peptide loaded 
MHC complexes on thymic stromal cells (Ashton-Rickardt et al., 1994; Ashton-
Rickardt & Tonegawa, 1994). Over a period of 3-4 days successive αβTCR 
combinations, produced by continuous TCR α-chain gene rearrangement, are tested for 
interaction with stromal MHC/peptide ligands. Those cells that do not interact with 
stromal MHC complexes during this time die from neglect, while low avidity 
interactions lead to positive selection and survival, high avidity interactions lead to 
negative selection through apoptosis (Anderson et al., 1998; Surh & Sprent, 1994). 
There is also evidence that other factors besides TCR avidity are involved in 
determining the outcome of thymic selection. Efficient positive selection is dependant 
upon interaction with peptide/MHC complexes on thymic cortical epithelial cells 
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whereas negative selection is most efficiently mediated by dendritic cells (Faro et al., 
2004). The reasons for this specialisation in selection are currently unclear; however it 
is likely that it may be linked to the repertoire of peptide presented by a certain cell type 
or the dependence upon additional costimulation and cell signalling to initiate either cell 
differentiation or cell death (Mariathasan et al., 1999).  
As a result of these selective processes, T cells emigrating from the thymus into the 
periphery display a low affinity for self peptide loaded MHC and represent a diverse 
pool of naïve T cells with varied specificity. However, the large majority of tumour 
antigens are in fact overexpressed self proteins; therefore the T cell selection process by 
its very nature eliminates those T cells that would be most tumour reactive! As a result 
immunotherapy seeks to boost the response of the remaining low/moderate affinity T 
cells in order to clear a tumour mass with the advantage that these T cells are less likely 
to induce autoimmunity elsewhere in the body. Such immunotherapeutics must be 
carefully formulated in order to ensure maximum costimulation of T cells upon antigen 
encounter in order to compensate for the lower affinity of the circulating antitumour T 
cells and prevent tolerance. 
1.6 Cancer vaccines, their design and limitations 
1.6.1 Considerations 
Growing tumours act to suppress the immune system; therefore any cancer vaccination 
strategy must overcome this by targeting a therapeutic strategy towards correctly 
activated antigen presenting cells. As a result, a large number of vaccination trials have 
utilised tumour derived peptides/antigens in conjunction with an adjuvant in order to 
maximise the chances of efficient immune stimulation (Berzofsky et al., 2004). To date 
the majority of cancer vaccine trials have focused on the generation of a CD8+ 
antitumour T cell mediated response as these cells have the ability to directly clear a 
tumour mass (Pardoll & Topalian, 1998). However in recent years it has become more 
apparent that CD4+ T cells are also important in cancer vaccines if a long lasting CD8+ 
antitumour response is to be generated (Wang, 2001). Thus the design of any cancer 
vaccine should be carefully considered in order to maximise therapeutic efficacy. 
Currently there is a wide range of cancer vaccine modalities available (Fig 1.15), each 
of which has its own advantages and disadvantages. Below, some of the most common 
of these are discussed. 
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Figure  1.15: Shows the various approaches available for antitumour vaccination. (A) 
Irradiated tumour cells transfected with a viral vector encoding cytokines designed to 
attract DC’s in order to maximise antigen presentation to the immune system. (B) DC’s 
can be directly loaded with TAA via a number of methods e.g. tumour lysates peptide 
etc. (C) DC can be locally supplied with antigen by direct injection, DC will then take 
this up and migrate to draining lymph nodes where the antigen is presented to T cells 
(taken from Berzofsky et al, 2004). 
1.6.2 Modified tumour cell vaccines 
The most plentiful supply of rejection antigens can be found within a tumour itself; thus 
the idea of utilising whole autologous tumour cells as a cancer vaccine arose. However 
this is difficult to apply within the clinic as large scale vaccine production is difficult 
and tumour tissue is often unavailable. Therefore other approaches have been developed 
that utilise more widely applicable allogeneic cell lines as vaccines (Berzofsky et al., 
2004). 
Tumour cells have been engineered to secrete a number of different cytokines with the 
idea of enhancing tumour recognition and destruction. Of the cytokines tested, GM-CSF 
appears to be the most effective. Expression of GM-CSF by the tumour cells leads to 
increased numbers of DC’s and other APC within the tumour microenvironment, 
specifically at the site of injection (Dranoff et al., 1993). The problem is that solid 
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tumours are often inaccessible for direct injection, therefore a patient must first undergo 
surgery to remove the primary tumour then receive immunotherapy in the hope that it 
would prevent relapse due to metastasis.  
Studies performed in patients with advanced prostate cancer (Simons et al., 1999) and 
metastatic malignant melanoma (Soiffer et al., 1998) used irradiated autologous tumour 
cells which had been transfected with a retroviral vector coding for GM-CSF, resulting 
in one partial response out of 21 melanoma patients. In a separate trial, 14 patients who 
had undergone surgery to remove pancreatic cancer were vaccinated with GM-CSF 
transfected allogeneic cancer cell lines, three of which remained disease free at 23 
months (Jaffee et al., 2001).  
1.6.3 Peptide based vaccines 
The discovery of the crystal structure of the MHC molecule and of the peptides bound 
to it in conjunction with anchor residue sequence motifs accounting for binding 
specificity of peptides to MHC molecules has made it possible to understand how T 
cells recognise antigen in the form of short peptides (Stern & Wiley, 1994). Native 
peptide vaccines have been used but strategies have also been developed to improve 
peptide immunogenicity and to steer the immune system towards the desired type of 
response. However individual peptides would only be useful in patients expressing the 
appropriate HLA molecules capable of presenting them (Berzofsky et al., 2004). 
Modification of the amino acid sequence of the peptides, referred to as epitope 
enhancement, can improve the ability of vaccines to generate a clinically significant 
response via several means: (1) increasing the affinity of peptide for the MHC 
molecule; (2) increasing TCR triggering; (3) inhibiting the proteolysis of the peptide by 
serum proteases (Berzofsky et al., 2004). It is extremely important whenever the peptide 
sequence is altered to confirm that the induced T cells are still capable of recognising 
the native peptide sequence.  
Another approach that has been applied to peptide vaccines is the use of adjuvants 
containing cytokines, chemokines, costimulatory molecules etc in order to amplify and 
direct the immune response (Berzofsky et al., 2001). Th1 CD4+ T cells and CD8+ 
cytotoxic T cells are crucial for antitumour immunity and are stimulated most efficiently 
by professional APC such as dendritic cells. Therefore it seemed logical to combine 
peptides with cytokines, to induce DC recruitment (GM-CSF), costimulatory molecules 
and promote DC maturation (CD40L) in conjunction with Th1 cytokines such as IL-12 
and IL-15 (Ahlers et al., 2002). The use of peptides with broad MHC class II binding, 
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endogenous helper epitopes or enhanced helper epitopes to stimulate CD4+ T cell help 
also has the ability to increase an antitumour CD8+ response (Ahlers et al., 2001). 
The most comprehensively studied clinical model for peptide vaccination is malignant 
melanoma. Rosenberg et al tested vaccination with native gp100209-217 (ITDQVPFSV) 
and found that it was only capable of inducing low levels of T cell activity in 2 of 8 
melanoma patients, whereas the enhanced epitope gp100 (g209-2M, sequence modified 
to IMDQVPFSV) generated strong T cell reactivity in 10 of 11 immunised patients 
(Rosenberg et al., 1998). Despite these T cell responses, only a single objective clinical 
response was reported. However, immunisation with the enhanced g209-2M epitope in 
conjunction with high dose IL-2 resulted in antitumour responses in 42% of patients 
with T cell reactivity in only 10% of patients. Additionally, there is quite a wide range 
of adjuvants to consider each of which has advantages and disadvantages, with usage 
limits imposed by law in some countries restricting the available choice. The problem is 
that results can vary depending upon the adjuvant chosen (Schaed et al., 2002). 
1.6.4 Recombinant viral vectors 
A number of trials and preclinical models are currently in progress that utilise 
recombinant viral vectors expressing tumour antigens such as PSA or CEA, some with 
immunomodulatory cytokines (Marshall et al., 2000; Rees et al., 2002; Zhu et al., 2000). 
A range of vectors has been used including adenovirus, vaccinia and avipox. The 
presence of high titres of antiviral neutralising antibodies could limit the use of such 
vectors, especially when multiple doses are required for effective therapy, except for 
fowlpoxes that do not seem to induce neutralising antibodies (Berzofsky et al., 2004). 
Resistance against poxviruses due to prior exposure could be potentially overcome by 
mucosal immunisation, which is capable of inducing both systemic and mucosal 
immunity (Belyakov et al., 1999). Immunodominance could also lead to problems as the 
immune response generated may focus upon the more potent viral antigens rather than 
against the weaker tumour antigens. The potency of such vectors may be enhanced by 
the addition of genes encoding immunostimulatory molecules or cytokines (Hodge et 
al., 1999; Lipsitch et al., 2003), many of which are now entering clinical trials. These 
vectors can also be used to transfect antigens into dendritic cells that can themselves be 
used as a form of vaccine, as described later. 
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1.6.5 DNA vaccines 
Intramuscular injection of naked DNA expression vectors has been shown to induce 
immune responses (Tang et al., 1992; Ulmer et al., 1993). These DNA vaccines target 
antigen into DC’s for endogenous processing and presentation to CTL in draining 
lymph nodes or into other cells for cross presentation without the requirement for viral 
vectors. Therefore there is no concern over immune competition from viral antigens or 
reduced therapeutic efficacy due to antiviral antibodies and potential risks from live 
virus are eliminated. These vaccines can also be further adapted to specific requirements 
by the use of constitutive, tissue or tumour specific promoters for selective expression 
(Berzofsky et al., 2004). 
The results of a number of plasmid DNA vaccine trials have now been published. Of 12 
patients with follicular lymphoma vaccinated with plasmids encoding tumour specific 
idiotypes four mounted a humoral anti-idiotype or a specific anti-idiotype T cell 
proliferative response (Timmerman et al., 2002). In a separate trial, 17 patients with 
metastatic colorectal carcinoma vaccinated with a plasmid encoding both CEA and 
hepatitis B surface antigen (HBs) as a control, six developed protective levels of anti-
HBs antibody but none mounted a response to CEA. However 4 out of 17 mounted an 
anti-CEA lymphoproliferative response (Conry et al., 2002). Therefore it would seem 
that DNA vaccines have not yet shown much promise as an antitumour therapeutic in 
the clinic. 
1.6.6 Dendritic cell vaccines 
As a consequence of the tumour microenvironment DC maturation and function can be 
impaired in cancer patients; therefore it seems logical that ex-vivo generated DC should 
form the basis of a therapeutic antitumour vaccination. Gabrilovich and colleagues 
reported improper CTL induction in conjunction with defects in DC function 
(Gabrilovich et al., 1996a; Gabrilovich et al., 1996b). Supernatants harvested from 
tumour cells were capable of suppressing DC maturation via VEGF (Gabrilovich et al., 
1996a; Gabrilovich et al., 1996b). However DC’s generated in vitro from bone marrow 
progenitors were found capable of stimulating allogeneic T cells and induced mutant 
p53 peptide-specific T cell responses (Porgador & Gilboa, 1995). Immunisation with 
mutant p53 peptide pulsed DC was able to inhibit the growth of established tumours in 
mice (Berzofsky et al., 2004). 
DC’s pulsed with a variety of therapeutics such as tumour lysates, peptides, nucleic 
acids encoding TAA either transfected into DC by virus or by electroporation and RNA 
have all proved effective to a varying extent (Berzofsky et al., 2004). Antigens can also 
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be targeted to DC’s by coupling to DC specific antibodies (Bonifaz et al., 2002). 
Transfer of genes encoding costimulatory molecules (B7) and cytokines (IL-12) into 
DC’s has also proven successful in boosting therapeutic efficacy (Zitvogel et al., 1996). 
One of the hurdles to overcome when using DC vaccination is the generation of large 
numbers of clinical grade human DC’s. Currently there are two commonly used 
techniques: (1) purification of immature DC precursors from peripheral blood (Fong & 
Engleman, 2000) and (2) ex vivo differentiation of DC’s from CD34+ haematopoietic 
progenitor cells or peripheral blood monocytes, usually by culture of monocytes with 
GM-CSF and IL-4. Immature DC can be matured in a variety of ways e.g. CD40 ligand, 
LPS, TNFα or Poly I.C. (Berzofsky et al., 2004). 
One experiment in humans raised concerns about the use of immature DC’s in the 
clinic, which could potentially lead to the generation of tolerance to the targeted 
antigens (Dhodapkar & Steinman, 2002; Jonuleit et al., 2000). Two healthy donors 
receiving immature DC’s pulsed with influenza matrix peptide (FMP) showed a 
reduction in the number of active FMP specific CD8+ T cells (Dhodapkar et al., 2001). 
As a result the recent protocols employed TNFα, CD40 ligand, monocytes conditioned 
media or cytokine cocktails to mature the DC (Nestle, 2000). 
The results of several DC cancer vaccine trials have now been reported. The first of 
these, conducted by Hsu et al, was for the treatment of cancer patients with follicular B 
cell lymphomas, which express a unique clonal B cell receptor (idiotype, Id) that can 
distinguish lymphoma cells from non-malignant lymphocytes. Ten patients were treated 
with peripheral blood derived DC’s pulsed with a tumour specific Id protein. Eight 
developed Id specific proliferative responses and one developed a specific CTL 
response (Hsu et al., 1996). Two patients had complete responses (CR) and one had a 
partial response (PR). A follow up study was conducted with a further 25 patients of 
which 15 out of 23 that completed the trial generated T cell and humoral anti-Id 
responses (Timmerman et al., 2002). 
Multiple myeloma (plasma) cells that also express unique clonal immunoglobulin 
idiotypes can be detected by CTL that recognise Id peptide presented on HLA 
molecules. Of 26 patients treated with Id pulsed DC after high dose chemotherapy and 
stem cell transplantation, four developed Id specific T cell proliferative responses. The 
stem cell transplant itself resulted in 5 CR and 21 PR, however 8 patients who partially 
responded had further reduction in their serum monoclonal spike post DC vaccination 
and of the four patients who developed an immune response two remained in CR at 35 
and 25 months after transplantation (Liso et al., 2000). 
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The efficacy of DC vaccines in patients with solid tumours has also been tested. Out of 
21 patients with recurrent or metastatic prostate cancer and elevated serum prostatic 
acid phosphatase (PAP) treated with rodent PAP pulsed DC, 10 developed T cell 
proliferative T cell responses against PAP (Fong et al., 2001). Among 16 patients with 
metastatic melanoma receiving peptide or tumour lysates-pulsed DC injected directly 
into lymph nodes, eleven mounted delayed type hypersensitivity responses to peptide 
pulsed DC and two had long lasting CR’s (Nestle et al., 1998). Out of 11 melanoma 
patients being treated with monocyte derived DC pulsed with a HLA-A1 restricted 
MAGE-3 peptide, eight developed a CTL response and some minor tumour regressions 
were observed (Thurner et al., 1999). 
The variable results produced by these trials could be the result of a number of variables 
such as the type and quality of the DC generated, the epitope loading method and the 
dose, route and frequency of vaccination. Therefore whilst the use of DC as a cancer 
vaccine is attractive in terms of their ability to thwart some tumour immune evasion 
mechanisms, there are still a number of technical issues to be resolved before these 
vaccines could be used routinely. 
1.6.7 Strategies to enhance cancer vaccines efficacy 
It is apparent that the hurdles created by evasion of the immune system hamper the 
majority of immune responses generated against a tumour. As discussed previously in 
section 1.5.1 there are a number of tumour-derived factors that can inhibit DC 
maturation and function, therefore the generation and maturation of these cells ex vivo 
can negate this problem. The use of immunomodulatory cytokines, chemokines and 
costimulatory molecules in conjunction with peptide epitope enhancement can also be 
used to improve T cell responses to a particular antigen. 
More recently research efforts have focused on the possibility of circumventing those 
mechanisms that serve to down regulate or attenuate immune responses. Tumours have 
adopted these mechanisms in order to evade immunosurveillance. T cells express 
inhibitory receptors themselves, the most studied of which is CTLA-4; this molecule 
binds to CD80 and CD86 leading to a reduction in T cell activation (Egen et al., 2002). 
Recently anti-CTLA-4 antibodies have been use in the clinic either alone or in 
conjunction with cancer vaccines in order to assess its therapeutic potential (Phan et al., 
2003). A significant number of objective responses were observed in a melanoma trial 
in conjunction with a number of autoimmune side effects, all of which ceased when 
treatment was stopped. 
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Another well studied regulatory mechanism is the CD4+ CD25+ regulatory T cell. These 
cells are induced by antigens, especially in the presence of high IL-2 but their action is 
not antigen specific (Thornton & Shevach, 2000). Either blocking or elimination of 
these cells has been shown to enhance tumour immunosurveillance and improve the 
efficacy of cancer vaccines (Shimizu et al., 1999). In fact concurrent blockade of CD4+ 
CD25+ regulatory T cells and CTLA-4 was found to be synergistic when applied in 
conjunction with a cancer vaccine (Sutmuller et al., 2001). 
A different approach is to try to selectively induce high avidity T cells, which have been 
shown to be more efficient at killing tumour cells and eradicating tumours (Yee et al., 
1999; Zeh et al., 1999). It was recently found that the use of a triad of costimulatory 
molecules (CD80, ICAM-1 and LFA-3) administered concurrently with a vaccine, could 
selectively induce CTL’s skewed toward higher avidity and more effective at killing 
tumour cells (Oh et al., 2003). Indeed, IL-15 expressed by a vaccine was found to 
selectively induce longer lived CTL that may be of higher avidity and more effective 
(Oh et al., 2003). It would seem likely that CD4+ T cell help is crucial in inducing such 
long lived CD8+ CTL, possibly by helper cell stimulation of DC to produce IL-15 when 
they present antigen to CTL (Gett et al., 2003; Janssen et al., 2003; Shedlock & Shen, 
2003; Sun & Bevan, 2003). Thus it would seem that the inclusion of CD4+ T cell 
epitopes in future cancer vaccine formulations might prove critical in order to prevent 
patient relapse.  
1.7 The central role of CD4+ T-cells in anti-tumour immunity 
Early experiments established the crucial role of CD8+ T cells in the recognition and 
eradication of tumour cells. The majority of studies demonstrated tumour regression 
after adoptive transfer of tumour specific CD8+ T cells into tumour bearing mice. 
Immunisation of animals with MHC class I peptides was also shown to induce tumour 
regression; however these models largely ignored the role of CD4+ T cells. When 
adoptive transfer therapies were applied clinically, despite the generation of CTL, 
objective anti-tumour responses were rarely observed (Cormier et al., 1997; Wang, 
2001). In animal models it was seen that CD4+ T cells played a central role in 
orchestrating the immune response against the tumour cells as well as directly 
mediating tumour rejection. In recent studies from this laboratory, it was seen that 
treating mice with established CT-26 tumours using DISC-HSV virus led to regression 
of tumours in about 70% of animals and that both CD4+ and CD8+ T cells were 
important for efficient tumour regression (Ali et al., 2002; Rees et al., 2002). Now that 
the importance of CD4+ T cells is clear, efforts to identify MHC class II restricted 
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peptides have intensified, leading to the discovery of a number of naturally processed 
class II peptides; these could potentially be incorporated into future cancer vaccines in 
conjunction with existing MHC class I peptides (Rojas et al., 2005; Touloukian et al., 
2000). 
Models of CD4+ T cell knockout mice and adoptive transfer of CD4+ T cells have 
clearly demonstrated the ability of CD4+ T cells to mediate tumour rejection without 
CD8+ T cells (Ali et al., 2002; Segal et al., 2002). Studies in severe combined 
immunodeficient (SCID) mice showed that human CD4+ T cells generated from PBMC 
of lung cancer patient could mediate rejection of autologous lung tumour xenografts in 
them despite tumour cells being HLA negative (Egilmez et al., 2002).  Tumour 
rejection by CD4+ T cells was mostly mediated directly by IFN-γ-dependent 
mechanisms, whereas in other models it has been shown to be through the recruitment 
of macrophages and/or eosinophils. IFN-γ has indeed been shown to have pro-apoptotic 
and anti-proliferative effect on tumour cells and was also shown to inhibit angiogenesis 
and by inducing up regulation of MHC class I molecules, making tumour cells more 
susceptible to CTL mediated killing (Assudani et al., 2006). The majority of studies 
suggest that CD4+ T cell mediated tumour rejection is not MHC restricted; however, 
some evidence suggests that CD4+ T cells can recognise tumour cells and lyse them in 
an MHC restricted fashion (Thomas & Hersey, 1998). Independent studies have shown 
CD4+ T cells to directly mediate tumour cell lysis through TRAIL, FasL and granzyme-
perforin dependent pathways, traditionally employed by CTL. However, this is unlikely 
to be the primary role for CD4+ T cells as most tumours are MHC class II negative 
(Assudani et al., 2006). Despite the fact that CD4+ T cells can mediate tumour rejection 
directly on their own, their main role involves orchestrating the immune response 
through CTL, and macrophages and eosinophils in certain cases. 
Clinical trials using adoptive transfer of CTL in cancer patients have also reinforced the 
value of CD4+ T cells. Adoptive transfer of CD8+ T cell clones illustrated that the 
transferred T cells could persist for prolonged periods of time provided that the antigen 
burden was low, however these cells rapidly disappeared if higher levels of antigen 
were present (Yee et al., 2002). Co-transfer of CD4+ T cell help with the CD8+ T cells 
has been shown to prolong the survival of adoptively transferred TIL (Yee et al., 2002). 
Therefore CD4+ T cell help is required for prolonged in vivo survival and expansion of 
tumour reactive CTL ex vivo. Some early work showed that it was possible to isolate 
tumour antigen specific CD4+ T cells from tumour infiltrating lymphocytes in 
melanoma patients (Topalian et al., 1994). Adoptive transfer of unfractionated T cells 
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into patients (CD4+ and CD8+ T cells) has been shown to promote tumour regression 
(Rosenberg & Dudley, 2004; Rosenberg et al., 2004). Such studies indicated that the 
full activation of auto-reactive CD4+ T cells was likely to be an important component 
currently missing from many clinical trials. 
Dudley and Rosenberg have pioneered work in the field of adoptive T cell transfer in 
the clinic. Results from the most recent trials support the notion that CD4+ T cells are 
critical for efficient immunotherapy. In early trials, cloned melanoma reactive T cells 
were adoptively transferred into 13 patients with metastatic melanoma followed by 
administration of IL-2 (Dudley et al., 2001). These transferred cells had high reactivity 
against a number of melanoma antigens when tested in vitro and yet not a single 
objective response was seen in any of the 13 patients. In the second trial, patients with 
metastatic melanoma were given cloned high avidity T cells that were transferred post 
non-myeloablative chemotherapy. This study utilised increasing doses of 
cyclophosphamide and fludarabine in conjunction with IL-2. No objective clinical 
responses were seen in 15 patients tested (Dudley et al., 2002). 
In both trials it was speculated that the poor persistence of the adoptively transferred 
clones was responsible for the lack of clinical responses. As a result the protocol for a 
subsequent clinical trial was modified to administer a heterogeneous population of TIL 
containing both CD4+ and CD8+ T cells. In this ongoing trial 35 patients have been 
treated, 18 of which (51%) have generated an objective clinical response, including four 
patients with a complete response. Thus administration of lympho-depleting 
chemotherapy in conjunction with a minimally cultured heterogeneous T cell 
population may be responsible for this increase in objective response rate. Moreover T 
cells were shown to persist for extended periods of time (up to two years) and this 
persistence correlated with clinical responses (Rosenberg & Dudley, 2004; Rosenberg 
et al., 2004). 
Although CD4+ T cells will undoubtedly prove useful in the clinic, the precise nature of 
T cell help required in order to further improve clinical efficacy of tumour-specific CTL 
is unclear. Is non-specific help, for example virally derived antigen such as Hepatitis B 
core antigen, the most effective way to promote CTL response or would protein specific 
T cell help i.e. the CTL epitope and the helper epitope derived from the same protein 
prove more effective? Preliminary transgenic mouse (C57bl/6-HHD II) studies 
performed utilising human class I p53 peptides in combination with either Hep B or 
mouse class II p53 peptides indicated that the latter was more effective and could boost 
both number and magnitude of CTL responses to a particular antigen in vitro (Horton 
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R, Unpublished data). Theoretically, if a pre-existing response to a class I restricted 
tumour antigen is present then there may also be a class II response to the same antigen. 
By immunising with class I and class II peptides derived from the same protein against 
which there is a prior immune response, it would seem logical that a stronger and 
possibly longer lasting anti-tumour response could be generated. Moreover, the nature 
of the T cell help required could be dependant on the peptides involved, which might 
dictate generation of either a Th1 or Th2 response. It is widely believed that cytokines 
secreted by Th1 cells facilitate CTL generation, whereas a Th2 cytokine profile might 
favour an antibody based response and be detrimental to CTL induction (Nishimura et 
al., 1999). 
Although most studies published to date suggest that CD4+ T cell help is required for 
the generation of memory CTL responses, some studies indicate that they are also 
essential in the priming phase of the CD8+ T cells. The requirement for CD4+ T cell 
help might be dependent on the MHC class I epitope affinity. Franco et al showed that 
peptides with high affinity for their MHC class I molecules did not require CD4+ T cell 
help (Franco et al., 2000). They observed that immunising mice with three different 
high affinity MHC class I epitopes generated CTL, irrespective of T cell help, whereas 
immunisation with subdominant epitopes required CD4+ T cell help for generation of 
CTL; the nature of help required to generate cytotoxic response itself was dependent on 
the class I peptide (Franco et al., 2000). This suggests that the generation of CTL is 
influenced by the period of MHC restricted peptide display on APC, TCR-MHC 
binding affinity/duration and whether or not CD4+ T cell mediated help is necessary. 
The formation of long lasting MHC-peptide-TCR complexes depends upon the binding 
affinity of the peptide and establishes a cross-talk between CD8+ T cell and the APC. 
This ultimately leads to activation of the APC and CTL generation in the absence of 
CD4+ T cell help. However, any conclusions drawn from transgenic mouse models or 
murine adoptive therapy experiments must be considered with caution as such data may 
not be directly applicable in humans. 
In specific circumstances, a primary CD8+ T cell response might be generated 
effectively in the absence of a helper response. In contrast, the memory response to 
secondary challenge upon re-exposure of animals to antigen is defective suggesting a 
critical requirement for CD4+ T cells in the initial memory priming phase (Shedlock & 
Shen, 2003). The requirement for CD4+ T cell help in the generation of optimal CTL 
responses might be dependent upon the antigen and the MHC class I epitope. However, 
because of their ability to enhance the anti-tumour CD8+ T cell response, many believe 
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that the generation of tumour specific CD4+ T cells should be an essential component of 
any clinical trial. 
Recently, it was shown that CD4+ T cells control the generation of memory CD8+ T 
cells via a TRAIL-dependent mechanism. CD8+ T cells primed in the absence of CD4+ 
T cell help, up-regulated TRAIL and upon secondary encounter with the antigen 
underwent activation induced cell death (AICD), whereas those primed in presence of 
help did not up-regulate TRAIL and were able to undergo significant clonal expansion 
on re-encounter of  antigen (Janssen et al., 2005). This potentially represents a complex 
mechanism through which the immune system avoids autoimmunity, as most of the 
CD8+ T cells generated in vivo to self antigens would occur in the absence of help. Thus 
on re-encountering the same antigen, T cells would undergo AICD. This could also 
explain the limited success in generating high affinity cancer antigen-specific CTL, as 
high affinity CTL would undergo AICD. 
It must be remembered that the frequency of naïve antigen specific precursor T cells is 
normally very low, hence, antigen carrying APC encountering such rare antigen-
specific CD4+ T cells and equally rare CD8+ T cells at the same time seems highly 
unlikely, although it has been argued that contact between APC and CD4+ T cells could 
be long lasting, providing sufficient time for the antigen specific CD8+ T cells to 
encounter this complex.  Ridge et al showed that DC can first engage CD4+ T cell and 
the cross talk between them through CD40-CD40L interaction licenses the DC to then 
activate naïve antigen specific CD8+ T cells at a later stage (Ridge et al., 1998). This 
two step model seems more realistic as the rare antigen specific CD8+ and CD4+ T cells 
do not have to come into contact with the few DC carrying the specific antigen at the 
same time. Recently, another two-cell dynamic model has been suggested by Xiang et 
al (2005). Their study reveals that during the initial encounter between antigen carrying 
APC and CD4+ T cells, along with the MHC-class II peptide complex/co-stimulatory 
molecules, CD4+ T cells also acquire the MHC-class I peptide complexes from DC. 
These activated CD4+ T cells can themselves act as APC for the naïve CD8+ T cells by 
virtue of displaying MHC class I peptide complex along with co-stimulatory molecules. 
Moreover, these CD4+ APC were able to effectively generate CTL and anti tumour 
immune response in a murine tumour model (Xiang et al., 2005). It seems possible that 
a number different help mechanisms act synergistically for optimum immune 
activation. Considering the above, it would seem that any cancer vaccination protocol 
unable to generate optimal CD4+ T cell help is unlikely to succeed as many T cells 
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reactive against high affinity epitopes are likely to have been deleted by either central or 
peripheral tolerance mechanisms (Hogquist et al., 2005).  
It is generally believed that tolerance is a consequence of anergy, exhaustion, 
ignorance, peripheral deletion or immunosuppression. Lymphocytes can remain alive 
for a prolonged period of time but become functionally hyporesponsive after antigen 
encounter. This anergy can either be clonal, under a growth arrest state after an 
incomplete activation, or adaptive as proliferation and effector functions are inhibited 
following a lack of co-stimulation or an excess of co-inhibition (Schwartz et al., 1989). 
The involvement of T-regulatory cells (Treg) as part of peripheral tolerance 
mechanisms has further complicated the picture and remains controversial (Ahmad et 
al., 2004). Treg are the major subset of regulatory T cells involved in tolerance against 
tumour cells and tumour immunotherapy; recent developments in the 
control/modulation of Treg may allow boosting of the action of cytotoxic and helper T 
cells against tumour cells. 
The Treg population accounts for 2% to 5% of the total population of CD4+ T cells in 
both rodents and humans and are generally characterised by a CD4+CD25+ phenotype 
(Assudani et al., 2006). They can either be generated naturally following selection in 
the thymus to create an anti-self repertoire or be induced in the periphery leading to 
expression of the CD25 marker upon encounter with immunosuppressive cytokines 
such as IL-10 or TGFβ or both (von Boehmer, 2005). Contrary to mice, CD25 
expression in humans is variable with a report describing a correlation between levels 
of CD25 expression by peripherally-induced Treg and the histological grade of a 
tumour (Talpur et al., 2006). However, another cell-specific marker is now used to 
identify Treg; the transcription factor foxp3. Foxp3 expression is undetectable in other 
lymphoid or non-lymphoid cells and is strongly linked with the immunosuppressive 
activity of natural or adaptive Treg (Chatila, 2005). Foxp3 protein on its own is 
sufficient to induce an immunosuppressive response in mice; however mechanisms in 
humans are more complicated and even the simultaneous injection of two isoforms of 
foxp3 is not enough to completely down-regulate the immune response suggesting that 
other factors such as target antigens are required for the generation of Treg (Allan et al., 
2005).  
Antigen specificities and molecular mechanisms of these Treg are largely unknown. 
Treg may derive from CD4+CD25- T cells which have been converted to CD4+CD25+ 
Treg because of suppressive cytokines present at the tumour site or after direct 
interaction with naturally occurring Treg according to the “infectious” tolerance theory 
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(Assudani et al., 2006). This is subject to controversy as another subset of 
CD3+CD4+CD25- T cells present in the non-adherent fraction of parenchymal 
splenocytes, has been shown to be strongly linked with progression of tumours in an 
established Balb/c colon carcinoma tumour model (Ahmad et al., 2004). Complete 
tumour regression was observed in 70% of mice treated; on the other hand in progressor 
mice, lymphocytes from the parenchymal fraction of the spleen were capable of 
negatively regulating AH-1 peptide-specific CTL against CT26 tumour cells. Contrary 
to the “infectious” tolerance theory developed by Dieckmann and colleagues, relying 
mainly on the secretion of IL-10 by anergised CD4+CD25- T cells to inhibit syngeneic 
CD4+ T cells (Dieckmann et al., 2002), the inhibition of CTL activity by these 
suppressive CD4+CD25- T cells occurred in a cell-to-cell contact dependant fashion 
similar to CD4+CD25+ Treg (M. Ahmad, unpublished results). Treg can deprive 
autoreactive T cells of autocrine IL-2; trigger the activation of the indoleamine 2,3-
dioxygenase in DC via an inhibitory molecule, cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4), causing immunosuppression of T cells; down-regulation of the 
expression of co-stimulatory molecules such as CD80 or CD86 or secrete the 
immunosuppressive cytokine TGFβ following engagement of CTLA-4 (Assudani et al., 
2006).  
Treg have been extensively studied in cancer patients and are mainly present within 
lymphoid tissues. There is also increasing evidence of their presence within peripheral 
blood and tumour-infiltrated lymphocytes. Curiel et al demonstrated the link between 
the presence of Treg in individuals with ovarian cancer and the decrease of tumour-
specific CTL activity coincidental with tumour growth (Curiel et al., 2004). A 
correlation was identified between high infiltration rates of CD4+CD25high cells into 
lymph nodes surrounding gastric tumours, when compared to infiltration of control 
distant lymph nodes, and impaired cell-mediated immunity in cancer patients (Kawaida 
et al., 2005). 
It has been proposed that Treg could be the major reason for failure of immunotherapy. 
Using a CT26 colon carcinoma model in Balb/c mice, depletion of Treg allowed the 
induction of both CD4+ and CD8+ anti-tumoural response. By depleting both Treg and 
CD8+ T cells, CD4+ T cells were also capable of rejecting MHC class II-negative CT26 
tumour cells via IFNγ-dependent anti-angiogenic activity. Restoration of the Treg 
population over time results in repression of the anti-tumour response (Casares et al., 
2003). For example vaccination utilising autologous tumour cells transfected with GM-
CSF was proven to be efficient in some subjects with severe disease such as advanced 
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melanoma, non-small cell lung carcinoma, ovarian carcinoma or myeloid leukaemia. T- 
and B-lymphocytes were found to be densely infiltrated in distant metastases resulting 
in extensive tumour necrosis (Assudani et al., 2006). However, despite obvious signs of 
improved immunity, the majority of vaccinated patients eventually evolved to 
progressive disease (Dranoff, 2002). More recently, a study showed that a CTL 
response was obtained after immunisation of melanoma patients with MHC class I 
peptide- or melanoma tumour lysate-pulsed antigen presenting cells which peaked at 
seven days post-immunisation. The CTL response was then in decline reaching the pre-
vaccine level 28 days after administration of the vaccine. This decrease correlated with 
the expansion of the IL-10-secreting Treg population in post-vaccine peripheral blood 
lymphocytes (Chakraborty et al., 2004). These results in mice and humans emphasise a 
similar role for Treg in both species, which is the maintenance of tolerance and the 
down-regulation of the anti-tumour response. 
The critical issue is to define a balance between maintenance of tissue integrity by 
avoiding autoimmune responses and induction of a potent tumour-specific immune 
response allowing successful tumour therapy. In view of the results reported in recent 
clinical trials, successful control of the Treg population appears to be necessary for 
formulation of an efficient cancer vaccine and generation of a potent long-lasting anti-
tumour response resulting in tumour eradication.  
There have been a number of methods proposed to counteract Treg and figure 1.16 
summarises some of these. Further work is required to clearly identify the different 
subsets of regulatory T cells, understand their interactions with effector cells, clarify the 
molecular mechanisms behind the maintenance of tolerance to tumour cells and boost 
the action of cytotoxic and helper T cells against tumour cells.  
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Figure  1.16: Mechanisms of inhibition of Treg suppressive activity and enhancement of 
cytotoxic and helper T-cell activity. A: Blockade of CTLA-4 using anti-CTLA-Ig. B: 
Reversal of TLR8 using CpG or polyG10. C: Elimination of Treg using the recombinant 
IL-2 diphtheria toxin conjugate DAB389IL-2. D: Blockade of GITR using anti-GITR-Ig. 
E: Production of IFNγ by cytotoxic T cells inhibiting Treg activity following co-
immunisation with SEREX-defined self-antigen and CTL epitope. Any of these five 
mechanisms allows blocking of Treg immunosuppressive activity while immunisation 
with a CTL epitope accompanied with a helper peptide triggers clonal expansion of 
antigenic peptide-specific cytotoxic T cells leading to tumour cell death. 
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1.8 Identification of MHC class II-restricted peptides derived from 
tumour antigens 
Research has focused upon the generation of MHC class I peptides over the last ten 
years; as a result a wide range of epitopes have been identified that could be applied 
clinically. However the importance of CD4+ T cells has now been recognised, thus 
there is a need for tumour immunologists to identify MHC class II restricted epitopes in 
order to improve the efficacy of future cancer vaccines. 
The identification of MHC class II epitopes has been approached in a number of ways. 
In order to streamline the process of peptide identification an indirect strategy known as 
“reverse immunology” was developed and is still in widespread use. In this system, a 
computer algorithm is used to screen the sequence of a tumour antigen for peptides 
containing preferred or tolerated anchor residues for a particular HLA allele. These 
peptides are then given a predicted binding score and can be chosen based upon their 
binding affinity to the desired HLA molecule. The chosen peptides are then tested for 
the ability to elicit peptide specific T cell responses in vitro; the natural processing of 
the parent antigen into these peptides by tumour cells is also investigated (Rojas et al., 
2005). T cells used to test the peptides can either be derived from MHC transgenic mice 
or from PBMC cultured from human blood samples. 
Another method using MHC transgenic mice was described by Touloukian et al in 
2000. In this case mice were immunised with the entire protein of interest, which was 
naturally restricted by processing into a range of peptides and presented to the mouse 
immune system. CD4+ T cell lines were established from the immunised mice. A 
computer algorithm was then employed to predict which sections of the protein used to 
immunise mice with would bind to transgenic DR4 molecules; peptides with a high 
binding score were synthesised and CD4+ T cell lines, in conjunction with splenocytes 
taken from immunised mice, used to test whether or not an immune response could be 
generated. Peptide specific production of IFNγ was judged to be indicative of a positive 
response (Touloukian et al., 2000). One advantage of this method was that the whole 
mutant protein was given to mice so any epitopes produced were naturally restricted, 
however it is uncertain whether the human antigen processing system would restrict a 
protein in the same manner. 
Wang et al (1999) employed a different approach; they generated an easily transfectable 
cell line with the ability to process and present class II restricted antigens to T cells. At 
the same time an Ii fusion library was created, targeting Ii fusion proteins to the 
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endosomal or lysosomal compartment for efficient antigen processing (Wang et al., 
1999). Assembly of the α and β chains of the MHC class II molecules as well as their 
association with the invariant chain (Ii) occurs in the endoplasmic reticulum. A 
targeting sequence in the cytoplasmic tail of Ii is responsible for the transportation of 
nonameric (αβIi)3 complexes from the endoplasmic reticulum to intracellular 
compartments with endosomal or lysosomal characteristics and ultimately into acidic 
endosomal or lysosomal like structures known as MHC class II compartments (Wang et 
al., 1999). Thus the cell line constructed was able to process and present the peptides 
produced by Ii-cDNA’s transfected from the library and was used to test 
immunogenicity by co-culture with CD4+ tumor infiltrating lymphocytes derived from a 
patient intramuscular metastatic lesion. The major advantage of this study was the range 
of cDNA’s that could be tested; the wide range of the library gave the potential for 
discovery of previously unknown immunogenic peptides from a range of different 
proteins, which could be tested against the T-cell lines. 
Halder et al. employed a biochemical approach for the isolation of the antigens for 
screening. In this study endogenous peptides bound to the constitutively expressed 
MHC class II molecules HLA-DR and HLA-DQ of the melanoma cell line FM3 were 
examined. Techniques such as narrow bore and capillary reversed-phase high 
performance liquid chromatography with subsequent spotting on polyvinylidene 
difluoride membranes, matrix assisted laser desorption ionization mass spectrometry 
and Edman microsequencing were able to isolate and identify a panel of self peptides 
from FM3 cells (Halder et al., 1997). Peptides bound to MHC can be eluted directly 
from the surface of tumour cells; following purification of these peptides, mass 
spectrometry can be used to determine isolated peptides of interest/significance. This 
approach has permitted the identification of peptides from the cell surface as well as 
enabling the definition of the molecular interactions between the MHC molecule and the 
peptide to which it is bound (Bjorkman et al., 1987; Clark et al., 2001; Falk et al., 1991; 
Hunt et al., 1992). Unfortunately this method requires large numbers of cells (>2x109) 
in order to facilitate the purification of minority peptide populations from within a 
complex mixture and provides no indication of the immunological relevance of the 
peptides isolated.  
Each of the above methods has advantages and disadvantages and should be employed 
appropriately in order to maximize the information gained within a particular project.  
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1.8.1 Rationale and outline of the study 
Since CD4+ T cells appear to be critical in mediating antitumour responses, this study 
aims to identify new MHC class II restricted peptides derived from melanoma antigens. 
Furthermore, the influence of MHC class II peptides on the generation of a CD8+ CTL 
response will be investigated. Identification of class II peptide targets could aid the 
development of more effective cancer vaccines as well as furthering our understanding 
of the role of CD4+ T cell help in an antitumour setting. It is proposed to combine 
peptide immunogenicity studies using MHC-transgenic mice with a classical reverse 
immunology approach in order to identify “novel” MHC class II restricted epitopes 
from melanoma associated antigens. 
To identify MHC class II restricted responses, HLA-DRβ1*0101 and HLA-DRβ1*0401 
transgenic mice will be immunised with MART-1 and Tyrosinase derived peptides. A 
computer-assisted algorithm generally available via the World Wide Web (SYFPEITHI; 
(Rammensee et al., 1999) will be used for the prediction of peptides binding to the 
HLA-DRβ1*0101 and HLA-DRβ1*0401 alleles. The algorithm is written in Object 
Pascal and works as follows; briefly, a two-dimensional data array is built up, where the 
letters of the amino acids represent the row index and the pocket numbers (within the 
MHC binding groove) represent the column index. The scores in the array matrix can 
then be addressed directly by a pair of indices. Starting at the first amino acid, the 
sequence is divided into peptides of the desired size and for each oligomer the sum of 
the scores for the amino acids contained is calculated. This process is then repeated until 
the end of the sequence is reached. As this program is evidence based, amino acids are 
scored based on their frequency in certain positions; therefore amino acids that are 
commonly found in anchor positions are given the score of ten, those that are rarely 
found in this postion are given a score of six and those that are unfavourable to binding 
given a negative score. In this way all the oligomers present within a sequence can be 
ranked and given a relative score. Peptides with a good binding score from the 
melanoma antigens MART-1 and Tyrosinase will be selected for peptide screening in 
FVB/N-DR1 and C57bl/6-DR4 transgenic mice. DC will be used as antigen presenting 
cells and the optimal conditions to mature DC for antigen presentation will be 
established. Studies will be undertaken to optimise the survival of activated T cells in 
order to facilitate more efficient peptide discovery, thus allowing the identification of 
MHC class II peptides. 
In order to determine whether CD4+ restricted peptides influence the generation of 
CD8+ T cell effectors, experiments will be performed in C57bl/6 HLA-A2 HHD II 
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transgenic mice utilising a panel of pre-existing p53 and HepB peptides. Why use p53 
class I and class II peptides for this study? Existing MART-1 and Tyrosinase class I and 
class II peptides will be available and represent the ideal choice to investigate the 
influence of class II helper peptides on the generation of CTL. This choice was made 
was due to lack of double transgenic mice expressing human MHC class I and human 
MHC class II molecules. The HHD II mice available are transgenic for human MHC 
class I (HLA-A2) but express mouse class II (I-Ab); the MART-1 and Tyrosinase 
peptides to be identified will not be I-Ab restricted and so could not be used in 
conjunction with HLA-A2 restricted MART-1/Tyrosinase peptides in these animals. In 
contrast I-Ab restricted p53 peptides have previously been identified which could be 
used in conjunction with HLA-A2 restricted peptides in order to test if protein specific 
helper epitopes could boost a CTL response. P53 is a self antigen, like MART-1 or 
Tyrosinase, so central and peripheral tolerance mechanisms are liable to act in the same 
manner regardless of the antigen employed in these experiments. Murine and human 
p53 genes are also readily available for cloning into a vector of choice, whereas murine 
MART-1 and Tyrosinase are unavailable without lengthy procedures for cloning the 
genes from murine genomic DNA. Therefore, because both peptides and murine/human 
DNA constructs are available for p53 and not MART-1 or Tyrosinase, p53 will be used 
as a surrogate model self antigen for the study of the influence of MHC class II peptides 
on the generation of a CTL response. The longevity of T cell responses generated by 
various class I and class II peptide combinations will also be investigated; in this way 
the optimal type of T cell help can be determined, which is essential for the formulation 
of future cancer vaccines. 
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2 Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Reagents and list of producers 
Reagents were stored as per manufacturer instructions and used before the expiry date. 
Culture media Company 
DMEM Bio Whittaker Europe 
RPMI Bio Whittaker Europe 
IMDM Bio Whittaker Europe 
  
Supplements to culture media Company 
Foetal calf serum Bio Whittaker Europe 
Glutamine Cambrex 
2-mercaptoethanol Gibco 
Penicillin/Streptomycin Gibco 
HEPES buffer Bio Whittaker Europe 
Fungizone Gibco 
Geneticin (G418) Gibco 
  
Other cell culture reagents Company 
DMSO Acros 
Trypsin Gibco 
Versene Gibco 
Lipopolysaccharide (LPS) Sigma 
DNAase Sigma 
Collagenase Calbiochem 
Polyinosinic polycytidylic acid (Poly I.C) Sigma 
Trypan blue Sigma 
Incomplete Freunds Adjuvant Sigma 
OM-197 OM-Pharma 
  
Molecular grade chemicals Company 
Glycerol Sigma 
Ethanol BDH 
Isopropanol Sigma 
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Plastic ware Company 
24 well tissue culture (TC) plates Sarstedt 
48 well TC plates Iwaki 
96 well (round bottom) TC plates Sarstedt 
T25 TC flasks Sarstedt 
T75 TC flasks Sarstedt 
T175 TC flasks Sarstedt 
Petri dishes (bacterial grade) Sarstedt 
Pasteur pipettes Scientific Laboratory Supplies (SLS) 
25ml pipettes Sarstedt 
10ml pipettes Sarstedt 
5ml pipettes Sarstedt 
1ml pipettes Sarstedt 
Cell scraper Sarstedt 
7ml bijoux Sterilin (SLS) 
15ml tubes Sarstedt 
30ml universal tubes  Sterilin (SLS) 
50ml tubes Sarstedt 
FACS tube Elkay 
1.5ml eppendorf Sarstedt 
0.5ml eppendorf Sarstedt 
0.2µm filters Sartorius 
0.5-10µl tips Sarstedt 
20-200µl tips Sarstedt 
200-1000µl tips Sarstedt 
10ml syringe BD 
Needle Microlance 3 (0.5x16mm) BD 
ELISA plates Costar 
1ml cryovials TPP 
2ml cryovials TPP 
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Kits Company 
ELISA:  
Mouse IL-5 R&D Systems 
Mouse IFN-γ R&D Systems 
Mouse GMCSF R&D Systems 
  
Protein assays:  
Bio-Rad Dc protein assay Biorad 
  
Lymphocyte depletions:  
Mouse CD8: Dynabeads mouse CD8 Dynal 
  
DNA extraction from agarose gel:  
Geneflow DNA isolation kit Geneflow 
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Company Address 
Bio Whittaker Europe Wokingham, UK 
Gibco Paisley, UK 
Sigma Gillingham, UK 
Acros Loughborough, UK 
Calbiochem Nottingham, UK 
MWG Biotech Germany 
R&D Systems Abingdon, UK 
BDH Leicester, UK 
Sarstedt Leicester, UK 
Nunc Loughborough, UK 
Iwaki Stone, UK 
Scientific Laboratory Supplies (SLS) Nottingham, UK 
Elkay Basingstoke, UK 
BD Cowley, UK 
Costar Loughborough, UK 
TPP Switzerland 
Biorad Hemel Hempstead, UK 
Dynal Bromborough, UK 
Promega Southampton, UK 
Fischer Scientific Loughborough, UK 
Serotec Oxford, UK 
Pharmingen Cowley, UK 
Harlan Loughborough, UK 
Diaclone Boldon, UK 
Dako Ely, UK 
Zymed Cambridge, UK 
OM-Pharma Switzerland 
 
 
 
 
 
 
Chapter 2: Materials and Methods 
 82 
2.1.2 Equipment 
 
Equipment Model/Company 
Cryostore Cryo 200, Forma Scientific 
-80°C freezer Ultima II, Revco 
PCR machine PCR Sprint, Thermo Hybaid 
Flow cytometer Epics XL-MCL, Beckman-Coulter 
Microcentrifuge Microcentaur, MSE 
Mikro 22R, Hettich Zentrifugen 
Centrifuge Mistral 1000, MSE 
Mistral 2000R, MSE 
Water bath Y14, Grant 
Cell harvester Filtermate harvester, Packard 
Drying cabinet Scientific Laboratory Supplies 
Safety cabinet Microflow biological safety cabinet, 
Walker 
Incubators CO2 water jacketed incubator, Forma 
Scientific 
Dynabeads separation unit MPC-E-1, Dynal 
Electrophoresis gel tank Mini Protean II, Biorad 
Power supply for electrophoresis Power Pac 300, Biorad 
Transfer Apparatus Trans Blot SD, semi dry transfer cell, 
Biorad 
Microscope Model PIM, World Precision Instruments 
ELISA plate readers Spectraflour, Tecan 
Model 680, Biorad 
Scintillation counter Top Count XP, Packard 
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2.1.3 Cell line description and media 
 
Tumour cell lines 
Name Tumour type HLA of interest Expression of 
tumour Ag of 
interest 
SaOs-2 Osteosarcoma HLA-A2 Transfected with 
p53 273 or p53 175 
NW145 Melanoma HLA-DR4 Mart-1 and 
Tyrosinase positive 
WM852 Melanoma HLA-DR4 Mart-1 and 
Tyrosinase positive 
EL4 HHD II Lymphoblastoma HLA-A2 - 
 
Hybridoma 
Name Specificity Species and Isotype 
FGK-45 Anti-mouse CD40 Rat IgG2a 
L243 Anti HLA-DR Mouse IgG2a 
N418 Anti-mouse CD11c Hamster IgG 
 
Other 
Name Description 
X-63 Myeloma transfected with murine GM-CSF gene 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Materials and Methods 
 84 
2.1.4 Cell line and hybridoma media 
 
Cell line Media Modification Origin 
SaOs-2/175 
DMEM+10% 
FCS+500µg/ml 
G418 
Transfected with 
p53 bearing p53 
175 mutation 
University of 
Sheffield 
SaOs-2/273 
DMEM+10% 
FCS+500µg/ml 
G418 
Transfected with 
p53 bearing p53 
273 mutation 
University of 
Sheffield 
SaOs-2/v 
DMEM+10% 
FCS+500µg/ml 
G418 
Transfected with 
vector alone 
University of 
Sheffield 
FGK-45 
IMDM+4% 
FCS+50µM 2-
mercaptoethanol 
- 
University of 
Leiden 
(Netherlands) 
L243 IMDM + 10% FCS - ECACC 
N418 RPMI + 10% FCS - ATCC 
X-63 IMDM+10% FCS+1mg/ml G418 
Transfected with 
mGM-CSF 
National Institute 
for Medical 
Research, London 
NW145 RPMI + 10% FCS - ESTDAB 
WM852 RPMI + 10% FCS - ESTDAB 
EL4 HHD II RPMI + 10% FCS 
+ 500µg/ml G418 
Transfected with a 
chimeric HLA-A2 
Institute Pasteur, 
France 
 
2.1.5 Primary culture medium 
Culture media was prepared and used within a month. Complete BM-DC media was 
prepared fresh just before use. 
 
Name Composition 
CTL/T cell media RPMI +  
10% FCS + 
20mM HEPES buffer + 
50µM 2-mercaptoethanol + 
50 U/ml penicillin/streptomycin+ 
0.25µg/ml fungizone 
BM-DC media RPMI +  
5% FCS + 
10mM HEPES buffer + 
50µM 2-mercaptoethanol + 
50 U/ml penicillin/streptomycin+ 
0.25µg/ml fungizone 
Complete BM-DC media BM-DC media + required % X63 
supernatant equivalent to 0.1ng/ml 
mGM-CSF 
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2.1.6 Buffers 
Buffers were prepared as indicated below: 
 
Name Composition 
PBS 
Freshly prepared each day 
1 tablet dissolved into 100ml dH2O 
(Oxoid) 
PBA 
Stored at 4°C 
PBS 
0.1% (w/v) BSA (Sigma) 
0.02% (w/v) sodium azide (Sigma) 
TBS 
Stored at room temperature 
10mM Tris (Sigma) 
150mM NaCl (Sigma) 
pH 7.4 
TBS-T 
Freshly prepared prior to each experiment 
TBS 
0.05% (v/v) Tween 20 (Sigma) 
1xTAE 
Freshly prepared from 10x solution 
stored at room temperature 
40mM Tris acetate (Sigma) 
1mM  EDTA (Sigma) 
Sample reducing buffer 
(Western Blot) Stored at room 
temperature 
0.5M Tris HCl (Sigma) 
2% (w/v) SDS (Acros) 
10% (w/v) glycerol (Fischer Scientific) 
1% (w/v) Dithiothreitol (Sigma) 
10x Running Buffer 
(Western Blot) Stored at room 
temperature 
0.25M Trizma base (Sigma) 
2M glycine (Fischer Scientific) 
1% (w/v) SDS (Acros) 
Transfer buffer  
(Western Blot) Stored at 4°C 
48mM Tris (Sigma) 
39mM glycine (Fischer Scientific) 
20% (v/v) methanol 
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2.1.7 Antibodies: anti mouse 
 
Specificity Species Isotype Coupling Dilution Clone Source 
Isotype control rat 
IgG2a 
Rat IgG2a No 1µl LO-DNP-16 Serotec 
Isotype control rat 
IgG2b 
Rat IgG2b No 1µl LO-DNP-1 Serotec 
Mouse CD80 Rat IgG2a No 1µl RMMP-1 Serotec 
Mouse CD40 Rat IgG2a No 
100µl 
supernatant 
FGK-45 
Dr Melief 
(Diehl et al, 
1999) 
Mouse I-A/I-E Rat IgG2a No 5µl 2G9 Pharmingen 
Mouse F4/80 Rat IgG2b No 1µl C1:A3-1 Serotec 
Mouse DEC 205 Rat IgG2a No 10µl NLDC-145 Serotec 
Mouse CD45R Rat IgG2a No 1µl RA3-6B2 Serotec 
Mouse CD62L Rat IgG2a FITC 1µl MEL-14 
BD 
Biosciences 
Mouse CD127 Rat IgG2b RPE 1µl SB/199 
BD 
Biosciences 
Isotype control 
Hamster IgG 
Hamster IgG No 1µl 530-6 Serotec 
Mouse CD11c Hamster IgG No 
100µl 
supernatant 
N418 
ATCC 
HB224 
 
2.1.8 Anti–human 
 
Specificity Species Isotype Coupling Dilution Clone Source 
Human p53 wt Mouse IgG2b No 
1:1000 for 
western blot 
DO-7 Pharmingen 
Human Mart-1 Mouse IgG2b No 
1:250 for 
western blot 
M2-7C10 Biomedia 
Human 
Tyrosinase 
Mouse IgG2a No 
1:500 for 
western blot 
T311 Zymed 
HLA-DR Mouse IgG2a No 
Supernatant 
2µg/ml purified 
L243 ATCC HB55 
Isotype control 
azide free 
Mouse IgG2a No 2µg/ml G155-178 Pharmingen 
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2.1.9 Secondary reagents 
 
Specificity Species Isotype Coupling Dilution Clone Source 
Rat IgG (mouse 
adsorbed) 
Goat - FITC 1:50 Polyclonal Serotec 
Rat IgG (mouse 
adsorbed) 
Goat - RPE 1:25 Polyclonal Serotec 
Mouse IgG Goat - FITC 1:50 Polyclonal Sigma 
Mouse IgG (Rat 
adsorbed) 
Goat - RPE 1:20 Polyclonal Serotec 
Mouse IgG Goat - HRP 1:1000 Polyclonal Dako 
Hamster IgG Goat - FITC 1:50 Polyclonal Serotec 
Streptavidin - - HRP 1:2500 - Zymed 
 
2.2 Methods 
2.2.1 Animals 
FVB/N-DR1 colonies were bred under licence at The Nottingham Trent University 
animal house. FVB/N-DR1 animals were received as a generous gift from D. M. 
Altmann. FVB/N-DR1 F2 mating positive animals were maintained inbred by ensuring 
they have a common F0 ancestor. Mouse class II (I-Ab) knockout C57bl/6 HLA-DR4 
mice were bought from Taconic, USA and bred at The Nottingham Trent University 
animal house in the same manner. C57bl/6 HLA-A2 HHD II transgenic mice were a 
kind gift from the Pasteur Institute, Paris. The HHD II transgenic mice are devoid of 
murine class I, but express a chimeric HLA-A2.1 molecule in which the α1, α2 and β2- 
microglobulin are human and the α3 domain murine. These were bred at the 
Nottingham Trent University animal house in the same manner as other mice. 
2.2.2 Peptide and peptide immunisation 
Peptides (Alta Bioscience) were dissolved in 100% DMSO to a working concentration 
of 10mg/ml and then stored at -80°C. Each mouse was immunised at the base of the tail 
with 100µl of a peptide/IFA emulsion containing 100µg of peptide in incomplete 
Freunds adjuvant (IFA, Sigma). For MHC class II immunisations, two rounds of 
immunisation with the same peptide were undertaken at seven-day intervals. For MHC 
class I peptides only one round of immunisation was required. Table 2.1 below indicates 
the source of the peptides used for immunisation experiments. 
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Peptide Protein of 
origin Sequence 
MHC 
restriction Source 
Mouse 
Strain Reference 
HA307-319 
Influenza 
Haemagglutinin PKYVKQNTLKLAT 
DRβ1*0101 
DRβ1*0401 
University 
of 
Nottingham 
FVB/N-
DR1 
C57bl/6 
HLA-DR4 
Sterkers et al, 
1984 
Mart-129-43 Mart-1 GIGILTVILGVLLLI DRβ1*0101 DRβ1*0401 
Alta 
Biosciences 
FVB/N-
DR1 
C57bl/6 
HLA-DR4 
- 
Mart-151-65 Mart-1 RNGYRALMDKSLHVG DRβ1*0101 DRβ1*0401 
Alta 
Biosciences 
FVB/N-
DR1 
C57bl/6 
HLA-DR4 
- 
Mart-1101-115 Mart-1 PPAYEKLSAEQSPPP DRβ1*0101 DRβ1*0401 
Alta 
Biosciences 
FVB/N-
DR1 
C57bl/6 
HLA-DR4 
- 
Tyrosinase4-18 Tyrosinase AVLYCLLWSFQTASG DRβ1*0101 DRβ1*0401 
Alta 
Biosciences 
FVB/N-
DR1 
C57bl/6 
HLA-DR4 
- 
Tyrosinase147-161 Tyrosinase SDYVIPIGTYGQMKN DRβ1*0101 DRβ1*0401 
University 
of 
Nottingham 
FVB/N-
DR1 
C57bl/6 
HLA-DR4 
- 
Tyrosinase481-495 Tyrosinase AAMVGAVLTALLAGL DRβ1*0101 DRβ1*0401 
Alta 
Biosciences 
FVB/N-
DR1 
C57bl/6 
HLA-DR4 
- 
p53217-225 p53 VVPYEPPEV HLA-A*0201 
University 
of 
Nottingham 
HHD A2 - 
p53264--272 p53 LLGRNSFEV HLA-A*0201 Alta Biosciences HHD-A2 - 
mp53108-122 Murine p53 LGFLQSGTAKSVMCT I-Ab 
University 
of 
Nottingham 
HHD-A2 - 
HepB128-140 
Hepatitis B 
core 
TPPAYRPPNAPIL I-Ab 
University 
of 
Nottingham 
HHD-A2 - 
OM-197217 p53 CERVVPYEPPEV HLA-A*0201 OM-Pharma HHD-A2 - 
OM-197108m Murine p53 CERLGFLQSGTAKSVMST I-Ab OM-Pharma HHD-A2 - 
 
Table  2.1: List and providers of peptides used for immunisation. 
2.2.3 Immunological methods: one step fluorescence activated cell sorting 
(FACS) 
2x105 cells were added to each FACS tube. These were washed twice in PBA by 
centrifuging twice at 400g for 3 minutes at 4°C. The fluorochrome conjugated antibody 
was then added at the appropriate concentration and incubated for 30 minutes on ice in 
the dark. Species matched isotype controls were used for each experiment. Cells were 
washed twice in PBA as above and then finally resuspended in 200-500µl of Isoton 
(BD). Samples were analysed on an Epics XL-MCL (Beckman-Coulter) flow 
cytometer. 
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2.2.4 Two step staining 
2x105 cells were added to each FACS tube. These were washed twice in PBA by 
centrifuging twice at 400g for 3 minutes at 4°C. The primary antibody was then added 
at the appropriate concentration and incubated for 30 minutes on ice in the dark. Once 
again, species matched isotype controls were used in each experiment. Cells were 
washed twice in PBA as above and incubated with the appropriate fluorochrome 
conjugated secondary antibody for 30 minutes on ice in the dark. Cells were washed as 
previously described and resuspended in 200-500µl of Isoton. Samples were analysed 
on an Epics XL-MCL (Beckman-Coulter) flow cytometer by gating on cells that had the 
forward and side scatter characteristics typical of dendritic cells At least 20000 cells 
were run per sample. 
 
2.2.5 Enzyme linked immunosorbent assay (ELISA) 
IFNγ, IL-5 and IL-1β ELISA was performed as per manufacturer’s instructions (R&D 
Systems). ELISA plates were purchased from Costar. Samples were run in either 
duplicate or triplicate and results were read using a 96 well plate reader (BioRad). 
 
2.2.6 Western Blotting: sample preparation 
Greater than 1x107 cells were cultured and harvested at 400g for 5 minutes at 4°. Cells 
were washed twice in serum free media to remove any remaining FCS containing 
media. The cell pellet was resuspended in 1-2ml of distilled water and homogenized for 
30 seconds to break up cell membranes. Following homogenization, lysates were left on 
an orbital shaker at 4°C for a further hour to ensure complete cell lysis. Lysate was then 
centrifuged at 10,000g for 30 minutes and the supernatant containing the proteins 
transferred to a fresh tube. Lysate supernatants were aliquotted into 50µl portions and 
frozen down at -80°C for later use. 
 
2.2.7 Protein assay for SDS PAGE samples 
The protein assay on frozen lysate samples was performed as per manufacturer 
instructions (Bio Rad DC Protein Assay). Standards were made by serially diluting a 
2mg/ml BSA solution in water. Standards were run in duplicate and samples were run in 
sextuplicate. 1:10 and 1:100 dilutions of the neat sample were also tested to ensure 
accurate spectrophotometric measurement. The reaction was left to develop for 15 
minutes and the plate was read at 750nm on a Bio Rad Model 680 microplate reader. 
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2.2.8 SDS PAGE and transfer 
Samples to be run were diluted 1:1 with reducing sample buffer and heated at 95°C for 
5 minutes. Biotinylated molecular weight markers were run with the samples. 10% 
polyacrylamide gels (2.3ml bis acrylamide, 1.8ml 1.5M Tris HCl pH 8.8, 3ml molecular 
grade water, 70µl ammonium persulphate and 7µl TEMMED) were used with a 4% 
stacking gel (1ml bis acrylamide, 1.8ml 0.5M Tris HCl pH 6.8, 4ml molecular grade 
water, 70µl ammonium persulphate and 7µl TEMMED). Samples were run through the 
stacking gel at 100V and through the resolving gel at 150V. Proteins were then 
transferred at 13V onto nitrocellulose membrane for 45 minutes using a semi-dry 
transfer system (BioRad) according to manufacturer instructions. 
 
2.2.9 Western blotting 
Membranes were stained with Ponceau S. The biotinylated marker lane and p53 positive 
control lane were then cut from the rest of the membrane. All membrane sections were 
washed 2 x 15 minutes in TBST to remove the Ponceau S. Membranes were then 
blocked overnight in 5% Marvel milk TBST at 4°C under constant agitation. The 
following day membranes were washed 2 x 15 minutes in TBST. Primary antibody was 
added at 1:1000 dilution in 5% milk TBST to the p53 +ve control lane or 1:500 to the 
lysate lanes (either αMART-1 or αTyrosinase antibody) and incubated for 3 hours at 
room temperature under constant agitation. The membrane containing biotinylated 
marker was incubated for 3 hours with just 5% marvel TBST and no antibody in the 
same way. Once 3 hours had elapsed all membranes were washed 4 x 15 minutes in 
TBST at room temperature. The secondary antibody (HRP conjugated goat anti-mouse 
antibody, Dako) was added to the p53 containing and the lysate containing membranes 
at a 1:1000 dilution in 5% milk TBST and incubated for 2 hours at room temperature. 
The membrane containing the biotinylated markers was incubated for 2 hours at room 
temperature with HRP conjugated-streptavidin (Dako) diluted 1:2500 in 5% milk 
TBST. Membranes were washed 4 x 15 minutes at room temperature in TBST and 
revealed using ECL chemiluminescence kit (Amersham). Hyperfilm ECL (Amersham) 
films were used to detect the luminescence. Films were then developed using an 
Xograph Imaging Systems Compact X4. 
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2.2.10 Murine dendritic cell generation and characterisation:  production of 
mGM-CSF using X63 cells 
X-63 cells were received from the National Institute for Medical Research in London 
and have been engineered to produce murine GM-CSF. The cells were grown to a 
density of 1x106/ml in media containing 1mg/ml of G418 to maintain GM-CSF 
production. Cells were then washed twice in media without G418 and re-suspended at 
2x105/ml in media without the antibiotic. After three days of culture, the supernatant 
was harvested, aliquotted and stored at -20°C. GM-CSF content of the supernatant was 
assessed by ELISA and was typically found to be between 0.2-0.4ng/ml. 
 
2.2.11 Murine BM-DC generation 
The method used was adapted from Inaba et al. Briefly mouse hind limbs were 
harvested and the marrow flushed out the bones with BM-DC media (Complete RPMI + 
5% FCS v/v, 1% glutamine v/v, 0.25µg/ml fungizone, 50U/ml penicillin/streptomycin, 
50µM 2 mercaptoethanol (2ME), 10mM HEPES). Cells were washed once and counted 
in white cell counting fluid (0.6% acetic acid) followed by trypan blue (Sigma) and 
resuspended at 106/ml. Cells were plated out in 24 well plates at 1 million cells per well 
in 1ml BM-DC media + required % of X63 supernatant (contains GM-CSF. Final [GM-
CSF] 0.1ng/ml). On day 2 and day 4, non-adherent cells were washed out by removing 
700µl of media from each well, and 750µl of fresh media added in its place. On day 6/7, 
cells were harvested, counted, and re-plated in 24-well plates at a density of 0.5 million 
per well in 1ml of BM-DC media + X63. 
2.2.12 BM-DC maturation 
BM-DC were matured using different agents. Replating alone was demonstrated to 
induce incomplete maturation; therefore, on day 7, 1µg/ml final concentration of 
lipopolysaccharide (LPS) was added overnight to cells to induce further maturation. 
Alternatively, Poly I.C. was also investigated for its ability to mature BM-DC both in 
conjunction with LPS and alone. The expression of cell surface markers was assessed 
by FACS analysis on fractions of these matured cells. The supernatant of the DC 
cultures was also harvested both before and after overnight incubation with the 
maturing agents for analysis of cytokine production. 
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2.2.13 BM-DC generation for proliferation assay 
BM-DC were prepared as described above with some modifications. On day 7, BM-DC 
were re-plated and incubated with 10µg/ml of the peptide of interest for 4-6 hours. 
Alternatively, DC’s were pulsed for 4 hours with tumour cell lysate. Lysates were 
prepared by water lysis of cells. LPS (Sigma) was then added at 1µg/ml to induce 
complete maturation. The cells were incubated overnight at 37°C, 5% CO2. The 
following day, BM-DC were washed twice in T cell media (Complete RPMI + 10% 
FCS v/v, 1% glutamine v/v, 20mM HEPES, 50µM 2ME, 50U/ml 
penicillin/streptomycin, 0.25µg/ml Fungizone), re-suspended in 2ml and then pulsed 
with 10µg/ml of peptide for 4-6 hours at 37°C, 5% CO2. These cells were plated at 5 x 
103 per well together with the responder cells in a round bottom 96 well plate.  
 
2.2.14 Double staining for FACS analysis of BM-DC phenotype 
Staining steps were done as described in section 2.2.4. A minimum of 2 x 105 BM-DC 
were used per tube. Cells were first stained with rat anti mouse CD45R, CD80, I-A/I-E, 
CD40 and F4/80 followed by the appropriate RPE conjugated goat anti rat secondary 
antibody. After washing, hamster anti-mouse CD11c antibody was added followed by a 
FITC conjugated goat anti-hamster secondary antibody in order to stain the DC. After 
two washes in PBA, cells were resuspended in 300-500µl of Isoton and analysed by 
flow cytometry. 
2.2.15 Splenocyte preparation and in vitro restimulation with peptide 
Spleens from immunised animals were harvested and flushed with T cell media. The 
spleen case was then digested using enzyme cocktail (0.1U/ml DNAase (Sigma) + 
1.6mg/ml collagenase (Sigma)) for 1 hour at 37°C. Fragmentation of the spleen was 
completed by pipetting the digested tissue up and down. The cell suspension resulting 
was then pooled with the flushed cells, washed once and plated out in 24 well plates at 
2.5x106 cells per well in 1ml of T cell media. 10µg/ml of the relevant peptide was added 
to the culture and the splenocytes were then put into culture at 37°C, 5% CO2. In 
parallel, control cultures of splenocytes were set up without peptide or with an irrelevant 
peptide as a control for specific cytokine release. On days 2 and/or 5, 100µl per well of 
culture supernatant was harvested for cytokine analysis. On day 6, splenocytes were 
then used as responder cells in proliferation assays. 
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2.2.16 Murine CD8+ T-cell depletions 
Cells were depleted using CD8+ Dynabeads (Dynal) as per the manufacturer’s 
instructions. CD8+ T cells attached to the beads were depleted using a magnet. The 
remaining cells were then pelleted, washed twice in PBS + 2% FCS and once in T cell 
media and used in subsequent experiments. Purity was ascertained by FACS analysis 
and typically the cells were 98% free of CD8+ T cells. 
2.2.17 Proliferation assay for murine T cells 
Responder cells (i.e. CD8+ depleted splenocytes) were counted and plated at 5x104 
cells per well in round bottom 96 well plates. Peptide-pulsed syngeneic BM-DC were 
used as antigen presenting cells. Responder cells were co-cultured with BM-DC either 
pulsed with the relevant peptide, an irrelevant peptide or no peptide. To ascertain the 
MHC restriction of the response an MHC class II blocking antibody was added to the 
culture. An isotype matched control antibody was also used in these experiments. 
2.2.18 Tritiated thymidine addition and plate harvesting 
Each culture was performed in triplicate or quadruplicate for approximately 60 hours. 
Tritiated thymidine (3H thymidine, Amersham) was added at a final concentration of 
0.037MBq/ml for 16 to 18 hours prior to cell harvesting. Cells were harvested onto a 96 
well UniFilter GF/C plate (Packard) and the plate was left to dry for 1 hour in a drying 
cabinet. 40µl of Microscint 0 (Packard) was added to each well and the plates were 
counted on a Top-Count scintillation counter (Packard). 
2.2.19 MLR reaction: BM-DC versus splenocytes 
BM-DC were prepared as described in section 2.2.11. Day 8 BM-DC from either 
FVB/N DR1 or C57bl/6 mice were used in these experiments. The T cell population 
used as responder cells in this assay was obtained from the non-adherent fraction of 
flushed splenocytes from naïve BALB/c mice. Responder cells were co-cultured with 
BM-DC for 3-4 days before 3H thymidine was added overnight. Each BM-DC to 
allogeneic splenocyte ratio culture was performed in triplicate. 
2.2.20 Splenocyte restimulation with BM-DC 
Splenocytes from immune animals were restimulated after 6 days in culture using 
peptide pulsed BM-DC as APC. Typically 1x106 splenocytes per well were plated in 48 
well plates together with 1x105 peptide pulsed BM-DC. Wherever possible a 1 DC to 10 
splenocyte ration was used. After 1 week, culture reactivity to the peptide was 
reassessed by proliferation.  
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2.2.21 Splenocyte preparation for cytotoxicity assays and in vitro 
restimulation with blast cells 
Splenocytes were harvested from immunised mice as described in section 2.2.5.1 and 
cultured in a 24 well plate at 2.5x106 cells/well in 500µl. To these, 5x105 blast cells 
pulsed with either the relevant or irrelevant peptide were then added in a volume of 500 
µl to give a final volume of 1ml in each of the wells. On day 6 of culture cells were 
harvested and used as effectors in a chromium release assay 
2.2.22 Blast cell preparation 
2 days prior to the harvesting of immunised spleens a naïve spleen was harvested and 
flushed as described in section 2.2.5.1. 1.5x106 splenocytes/ml were put into culture at 
370C, 5%CO2 in T cell media containing 25µg/ml lipopolysaccharide and 7µg/ml 
dextran sulphate in a T75 culture flask. On the day of immunised splenocyte harvesting, 
LPS treated naïve splenocytes were irradiated (3000 rads) and washed twice in T cell 
media. Cells were then counted and resuspended at 20x106 cells/ml and incubated with 
the required peptides for at least 1 hour. Following incubation cells were washed, 
counted and resuspended at 1x106 cells/ml. 500µl of the required peptide pulsed cell 
suspension was then added to each well of splenocytes from immunised mice. 
2.2.23 Target cell culture 
EL4 HHD II HLA-A2 cells were cultured routinely for use in chromium release assays. 
A suitable number of EL4 HHD II cells were passaged into several T25 flasks and 
pulsed overnight with 10µg/ml of relevant or irrelevant peptides as required. The 
following morning cells were harvested and spun down. Cells were resuspended in 
residual media and labelled with 1.85MBq of 51Cr for 1 hour in a 37°C water bath. Cells 
were washed and resuspended in 1ml of serum free media containing a further 1µg/ml 
of peptide. Cells were put back into the 37°C water bath for 45 minutes to allow them to 
rest. A final wash was done and target cells were counted in trypan blue. Cells were 
then adjusted to 5x104/ml and used as targets in a chromium release assay. 
2.2.24 Cytotoxicity assay 
Splenocytes generated as described in section 2.2.21 are referred to as effector cells. On 
day 6 effectors were harvested and cell number adjusted to 5x106 cells/ml. 100µl of 
effectors was added to the first well of a round bottom 96 well plate. In the next well 
100µl of effectors were then serially diluted 1:1 in CTL media. A fixed volume of 
targets was then added to each of these wells to give a range of effector to target ratios 
ranging from 100:1 to 13:1. Each ratio was cultured in either triplicate or quadruplicate.  
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In order to calculate chromium release and therefore a measure of cell killing, the 
potential maximum and spontaneous release was measured and calculated. For 
maximum release 100µl of target cells was added to 80µl of CTL media and 20µl of 1% 
SDS. Spontaneous release was determined by adding 100µl of target cells to 100µl of 
CTL media. 
96 well plates were incubated for 4 hours in a lead box at 37°C, 5%CO2 after which 
time 50µl of the supernatant was harvested onto Luma plates taking care not to disturb 
the cell pellet. Luma plates were then dried over night in a warm air cupboard and 
counted using a top-count gamma counter. 
The specific percentage lysis was calculated using the following formula: 
 
( )
( ) % 100 release sspontaneou- release maximum
release sspontaneoureleasealexperiment
tycytotoxicipercentage
x
−
=  
2.2.25 Molecular biology and cell transfections: construction of murine and 
human p53 vectors 
PCR reaction mixtures were made up in the same manner for both the murine and 
human PCR. Tubes were prepared as follows: 
 
Volume (µl) Constituent 
33.7 Water 
10 5x buffer 
0.8 dNTP’s 
2 Fwd primer 
2 Reverse primer 
1 Template 
0.5 Phusion polymerase 
 
A blank control was always included where the DNA template was replaced with water. 
PCR conditions for murine and human PCR were very similar. The only variable was 
the denaturation and extension temperatures. This was dependant upon the Tm of the 
primers as Phusion polymerase works best at 2°C above the Tm. PCR conditions were as 
follows: 
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Murine PCR 
Step Temperature (°C) Time No. 0f cycles 
Initial denaturation 98 30s 1 
Denaturation 98 10s 35 
Extension 75.5 1min 35 
Final extension 75.5 10min 1 
Pause 4   
 
Human PCR was identical except that denaturation and extension steps were carried out 
at 75.9°C. PCR samples were then run on a 1% agarose gel as described below. 
2.2.26 DNA Separation on Agarose Gels 
A 1% agarose gel was used to run DNA samples. Briefly, 0.5g of agarose was added to 
50 ml of TAE in a conical flask and micro waved until all the agarose had dissolved into 
solution. 5µl of ethidium bromide was then added to the mixture. The gel mixture was 
poured into a tray and allowed to polymerise for at least an hour before use. Once the 
gel had set it was placed into a gel tank with enough TAE to just cover the gel. DNA 
was loaded into the required number of wells with 2µl of Orange G per well to visualise 
how far DNA had run. 2µl of 1kb plus DNA ladder was also run on the same gel to 
allow determination of band sizes. The gel was then run at 65V for approximately 1hr 
30 minutes to allow proper separation of DNA bands. 
2.2.27 Band Extraction of DNA 
DNA was run as described above on a 1% agarose gel. Bands were then visualised by 
placing the gel on a U.V. transilluminator. The DNA of interest was then excised into 
an eppendorf using a scalpel. DNA was then extracted using a Geneflow DNA isolation 
kit as per manufacturer’s instructions. Briefly, 3 volumes of NaI was added to the 
eppendorf containing the gel plug and incubated in a 55°C water bath until the gel was 
completely dissolved. 30µl of a glass powder suspension was then added to the 
eppendorf and incubated at room temperature for 5 minutes with intermittent mixing. 
Following incubation the DNA, now bound to the glass powder, was washed three times 
by micro centrifuging at 14, 000 rpm, discarding supernatant and resuspending the glass 
powder in wash buffer. After the last wash as much supernatant was removed as 
possible and the pellet resuspended in 30µl of option 4 water. DNA was eluted from the 
glass powder by incubation in a water bath at 55°C for 5 minutes. The sample was then 
micro centrifuged at maximum speed for 45 seconds and the supernatant containing the 
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DNA harvested into an eppendorf. Elution was repeated one more time to increase DNA 
recovery by ~15%. 
2.2.28 Enzyme Digestion 
PCR produced a blunt ended product; therefore it was necessary to do a Bam HI, Hind 
III double enzyme digest in order to generate the correct overhangs for ligation. 
Typically 3µl of DNA was incubated in a water bath at 37°C for 2-3 hours with 1µl of 
Bam H1, 1µl Hind III, 1µl 10x BSA, 1µl Buffer E and 3µl of option 4 water in an 
eppendorf. The resulting digest was then run on an agarose gel and band extracted as 
described in sections 2.2.26 and 2.2.27. 
2.2.29 Ligation 
Ligation of p53 genes into the eGFP-N1 was done using T4 ligase (Promega) as per the 
manufacturer instructions. Briefly, 7.5µl of the required p53 insert was added to 1µl of 
Bam H1 Hind III double digested Plasmid with 1µl of T4 buffer and 0.5µl of T4 ligase. 
This mixture was then left at room temperature for four hours in order to complete the 
ligation process. 
2.2.30 Transformation into XL-1B and bulking up 
XL-1B is a specific strain of E.coli used for routine cloning procedures which has been 
rendered competent for nucleotide transformation and then frozen down at -80°C. For 
transformation, a previously prepared aliquot of competent XL-1B was taken and 
defrosted on ice. 10µl of the ligation mix was then added to the XL-1B and incubated 
on ice for 30 minutes. Following incubation cells were heat shocked for 3 minutes at 
42°C in water bath, after which time they were placed back on ice to cool. 500µl of LB 
media was then added and cells were incubated at 37°C in a shaker for 1 hour. During 
the hour incubation, two 30µg/ml kanamycin agar plates were poured and allowed to set 
in a laminar flow hood. 200µl of the transfected cell mixture was then taken and spread 
onto each of the agar plates using a flamed glass spreader. Plates were left on the bench 
for 5 minutes to allow the absorption of media before being inverted and put into a 37°C 
incubator overnight. 
The following morning 10 universals containing 3ml of LB plus 30µg/ml of kanamycin 
were set up. Isolated colonies from the agar plates were then picked using a pipette tip 
and cells were placed in a 37°C shaker to grow overnight. 
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2.2.31 DNA isolation and sequencing 
1.5 ml of each of the overnight cultures, prepared as above, was harvested and the 
bacteria pelleted by centrifuging at 14,000rpm for 5 minutes. Pellets were then 
resuspended in 100µl of cold GTE and incubated for 5 minutes. Following this 
incubation 200µl of 1% SDS/0.2M NaOH was added and the pellets incubated on ice 
for 5 minutes. 150µl of KoAc was added, the samples vortexed and incubated on ice for 
a further 5 minutes. Samples were centrifuged as before and supernatants collected. 
800µl of chloroform-isoamyl alcohol was then added and the samples were vortexed 
then centrifuged as before for 5 minutes. Once again supernatants were collected and 
1ml of absolute ethanol added to each sample. These were then incubated at room 
temperature for 15 minutes. Samples were centrifuged at 14,000 rpm for 15 minutes in 
order to pellet DNA. Supernatants were discarded and the DNA pellets washed with 
500µl of 70% ethanol. Samples were centrifuged at 14,000rpm for 5 minutes and the 
tubes inverted onto tissue paper to dry out the DNA. Samples were then air dried for 30 
minutes. Finally the DNA was resuspended in 50µl of molecular grade water with 
RNAase (final concentration of 20µg/ml).  
2.2.32 DNA transfection of EL4 HHD II 
Lipofectamine 2000 was used to transfect the EL4 HHD II cells as electroporation was 
found to result in very high cell mortality. Transfection was done as per manufacturers 
instructions. The following procedure was used to transfect the adherent EL4 HHD II 
cells in a 24 well plate. Four wells of each transfectant, i.e. eGFP empty vector, eGFP 
mP53 and eGFP hp53 were set up. A day before transfection was done the required 
number of wells were set up with 2x105 cells per well in 500µl of culture media. The 
following day 1µg of DNA was diluted in 50µl of culture media for each well. At the 
same time 2µl of Lipofectamine was diluted in 50µl of culture media for each well. 
Lipofectamine was then incubated for 5 minutes at room temperature. The required 
amounts of DNA and Lipofectamine were combined, mixed and incubated at room 
temperature for 20 minutes. 100µl of the required mixture was then added to each of the 
wells containing cells and medium. Wells were mixed by gently rocking the plate back 
and forth. 24 hours later media in the wells was removed and 1ml of fresh culture media 
was added in its place. Cells were then left to grow to confluency after which time the 
cells were pooled and put into culture in T25 flasks. 
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2.2.33 Creation of stably transfected cell lines 
EL4 HHD II cells transfected with eGFP do not contain a unique mammalian antibiotic 
resistance cassette for cell selection. Therefore 48 hours after transfection, cells were 
harvested from T25 flasks and sorted on a Coulter EPICS MCL/XL for GFP positive 
cells. These were collected into a sterile FACS tube containing growth media without 
G418. Cells were then put back into culture in 24 well plates to bulk up. Repeated 
sorting was performed until cells were highly positive for the GFP containing vectors. 
2.2.34 Novel peptide delivery systems: peptide conjugated beads 
Nanobeads, obtained from Prof. M. Plebanski, were coated with a number of different 
p53 peptides for use in immunisation. The equivalent peptide concentration on these 
beads was 1mg/ml; therefore 100µg of peptide could be delivered in a 100µl nanobead 
immunisation as normal making the results comparable to peptide based experiments. 
Once again all immunisations with nanobeads were performed in exactly the same 
manner as for peptides. 
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3 Chapter 3: BM-DC characterisation in HLA-DR1, DR4 
and HHD II transgenic mice 
3.1 Introduction 
Dendritic cells are specialised antigen presenting cells that have an unrivalled ability to 
initiate a primary immune response; thus an understanding of their biology is central to 
any epitope screening process such as this study. DC’s are a heterogeneous population 
of cells produced in the bone marrow in response to growth and differentiation factors 
such as GM-CSF. There are three stages of differentiation for all DC subtypes: 
precursors, immature DC and mature DC (O'Neill et al., 2004). In human blood there 
exist two types of DC; one set have a monocytoid appearance and are known as myeloid 
DC (MDC), the other set have morphologic features similar to those of plasma cells and 
thus are known as plasmacytoid DC (PDC). MDC and PDC are very different from each 
other; their tissue distribution, cytokine production and growth requirements are all 
dissimilar. PDC have been shown to be important in innate antiviral immunity, they are 
found mostly in blood and lymphoid organs as well as being the principal IFNα 
producing cells in the body. They are also capable of activating antitumour responses 
but their therapeutic potential has been largely ignored as it is extremely difficult to 
obtain large numbers of cells (Fonteneau et al., 2003; Salio et al., 2003). MDC, which 
are the focus of this chapter, are found in a wide variety of tissues where they can be 
classified into two further subtypes; Langerhans cells and interstitial, dermal or 
submucosal DC (Ebner et al., 2004). 
Immature DC’s are involved in antigen uptake, processing and presentation; they 
capture bacteria, viruses, dead or dying cells, proteins and immune complexes via 
endocytosis and pinocytosis. They also have a range of cell surface receptors designed 
to facilitate antigen uptake, many of which are involved in cell signalling or cell-cell 
interactions. DC process these captured antigens into peptides, which are then loaded 
onto MHC class I and II molecules. These are then transported to the cell surface for 
presentation to antigen specific CD4+ and CD8+ T cells (O'Neill et al., 2004) (see 
section 1.3.3). Endogenously processed proteins generate peptides that are loaded onto 
MHC class I molecules in the endoplasmic reticulum whereas exogenously derived 
antigens are degraded into peptides in endosomes and loaded onto MHC class II 
molecules (O'Neill et al., 2004). Exogenously derived antigen can also be “cross 
presented” on MHC class I, which allows DC to generate both CD4+ and CD8+ T cell 
responses to exogenous antigen (Fonteneau et al., 2002). 
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The maturation of DC’s is a terminal differentiation step that transforms them from cells 
specialised for antigen uptake and processing into cells specialised for T cell 
stimulation. DC maturation can be induced by pathogen products or by host 
inflammatory responses/tissue damage. These are often collectively termed “danger 
signals” (Matzinger, 2002). Once the cells have matured, phagocytic uptake is reduced 
in conjunction with development of cytoplasmic extensions, migration to lymphoid 
tissues and it enhances DC ability to activate T cells. Maturation signals act on DC’s via 
a number of receptors that initiate intracellular signalling including CD40L, TNFα, IL-
1, and IFNα. Microbial products and protein released by damaged host tissues elicit DC 
maturation via Toll-like receptors (TLR’s), a family of trans-membrane receptors. Thus 
far 11 TLR’s have been defined, each with its own individual expression pattern and 
recognising differing molecules (O'Neill et al., 2004). TLR’s act through MyD88, which 
initiates a signalling cascade activating NFκB and MAP kinases, inducing gene 
expression of inflammatory cytokines such as TNFα, IL-1 and IL-6 (Kopp & 
Medzhitov, 2003). In DC’s the signalling pathways triggered can influence the type of T 
cell response generated, therefore TLR agonists can be used to target particular DC 
subsets and generate desired T cell responses (Agrawal et al., 2003). 
Once DC are fully matured they have an enhanced ability to present peptides in the 
context of MHC class I and class II as well as enhancing cross presentation. Adhesion 
and costimulatory molecule expression is also up regulated in conjunction with 
induction of cytokine/chemokine secretion, all of which are essential for the formation 
of the immunological synapse and recruitment of further monocytes, DC’s and T cells 
to the tumour site. Lastly, maturation confers the ability for DC’s to migrate from the 
tissue of origin to lymph nodes. This is mediated via DC chemokine receptors such as 
CCR1, 5 and 7 (O'Neill et al., 2004). 
DC’s prime T cell responses in the secondary lymphoid organs such as the lymph 
nodes, spleen or mucosal lymphoid tissues (Bousso & Robey, 2003). Once naïve T cells 
have been effectively primed they undergo clonal expansion and differentiation into 
memory cells and cytokine secreting effector cells. The strength of the T cell responses 
generated is dependant upon a number of factors: antigen concentration on the DC, 
affinity of the corresponding T cell receptor for the peptide loaded MHC (pMHC), the 
state of DC maturation and the type of maturation stimulus (Gett et al., 2003). To 
illustrate this, T cell stimulation by immature DC’s leads to initial T cell proliferation 
but only short term survival, whereas stimulation by mature DC results in long term 
survival and differentiation into memory and effector T cells (Gett et al., 2003). Once 
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primed the enhanced survival of T cells, known as T cell fitness, is characterised by 
resistance to cell death in the absence of cytokines and responsiveness to the 
homeostatic cytokines IL-7 and IL-15, which enhance T cell survival in the absence of 
antigen (van Stipdonk et al., 2003). 
Recently it has been reported that CD4+ T cell help is required at the time of priming in 
order to generate CD8+ T cell memory; this effect is thought to be mediated by 
CD40/CD40L interactions between CD4+ T cells and DC’s (Schoenberger et al., 1998). 
Other T cell surface proteins are involved in the generation of long lived T cell 
responses/memory and have corresponding ligands that are present on activated DC’s. 
For example, members of the TNF receptor superfamily such as OX40 and 4-1BB, 
which may be critical for both the initiation and maintenance of long lived T cell 
immunity (O'Neill et al., 2004). 
As a result of the importance of DC’s in the priming of an immune response it is vital 
that they are fully characterised in order to ensure the desired effect is achieved. It has 
been shown that antigen presentation by immature DC can lead to tolerance; this can be 
achieved via abortive proliferation and anergy of antigen specific T cells, whereas 
mature DC induce a full effector T cell response (Bonifaz et al., 2002; Steinman et al., 
2003). Immature DC’s are also capable of mediating tolerance through the induction of 
CD4+ and CD8+ Treg that suppress the immune system via secretion of IL-10 and 
TGFβ. This is in contrast to naturally occurring Treg that regulate immunity in a cell-
cell contact dependant manner (Jonuleit & Schmitt, 2003; Sakaguchi, 2003). Mature 
DC’s are capable of inhibiting Treg cells via the secretion of IL-6 and surface 
expression of CD40 may be an important factor in determining whether T cell priming 
results in effective immunity or suppression. Those antigen experienced DC’s that lack 
CD40 prevent T cell priming, suppress previously primed immune responses and induce 
IL-10 secreting CD4+ T cells (O'Neill et al., 2004). 
In mice DC’s can be generated from either blood or from bone marrow, however the 
yields of cells are very different. Approximately 1 million cells can be produced from 
blood samples; however DC’s generated from bone marrow flushed from mouse hind 
limbs yields approximately 5 million or more DC’s (Inaba et al., 1992a; Inaba et al., 
1992b). Inaba and co-workers stated that MHC class II rich DC’s can be generated from 
bone marrow, although marrow itself lacks mature DC’s; therefore a method of culture 
was developed in order to generate large numbers of mature DC’s. Firstly bone marrow 
was flushed out of the mouse tibia and femur; the red blood cells were then lysed and 
MHC class II positive cells depleted. The remaining cells were then cultured with GM-
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CSF. Repeated cell washes were performed in the first 2-4 days in order to remove 
granulocytes; this left behind loosely attached proliferating clusters of cells. After 
approximately 4-6 days these clusters were removed, isolated by sedimentation and 
upon re-culture in medium containing GM-CSF, large numbers of DC’s were released. 
These cells were easily identified as DC’s by their cellular morphology and antigen 
repertoire determined by monoclonal antibody staining (Inaba et al., 1992a) and they 
were found to be capable of eliciting strong responses in mixed lymphocyte reaction 
experiments (Inaba et al., 1992a). 
For the purposes of the present study DC’s were generated from mouse hind limbs, 
rather than from blood, according to the basic method as described by Inaba et al 
modified to generate BM-DC from HLA-DR1, DR4 and HLA-A2 transgenic mice. 
Since these cells were to be used as antigen presenting cells for in vitro assays it was 
deemed essential to fully characterise these cells for cytokine production, surface 
molecule expression and to optimise protocols for maturation of DC’s derived from 
each transgenic mouse strain in order to provide appropriate culture conditions for 
detecting MHC-peptide responses. 
   
Chapter 3: BM-DC characterisation 
 104 
3.2 Results 
3.2.1 Phenotypical characterisation of BM-DC from FVB/N-DR1, 
C57bl/6-DR4 and C57bl/6 HHD II mice 
3.2.1.1 BM-DC are generated upon culture of bone marrow cells with 
mGM-CSF 
BM-DC were produced using a modified version of Inaba’s method (Inaba et al., 
1992a). Briefly, mouse hind limbs were harvested and the marrow flushed out with DC 
media. Cells obtained were then cultured in the presence of GM-CSF for 7 days in 24 
well plates. Non-adherent cells were removed by gentle washing on days 2 and 4, with 
75% of fresh GM-CSF containing media being replaced in each well. On day 7, the non 
adherent cells were harvested and replated with LPS to induce maturation. Fractions of 
these cells were collected on days 0, 3 and 8 and analysed by flow cytometry for the 
expression of cell surface markers for DC (DEC205 and CD11c) and B cells (CD45R) 
(see chapter 2 section 2.2.4 for further details).  
It can be seen that by day 8, after two washes and replating, that DC’s represent the 
dominant cell population in the culture (Fig 3.1 A). As CD11c levels increased it was 
observed that DEC205 expression levels decreased; this was particularly clear on day 8 
and is likely to be due to cell maturation and down regulation of expression of “antigen 
uptake receptors”. Concurrent with changes in cell surface marker expression, 
morphological differences were also observed between immature cells and day 8 mature 
cells (Fig 3.1 B and C respectively); immature DC had a rounded shape whilst mature 
cells became more flattened with extensive dendrites resulting in a massive increase in 
surface area. 
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Figure  3.1: (A) Percentage of cells positive for B cell and DC surface markers. On day 
0, 3 and 8, non adherent cells were stained for cell surface markers on DC (DEC205, 
CD11c) and B cells (CD45R). By the end of the culture DC’s represent the majority cell 
type in the culture. This is a representative result showing expression patterns across all 
mouse strains. Morphological differences can be seen between immature (B) and mature 
DC (C). At least 20,000 cells were run through FACS. 
3.2.1.2 BM-DC generated from all mouse strains express MHC II and 
costimulatory molecules 
The expression levels of the costimulatory molecules CD40 and CD80, MHC class II 
molecules and the DC adhesion molecule CD11c were assessed by flow cytometry of 
dendritic cells on days 8, 9 and 10 of in vitro culture (Fig 3.2).  
Expression of CD11c was observed on days 8, 9 and 10, although DC expression levels 
of CD11c were found to decrease after day 8 indicating that these cells were dying upon 
prolonged culture (Fig 3.2). It was also consistently observed that day 8 DC expressed 
higher levels of CD40, CD80 and MHC class II molecules than on earlier days (results 
not shown). In contrast, by day 10 expression levels of all surface molecules and cell 
counts have decreased markedly, suggesting that the cells are reaching the end of their 
life span. 
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Figure  3.2: Cell surface marker expression on BM-DC on day 8, 9 and 10. BM-DC 
generated from all transgenic mouse strains were stained for CD11c, I-A (murine MHC 
class II), CD80 and CD40 on day 8, 9 and 10. The black line represents staining with an 
isotype control antibody and the red line shows staining for the cell surface marker 
under test. Day 8 BM-DC expressed the highest levels of costimulatory molecules. 
These results are representative data of four experiments in all transgenic strains with at 
least 20,000 cells analysed per sample. 
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3.2.2 Phenotypical characterisation of BM-DC following maturation with 
LPS, Poly I.C. or LPS + Poly I.C. 
Although it is possible to generate functional DC’s from all three transgenic mouse 
strains in exactly the same manner it was postulated that an improvement in peptide 
epitope screening might be engendered by the use of strain specific DC maturation 
protocols. As such, DC’s from each transgenic mouse strain were generated and then 
subjected to three different maturation agents; LPS, Poly I.C. and a combination of the 
two. Surface molecule expression patterns and cytokine production from all three 
transgenic mouse strains was then compared in order to elucidate an optimal DC 
maturation protocol. 
3.2.2.1 Strain specific differential marker expression is observed on 
maturation 
Day 7 BM-DC were replated in the presence of LPS, Poly I.C. or a combination of LPS 
+ Poly I.C. After overnight culture, DC’s were harvested and expression levels of 
CD40, CD80 and HLA-DR/A2 were quantified by FACS analysis of in FVB/N-DR1, 
C57bl/6-DR4 and C57bl/6-HHDII transgenic BM-DC. Cells derived from three mice of 
each strain were tested and the results averaged. Although these results did not reach 
statistical significance (as tested by Mann Whitney U) there was a strong trend; in DR1 
mice Poly I.C was clearly able to elicit the highest levels of costimulatory molecule 
expression; however, in the C57bl/6-DR4 mice a combination of both LPS and Poly 
I.C. induced maximal levels of costimulatory molecules. C57bl/6 HHD II transgenic 
BM-DC’s were also able to respond well to the combination of LPS and Poly I.C. 
(Figure 3.3). It can be noted that the BM-DC’s derived from the two types of transgenic 
mice created from the same background responded to maturation stimuli in a very 
similar fashion, whereas those derived from the FVB/N strain behaved differently, 
emphasising the need to fully characterise murine BM-DC culture conditions prior to 
use. 
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Figure  3.3: Differential surface marker expression by transgenic murine DC’s. Day 8 BM-DC’s from the three transgenic mouse strains were stained for CD40, 
CD80 and HLA-DR/A2 expression. In DR1 mice Poly I.C. induces the highest levels of costimulatory molecules whereas the two C57bl/6 based transgenic mice 
responded better to the combination of both LPS and Poly I.C. These results are the average values of three experiments with at least 60,000 cells analysed in total. 
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3.2.2.2 IL-1β production by BM-DC following maturation 
Culture supernatants were collected from day 7 BM-DC and these cells were replated in 
the presence of LPS, Poly I.C. or a combination of LPS + Poly I.C. After overnight 
culture a second supernatant sample was taken. IL-1β levels in these culture 
supernatants were then quantified by ELISA analysis on samples from FVB/N-DR1, 
C57bl/6-DR4 and C57bl/6-HHDII transgenic BM-DC. 
Day 7 BM-DC from all transgenic mouse strains failed to produce significant levels of 
IL-1β; this was consistent with the DC’s being immature at this stage. However it was 
clear that the addition of any type of maturation agent was able to elicit IL-1β 
production by BM-DC from all mouse strains, although strain specific differences were 
observed. In DR1 mice Poly I.C. was only able to induce low level production of IL-1β, 
whereas LPS and the combination of LPS + Poly I.C. elicited high levels of IL-1β 
(Figure 3.4). In DR4 mice Poly I.C. alone and the combination of LPS + Poly I.C. was 
only able to elicit low levels of IL-1β; however LPS was able to initiate higher levels of 
IL-1β. It is interesting that the level of IL-1β produced by DR1 BM-DC is double that 
of the DR4 BM-DC generated under the same conditions (Figure 3.4). Finally, the HHD 
II DC’s produced little IL-1β in the presence of Poly I.C. but generated large amounts in 
response to both LPS alone and LPS + Poly I.C. Despite sharing the same murine 
genetic background, HHD II DC’s produced double the amount of IL-1β than DR4 
DC’s produced under the same conditions. 
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Figure  3.4: IL-1β production by day7 and day8 DC’s from all three transgenic mouse 
strains. BM-DC were cultured overnight in the presence of a number of maturation 
stimuli, IL-1β production was then assessed by ELISA analysis of culture supernatant. 
These data are representative of three experiments and were highly reproducible. For all 
mouse strains, n = 3 and significance was determined using a paired T test 
 
These data collectively demonstrate that strain specific DC maturation protocols are 
required in order to generate optimal costimulatory molecule expression and cytokine 
production. 
 
* P = 0.01 
** P = 0.007 
* P = 0.043 * 
P = 0.038
 
* P = 0.011 
** P = 0.007 
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3.3 Discussion 
BM-DC were generated utilising a method modified from an original paper by Inaba 
and co-workers (Inaba et al., 1992a). This modified protocol did not employ the 
depletion of erythrocytes, MHC class II positive cells, granulocytes or lymphocytes 
from the bone marrow culture as described in the original paper, since it has been 
demonstrated that the depletion of MHC class II positive cells can lead to a reduction in 
the final yield of dendritic cells due to some DC precursor cells expressing MHC class 
II molecules (Lutz et al., 1999). This study showed that following a week of culture in 
the presence of GM-CSF with washing on days 2 and 4 allowed the CD11c positive DC 
population to become dominant within the culture. The expected morphological changes 
also occurred with the rounded DC precursors becoming mature dendritic cells with 
extensive dendrites (Figure 3.1) 
A previous study showed that the DC culture is contaminated by granulocytes; 
supernatant washes on days 2 and 4 were shown to remove these cells effectively. In 
this study it was demonstrated that BM-DC could be produced from DR1, DR4 and 
HLA-A2 transgenic mice; after maturation with LPS all strains produced optimal 
marker expression on day 8 of culture with cells beginning to die by day 10 (Figure 
3.2). 
On average, 10-12 x 106 day 7 DC’s could be generated from all strains of transgenic 
mice; recovery on day 8 after overnight replating was typically 40%, 4-5 x 106 day 8 
DC were generated from each BM harvest. This proved to be more than sufficient to 
provide DC’s for use in proliferation assays at 5 x 103 DC’s per well. 
Although DC’s can be generated in the same manner from all transgenic mice it was 
thought necessary to characterise the response of FVB/N-DR1, C57bl/6-DR4 and 
C57bl/6- HHD II BM-DC to LPS and Poly I.C. to ensure that the best T-cell activation 
profile could be obtained. BM-DC were subjected to a number of maturation treatments, 
LPS alone, Poly I.C. alone and LPS + Poly I.C. Supernatant samples were taken for 
later IL-1β ELISA analysis and expression levels of CD80, CD40 and HLA-DR/A2 
were monitored by FACS.  
When culturing BM-DC with LPS and Poly I.C. alone or in combination various strain 
specific responses were seen. It was demonstrated that FVB/N-DR1 and C57bl/6-DR4 
BM-DC responded best when matured with only LPS. However the C57bl/6 HHD II 
BM-DC produced maximal IL-1β and co-stimulatory molecule expression in response 
to the combination of LPS and Poly I.C. (Figure 3.4). 
The striking differences observed between the three mouse strains in terms of IL-1β and 
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costimulatory molecule expression highlights the need to characterise the cellular 
responses to different maturation agents. However it is unclear why differences 
occurred between FVB/N-DR1, C57bl/6-DR4 and C57bl/6-HHD II mice with regard to 
both IL-1β production and surface marker expression or why is it that the use of LPS + 
Poly I.C. does not induce a significantly greater increase in IL-1β production or surface 
marker expression than LPS or Poly I.C. alone. 
It is certain that there exists a difference in immune responses when comparing mice of 
differing background (Koster et al., 1986). In this system it is possible that the 
transgenes themselves may have an effect on the maturation behaviour of the BM-DC 
due to knock-outs/insertions.  
LPS and Poly I.C. are liable to intersect on the same signalling pathway as both of these 
are bound by toll like receptor (TLR) family members (Bendelac & Medzhitov, 2002). 
If separate signalling pathways do not exist then it is likely that multiple gene activation 
signals sent down the same signalling pathway would not have a cumulative stimulatory 
effect, hence the lack of a significant increase in IL-1β and marker expression when 
LPS + Poly I.C was used to mature BM-DC. 
This initial study has resulted in a standardised method for the production of FVB/N-
DR1, C57bl/6-DR4 and C57bl/6-HHD II murine BM-DC for use in T cell proliferation 
assays. Such optimisation of DC’s is essential to ensure that any peptide screening 
process is as efficient as possible.  
 
Chapter 4: Peptide identification and Vitamin E 
 113 
4 Chapter 4: Identification of novel immunogenic HLA-
DR1/DR4 restricted peptides from tumour associated 
antigens using HLA DR1/DR4 transgenic mice and the use 
of Vitamin E 
4.1 Introduction 
As discussed in chapter 1, CD4+ T cells play a central role in adaptive immunity and in 
an antitumour response. These cells govern antigen specific immunity by either 
inducing a Th1 or a Th2 response, which induce a CTL or B cell response respectively 
(Fig 4.1). Since tumour cells can be considered as altered self cells they are usually 
destroyed by CTL capable of recognising the altered or over expressed self antigens 
displayed on the surface of tumour cells. Therefore it is generally thought that the 
development of a Th1 antitumour CTL response is likely to be more effective in 
inducing tumour regression. 
Although CD8+ T cells are important in the clearance of a tumour mass the role of the 
CD4+ T cells should not be underestimated. For example, the depletion of CD4+ T cells 
by antibodies or the use of CD4-knockout animals has demonstrated that these helper 
cells are essential for the induction of antigen specific CD8+ T cell responses (Ali et al., 
2000; Hung et al., 1998). CD4+ T cells recognise antigen on the surface of DC’s and in 
turn activate other antigen loaded DC’s. Once activated, these DC’s become competent 
to prime CTL’s that recognise an MHC class I epitope presented on the same DC. 
Therefore activation of APC’s by CD4+ T cells via antigen specific recognition and 
CD40-CD40L interaction is essential in the priming of CTL’s (Bennett et al., 1998; 
Ridge et al., 1998; Schoenberger et al., 1998). The lack of such properly activated DC’s 
in the absence of T helper cells can lead to CD8+ T cell tolerance rather than an 
antitumour response. 
In addition to their role in CTL priming, CD4+ T helper cells are also essential for the 
maintenance of CTL effector function by secreting cytokines such as IL-2, required for 
CD8+ T cell growth and proliferation, as well as initiating T cell differentiation into 
memory cells via secretion of IL-7 and IL-15 (Shedlock & Shen, 2003; Sun & Bevan, 
2003; Wang, 2001). 
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Figure  4.1: CD4+ T cells play a central role in regulating the host immune responses 
through the following mechanisms. (a) CD4+ T cells provide crucial help in the priming 
of CD8+ T cells via activation of antigen-presenting cells (APCs). (b) CD4+ T cells 
secrete cytokines required for maintaining CD8+ T cell function and proliferation. (c) 
CD4+ T cells can inhibit tumor growth directly or indirectly e.g. TNF release or direct 
cytotoxicity. (d) CD4+ T cells provide help for B-cell activation. Thus, both CD8+ T 
cells and antibody production require the crucial help of CD4+ T cells (Wang, 2001). 
 
It has been shown in adoptive transfer experiments that CD4+ T helper cells are capable 
of mediating tumour regression in the absence of CD8+ CTL (Mumberg et al., 1999). 
Their importance has also been highlighted in a number of other models (Ali et al., 
2002; Egilmez et al., 2002), including those utilising CD4 knockout animals that 
consistently failed to control tumour outgrowth (Hung et al., 1998). The majority of 
tumours do not express MHC class II molecules; CD4+ T-cell-mediated antitumour 
immunity does not require direct contact between T cells and tumour. There are a 
number of mechanisms by which CD4+ T cells mediate tumour eradication, several 
studies suggest that cytokines such as IFNγ that are secreted by CD4+ T cells are 
involved in antitumour and anti-angiogenic activities in conjunction with direct killing 
via trail mediated apoptosis (Mumberg et al., 1999; Qin et al., 2003). Other studies have 
proposed that CD4+ T cells eliminate tumours through activation and recruitment of 
effector cells including macrophages and eosinophils (Gjertsen et al., 1996; Greenberg, 
1991; Mumberg et al., 1999). 
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Due to the central role that CD4+ T cells play in immunity and the influence they exert 
over CD8+ CTL it seems critical to include both class I and class II epitopes in any 
future vaccine strategy in order to maximise the therapeutic impact. Therefore a 
research priority should be the identification of MHC class II epitopes for as many 
cancer types as possible. 
There are a number of different strategies for the identification of MHC class II 
epitopes: reverse immunology involving the use of computer algorithms to predict 
potential peptides that may bind to a particular MHC; the use of transgenic mice to 
generate T cell lines that can then be tested for peptide specificity; creation of a cell line 
expressing tumour antigen Ii fusion libraries in conjunction with TIL reactivity testing; 
and the direct elution of peptides from the cell surface followed by mass spectrometry 
sequence analysis (Halder et al., 1997; Rojas et al., 2005; Touloukian et al., 2000; Wang 
et al., 1999). Each of these techniques has advantages and disadvantages both in terms 
of cost and the speed of the process. However for the purposes of this study a reverse 
immunology approach in conjunction with the use of transgenic mice was thought to be 
most appropriate. 
The web based computer assisted algorithm SYFPEITHI was used to predict 15mer 
epitopes that could potentially be immunogenic in the context of both HLA-DR1 and 
HLA-DR4; this would maximise the clinical potential of any immunogenic peptides 
discovered (http://www.syfpeithi.de/home.htm). In this respect, the repertoire of 
peptides to test was rapidly reduced to those that might be of potential interest. Previous 
studies within our laboratory have demonstrated that the predictive ability of the 
SYFPEITHI program is approximately 60%; therefore relative confidence can be placed 
in the system. When a peptide epitope is produced by the program it is given a score out 
of a possible maximum of 36, it is thought that the minimum desirable score for a 
peptide of interest should be 20 as this represents optimal binding by the two critical 
anchor residues within the peptide. Very high scoring peptides are usually avoided as 
these epitopes are derived from self antigens, hence immune tolerance could be an 
issue. 
Once a group of peptides has been selected they are used to immunise transgenic mice 
in order to ascertain immunity. T cells harvested from murine spleens can be co-
cultured with peptide pulsed dendritic cells in a proliferation assay to investigate if the 
peptide is capable of initiating a CD4+ proliferative response. Any peptides able to elicit 
a response can then be taken on for further testing to determine if the epitope is liable to 
be produced by natural processing of the parent antigen. In the case of this study, 
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MART-1 and Tyrosinase were the candidate antigens chosen for peptide screening in 
this manner. There is evidence that a reasonable level of immunity to these self-antigens 
exists even in healthy donors (Halder et al., 1997; Takeuchi et al., 2003); thus it should 
be possible to boost this existing immunity in order to eradicate a tumour. Due to only a 
small number of MHC class II restricted peptides being identified for MART-1 and 
Tyrosinase it was thought worthwhile to define further MHC class II restricted epitopes 
for these two MAA in order to boost future vaccine efficacy.  
The success of an immune response is not solely due to the immunogenicity of a 
peptide. Reactive oxygen species produced under chronic inflammatory conditions can 
severely impair the immune system; long standing and acute exposure of T cells to 
oxidative stress leads to the loss of transcription factor activity and reduced cytokine 
production in response to antigen stimulation (Flescher et al., 1998). Oxidative stress 
can also interfere with other signal transduction pathways leading to inhibition of T cell 
proliferative responses to IL-2 (Bingisser et al., 1998) and as a result can impact on the 
efficacy of an immune response in cancer patients via inhibition of the 
activated/memory T cells (Malmberg et al., 2001). Since this situation occurs in vivo 
then it is likely that radical build up in T cell culture could impact upon proliferation 
assay results when screening for peptide immunogenicity in vitro. 
Vitamin E acts as an antioxidant in vivo and neutralises radicals that would otherwise do 
damage to tissues. In particular the action of vitamin E against H2O2 induced stress is 
important. H2O2 has been linked with a reduction in production of T cell effector 
cytokines, including IL-2, IFNγ and TNFα, in activated and memory T cells leading to 
tolerance of potentially immunogenic epitopes and the effect appears to be mediated by 
interference in the NF-κB signalling pathway, known to regulate the production of these 
cytokines (Malmberg et al., 2001). 
The in vivo influence of vitamin E was demonstrated in patients with advanced 
colorectal cancer that were given, prior to chemo or radiotherapy, a daily dose of 750mg 
of vitamin E for a period of two weeks. This led to an increase in patient CD4:CD8 
ratios and enhanced the capacity of their T cells to produce IL-2 and IFNγ. In ten of the 
twelve patients tested an increase of 10% or more (average 22%) in the number of T 
cells producing IL-2 was seen after the two week regimen of vitamin E (Malmberg et 
al., 2002). Therefore if the addition of vitamin E was able to elicit such effects in a 
complex in vivo environment then it would seem logical that it might be able to improve 
T cell survival and proliferation in vitro. Hence vitamin E was included in culture media 
in order to ascertain if any improvements in peptide screening could be gained. 
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4.2 Results 
4.2.1 Addition of Vitamin E to T cell cultures: determination of optimal 
concentration 
 
The findings of Malmberg et al in 2001 prompted the investigation of the potentially 
beneficial effects that the addition of vitamin E may have on in vitro T cell culture 
(Malmberg et al., 2001). A range of vitamin E concentrations were titrated using a 
FACS based assay in order to determine the optimal level for reducing T cell stress. 
Dihydrodichlorofluoresceindiacetate (DCFDA) is a chemical compound that fluoresces 
at the same wavelength as FITC when it becomes oxidised, thus when hydrogen 
peroxide and its associated radicals build up in T cell culture over a week then DCFDA 
would become oxidised. Therefore stress can be measured in terms of fluorescence: 
more stress equals increased fluorescence. T cells from DR1, DR4 and HHD II 
transgenic mice were cultured as normal with a range of concentrations of Vitamin E. 
Cells were harvested, the DCFDA added and then samples were run on the FACS 
machine (Figure 4.2). 
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Figure  4.2: The titration of stress levels in DR4 T cells. A FACS based assay using the 
chemical compound DCFDA allowed direct measurement of T cell stress levels when 
cultured in the presence of a range of vitamin E concentrations. This graph is 
representative of triplicate experiments from DR1, DR4 and HHD II transgenic mice. 
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As the vitamin E concentration increased the levels of stress (measured by H2O2 
production) decreased until it plateaued out after 20mg/l; addition of higher 
concentrations yielded little further benefit (Figure 4.2). The normal physiological 
concentration of vitamin E ranges from 5-15mg/l, therefore as T cell stress is low at 
15mg/l this concentration was adopted for further experiments (Figure 4.2). 
 
4.2.2 Peptide immunisation in IFA followed by in vitro restimulation in 
either the presence or absence of Vitamin E permits the detection of 
immunogenic MHC class II restricted peptides 
 
Having determined the optimal concentration of vitamin E for use in in vitro assays, 
FVB/N-DR1 and C57bl/6-DR4 transgenic mice were immunised with the previously 
reported immunogenic influenza haemagglutinin derived HA307 peptide (Flu) (Sterkers 
et al., 1984) in IFA and a second injection given one week later. Seven days after the 
second injection, mice were sacrificed and the splenocytes cultured in vitro for one 
week either in the presence or absence of vitamin E. Proliferation was greater for the T 
cells cultured in the presence of the relevant HA307 peptide when compared to those 
cells cultured without peptide or with an irrelevant peptide. This proliferation was 
blocked by the addition of an anti-class II antibody to the cultures indicating that these 
proliferative responses could be attributed to the DR1/DR4 molecules. It can be seen 
that there are also clear proliferative differences between those cells cultured in the 
presence of vitamin E and those cultured without (Fig 4.3). When vitamin E was added 
to DR1 T cells a highly significant proliferative difference was observed between the T 
cells cultured in the presence of the relevant and irrelevant peptides (P = 0.002 by 
paired T test, n = 3). However in the absence of vitamin E these T cells failed to 
proliferate in a peptide specific manner (Figure 4.3). When vitamin E was added to DR4 
T cells a similar pattern of results was seen; once again a highly significant proliferative 
difference was observed between the T cells cultured in the presence of the relevant and 
irrelevant peptides (P = 0.004 by paired T test, n = 3). In the absence of vitamin E these 
T cells failed to proliferate in a peptide specific manner, although in this case the 
difference was no so pronounced (Figure 4.3). 
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Figure  4.3: Proliferative differences observed in the presence and absence of vitamin E. 
T cells were harvested and cultured as normal in either the presence or absence of 
15mg/l of vitamin E. Proliferation assays were then done as normal in order to compare 
the effects. It can be seen that for both DR1 and DR4 mice, vitamin E had a beneficial 
effect on proliferation and peptide specific responses. These results are representative of 
triplicate experiments. For each graph; n = 3 and statistical significance was determined 
by paired T test 
 
It was also thought prudent to investigate the potential effects that vitamin E might have 
upon the production of the cytokines IFNγ and IL-5 in order to determine if addition of 
vitamin E to T cell culture influenced the cytokine profile or not. T cells were cultured 
as normal in the presence or absence of vitamin E; one further control was added by 
culturing the T cells in the presence of the solvent used to dissolve the vitamin E to 
ensure that this was not responsible for the effects seen. Culture supernatants were 
harvested from DR1 and DR4 T cells on day 5 of the in vitro culture and ELISA was 
performed using detection kits as per manufacturers’ instructions (Figure 4.4). 
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Figure  4.4: Cytokine production by T cells in the presence and absence of vitamin E. Peptide specific production of both IFNγ and IL-5 was observed. 
However, it can be seen that the cytokine profile of the T cells tested was unaffected by the presence of vitamin E. These results are representative of 
triplicate experiments with each graph displaying n = 2 for supernatant samples analysed. 
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DR1 transgenic T cells were able to produce both IFNγ and IL-5 in a peptide specific 
manner whether cultured in the presence of vitamin E or not. No statistical difference 
between the Flu with vit E and the Flu peptide without vit E was observed (P > 0.05, 
when n = 2). It is also clear that the solvent used to dissolve the vitamin E does not 
mediate any effects on T cell cytokine production. The same was true for DR4 T cells, 
which also produced IFNγ and IL-5 in a peptide specific manner but were unaffected by 
the addition of vitamin E to the culture. 
These data demonstrated that the addition of vitamin E to T cell culture could be 
beneficial when screening for peptide immunogenicity as the proliferation difference 
between vitamin E treated and non treated cells was startling. The fact that cytokine 
production was unaffected does not detract from the benefits of vitamin E addition to in 
vitro T cell culture. The use of vitamin E in T cell culture media was therefore extended 
to routine peptide screening protocols. 
 
4.2.3 Extension of the use of vitamin E allowed identification of 
immunogenic MHC class II peptides in HLA DR1/DR4 transgenic 
mice 
Following the results of assays using the HA307 Flu peptide in conjunction with vitamin 
E, the range of peptides under test was extended. The SYFPEITHI web based algorithm 
(available at http://www.syfpeithi.de/home.htm) was used to predict peptide epitopes 
for HLA-DRβ1*0101 and HLA-DRβ1*0401 from the MART-1 and Tyrosinase proteins 
(Table 4.1).  
 
Peptide Protein of 
origin 
Sequence Binding score 
(DR1/DR4) 
Mart-129-43 Mart-1 GIGILTVILGVLLLI 22/20 
Mart-151-65 Mart-1 RNGYRALMDKSLHVG 29/22 
Mart-1101-115 Mart-1 PPAYEKLSAEQSPPP 36/22 
Tyrosinase4-18 Tyrosinase AVLYCLLWSFQTASG 25/28 
Tyrosinase147-161 Tyrosinase SDYVIPIGTYGQMKN 23/26 
Tyrosinase481-495 Tyrosinase AAMVGAVLTALLAGL 28/26 
 
Table  4.1: MART-1 and Tyrosinase peptides selected for testing in transgenic mice. 
Each of these epitopes was selected from the human protein sequence on the basis of 
being a promiscuous binder to both DR1 and DR4. 
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DR1 transgenic mice were immunised with the peptides in IFA as normal (shown in 
table 4.1). Following a 1 week in vitro restimulation with peptide, splenocytes were 
depleted of CD8+ T cells and used as responder cells in a proliferation assay. DR1 
transgenic mice were unable to generate a peptide specific immune response against 
Mart-151-65, Tyrosinase4-18, and Tyrosinase481-495. An inconsistent peptide specific 
response was generated against Mart-1101-115 but strong peptide specific responses were 
generated against Mart-129-43 and Tyrosinase147-161 (Figure 4.5). Mart-129-43 and 
Tyrosinase147-161 were consistently capable of generating proliferative responses that 
were abolished by the addition L243 antibody to the proliferation assay, indicating that 
the response was MHC class II restricted. The use of an isotype control antibody had no 
inhibitory effect demonstrating that the addition of an antibody to the culture was not 
responsible for proliferative suppression. Supernatants were harvested from the bulk T 
cell cultures for ELISA analysis; cytokine testing was performed using kits from R&D 
systems for IFNγ and IL-5 (Figure 4.6). 
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Figure  4.5: Representative responders demonstrating peptide specific DR1 T cell proliferative 
responses generated against Mart-129-43, Mart-1110-115 and Tyrosinase147-161. It can be seen that 
peptide specific proliferation was blocked by the addition of L243 antibody demonstrating that 
the proliferative responses were MHC class II restricted. The number of responders is shown in 
the right hand column. Statistical significance was determined by paired T test and n = 3 for 
each graph. 
DR1: Mart-1101-115 (PPA) vs Irrelevant + vit
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
CP
M
A
T cell PPA Flu DR PPA + L243 PPA + iso
DR1: Mart-129-43 (GIG) vs Irrelevant
0
2000
4000
6000
8000
10000
CP
M
A
T cell GIG Flu DR GIG + L243 GIG + iso
* 
P = 0.034
 
*** 
P = 0.000
 
DR1: Tyrosinase147-161 (SDY) vs Irrelevant
0
2000
4000
6000
8000
C
PM
A
T cells SDY irrel SDY + L243 SDY + iso no pept
* 
P = 0.050
 
Chapter 4: Peptide identification and Vitamin E 
 124 
 
 
2/2 mice produced 
IFNγ 
 
Mart-1101-115 elicited no peptide specific cytokine production  
 
1/2 mice produced 
IFNγ 
 
Figure  4.6: Cytokine production by DR1 T cells restimulated in vitro with peptide. 
Peptide specific cytokine production was seen for all peptides tested except Mart-1101-
115. Supernatants tested were derived from T cells that responded in a peptide specific 
manner in proliferation assays. Each graph represents n = 2 for the supernatant sample 
analysed. 
 
It can be seen that the Mart-129-43 peptide was able to elicit high levels of peptide 
specific IFNγ production in several mice; no IL-5 production was seen. However the 
Mart-1101-115 peptide produced no IFNγ or IL-5 despite generating a strong proliferative 
response in several mice (results not shown). Finally the Tyrosinase147-161 peptide 
induced strong IFNγ production in one of two mice tested. 
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As above, DR4 transgenic mice were immunised with the peptides in IFA (shown in 
table 4.1) and restimulated with peptide, splenocytes were depleted of CD8+ T cells and 
a proliferation assay performed as normal. DR4 transgenic mice were unable to generate 
a peptide specific immune response against Mart-129-43, Mart-151-65, Tyrosinase4-18, and 
Tyrosinase481-495. A weak peptide specific response was generated against Mart-1101-115 
but a strong peptide specific response was generated against Tyrosinase147-161 (Figure 
4.7). Tyrosinase147-161 was consistently capable of generating proliferative responses 
that were abolished by the addition L243 antibody to the proliferation assay, indicating 
that the response was MHC class II restricted. Supernatants were harvested from the 
bulk T cell cultures for ELISA analysis; cytokine testing was performed using kits from 
R&D systems for IFNγ and IL-5 (Figure 4.8). It can be seen that the Mart-1101-115 
peptide was able to elicit peptide specific IFNγ production in one mouse; no IL-5 
production was seen. Finally the Tyrosinase147-161 peptide induced strong IL-5 
production in three quarters of the mice tested; no IFNγ production was seen. 
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Figure  4.7: Representative responders demonstrating peptide specific immune responses 
generated against Mart-1101-115 and Tyrosinase147-161. In all cases it can be seen that 
peptide specific proliferation is blocked by the addition of L243 demonstrating that the 
proliferative responses is MHC class II restricted. The number of responders is shown 
in the right hand column. Statistical significance was determined by paired T test and n = 3 
for each graph. 
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Figure  4.8: Peptide specific cytokine production by in vitro restimulated T cells.    
Mart-1101-115 and Tyrosinase147-161 were capable of initiating peptide specific cytokine 
production. Supernatants tested were derived from T cells that responded in a peptide 
specific manner in proliferation assays. Each graph represents n = 2 for the supernatant 
sample analysed. 
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In summary, a number of DR1 and DR4-restricted peptides were tested for the ability to 
induce T cell proliferation and cytokine production, some of which were able to initiate 
proliferative and cytokine responses in DR1 mice some in DR4 mice and one peptide in 
both (Tyrosinase147-161). A table summarising the results is shown below (Table 4.2): 
 
Protein Peptide Sequence (residue no.) Allele 
restriction 
Binding 
score* 
No of +ve 
tests/total 
IFNγ +ve 
tests/total 
IL-5 +ve 
tests/total 
DR1 22 3/8 2/2 1 0/2 (29-43) GIGILTVILGVLLLI 
DR4 20 0/8 0/4 0/4 
DR1 29 0/4 0/4 0/4 (51-65)RNGYRALMDKSLHVG 
DR4 22 0/4 0/4 0/4 
DR1 36 2/7 0/4 0/4 
MART-1/Melan-A  
(101-115) PPAYEKLSAEQSPPP 
DR4 22 2/8 1/4 2 0/4 
DR1 25 1/6 0/6 0/6 (4-18) AVLYCLLWSFQTSAG 
DR4 28 0/4 0/4 0/4 
DR1 23 2/6 1/2 3 0/2 (147-161) SDYVIPIGTYGQMKN 
DR4 26 5/8 0/4 3/4 4 
DR1 28 0/4 0/4 0/4 
Tyrosinase 
(481-495) AAMVGAVLTALLAGL 
DR4 26 0/4 0/4 0/4 
* binding scores are out of a possible maximum of 36 
1
 average of ~ 200pg/ml IFNγ; 2 70pg/ml IFNγ; 3 220pg/ml IFNγ; 4 average of ~350 pg/ml IL-5 
Table  4.2: A summary of peptide responses in DR1 and DR4 transgenic mice. Only the 
Tyrosinase147-161 peptide was able to elicit strong responses in both transgenic mouse 
strains. Numbers shown in red indicate strong responses 
4.2.4 Is the immunogenic Tyrosinase MHC class II restricted peptide 
Tyrosinase147-161 (SDY) produced by proteasomal processing? 
The previously shown results demonstrated that the Tyrosinase147-161 peptide was able to 
initiate peptide specific proliferative and cytokine responses in both DR1 and DR4 
transgenic mice. As a result this epitope was designated the lead peptide as it could 
potentially be very useful in the clinic due to its promiscuous HLA binding. Therefore it 
was important to determine whether or not this epitope might be produced by 
proteasomal processing of the parent antigen by dendritic cells. Tumour cells constantly 
shed antigen and DC’s in the local environment process the protein into peptides that 
are displayed on the DC cell surface for T cell recognition; the aim was to replicate this 
process by using lysates derived form tyrosinase containing cell lines in order to 
determine if the Tyrosinase147-161 peptide is naturally produced by DC protein 
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processing mechanisms. Several cell lines were cultured, some of which had low levels 
of tyrosinase expression and others with higher expression levels; these cells were then 
used to produce cell lysates that were used in later experiments. 
4.2.4.1 Western blotting of protein lysates 
Protein lysates were produced by water lysis of >109 cells followed by homogenisation. 
Supernatants were then recovered by centrifugation and protein content quantified using 
a BioRad protein assay kit. Samples were then run on a polyacrylamide gel, transferred 
to nitrocellulose and used for western blotting. In this way levels of tyrosinase within 
the protein samples could be determined; although there were no totally negative 
samples to use as a control it was reasoned that a tyrosinase low lysate could be used 
instead (Figure 4.9). 
 
 
 
Figure  4.9: Western blotting of cell lysates. 25µg of NW145 and WM852 melanoma 
cells lysates were used for western blotting. It can be seen that WM852 contains low 
levels of tyrosinase. 
 
A lysate produced from a p53 transfected cell line was used as an internal positive 
control for each western blot (lane 1). Blotting experiments demonstrated that the 
WM852 cell lysate contained low levels of tyrosinase and therefore could be used as a 
control lysate in proliferation assays (lanes 3+4). In contrast the NW145 cell line was 
shown to contain much higher levels of the tyrosinase protein and could therefore be 
used to test for proteasomal protein processing into the Tyrosinase147-161 epitope (lanes 
5+6). 
DR1 and DR4 transgenic mice were immunised with the Tyrosinase147-161 epitope in 
IFA as normal (shown in table 4.1). Following a 1 week in vitro restimulation with 
peptide, splenocytes were depleted of CD8+ T cells and used as responder cells in a 
proliferation assay. Lysate fed BM-DC were used as antigen presenting cells in order to 
determine the presence of the naturally produced Tyrosinase147-161 epitope on the DC 
 1 2 3 4 5 6 
p53 +ve 
control 
58KDa WM852 NW145 
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cell surface. Proliferation was quantified according to the standard protocol utilising 
tritiated thymidine. It can be seen that the protein lysate was able to elicit a lysate 
specific response in both DR1 and DR4 transgenic mice. 
 
 
 
 
Figure  4.10: Representative responders demonstrating Tyrosinase high lysate induced 
proliferation by T cells from Tyrosinase147-161 immunised mice. Both DR1 and DR4 
peptide specific T cells were able to respond in a specific manner to cell lysates 
containing Tyrosinase. Statistical significance was determined by paired T test and n = 3 
for each graph. 
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The fact that T cells from Tyrosinase147-161 immunised mice were able to respond 
specifically to BM-DC “fed” with a tyrosinase containing lysate would indicate that the 
Tyrosinase147-161 epitope was produced by proteasomal processing of the parent protein 
in both DR1 and DR4 transgenic mice. 
4.3 Discussion 
 
Numerous MHC class I-restricted tumour associated antigens recognised by 
melanoma specific CD8+ T cells have been identified, therefore a wide range of 
potential therapeutic targets exist (Zarour et al., 2000), however for long lasting 
immune responses to be generated against such antigens CD4+ T cell help is required 
(Gao et al., 2002). The requirement for such help is almost certainly necessary to 
promote CD8+ T cell responses to moderate/low affinity peptides (Gao et al., 2002), 
although it has been shown in vitro that high affinity CD8+ T cells do not require 
help (Franco et al., 2000). Hence in the absence of help it is likely that CD8+ 
responses to self antigens are transient. 
The possibility that tolerance could be generated when therapy is directed only to 
MHC class I peptides has been suggested (Wang et al., 2003) and depends upon the 
context in which an antigen is presented to the immune system. For example the 
outcome of inflammation or tissue destruction that occurs during viral or bacterial 
infection is typically activation, however when an antigen is expressed 
endogenously, in the absence of “danger signals” that accompany tissue destruction 
and inflammation, the usual outcome is immunologic tolerance (Pardoll & Topalian, 
1998). CD4+ T cells can break tolerance, as they are capable of effectively priming 
DC. These primed DC up regulate the expression of costimulatory molecules 
necessary for the activation of the MART-1/Tyrosinase tumour specific CD8+ T cell 
population (Colaco, 1999; Ridge et al., 1998). 
Given the importance of CD4+ T cell help in the generation of CTL it is essential that 
MHC class II-restricted melanoma epitopes are identified and evaluated for their 
potential use in cancer vaccines Melanoma differentiation antigens such as MART-1 
and Tyrosinase have been shown to be immunogenic in healthy donors and 
melanoma patients as well as being over expressed in melanoma (Kobayashi et al., 
1998; Takeuchi et al., 2003); therefore they represent appropriate targets for 
immunotherapy. 
The present study focused on MHC class II peptide identification in conjunction with 
improving the survival of CD4+ T cells in vitro thereby increasing the efficiency of 
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the method used to identify novel T cell epitopes. Malmberg et al in 2002 showed 
that an increase in cancer patient survival could be elicited by the oral administration 
of high doses of Vit.E. Furthermore, clinical trials have reported that the CD4+ T cell 
responses were boosted by up to 22% in some patients (Malmberg et al., 2002). It 
was therefore hypothesised that the addition of Vit.E to T cells in vitro would be 
beneficial for assessing immune reactivity. Indeed the level of T-cell stress was seen 
to decrease with increasing concentrations of Vit.E (Figure 4.2). A large decrease in 
stress was seen as the vitamin E concentration was increased from 1-15mg/l; 
however further increases in concentration yielded little improvement in stress 
levels, thus it was decided to use 15mg/l in vitro. This concentration also represents 
the maximum vitamin E concentration found in normal blood, therefore it was 
reasoned that it would not be detrimental to the T cells in culture. 
After initial titration experiments were completed it was decided to employ vitamin 
E in conjunction with a known peptide in order to test its effects on T cell 
proliferation and cytokine production. DR1 and DR4 transgenic mice were 
immunised twice at weekly intervals with the HA307 influenza haemagglutinin 
peptide (Sterkers et al., 1984). Mice were then sacrificed and the T cells put into 
culture with peptide; half of those T cells recovered from each mouse were cultured 
with vitamin E and the other half cultured without in order to allow a direct 
comparison of T cell proliferation and cytokine production. T cells were depleted of 
CD8+ cells and proliferation assays performed as normal. It is clear that the presence 
of vitamin E in vitro significantly enhanced CD4+ T cell proliferative responses to 
the previously identified HA307 class II peptide in both DR1 and DR4 transgenic 
mice (Figure 4.3).  
Supernatant samples were harvested on day 5 from the same T cell cultures and 
analysed by ELISA in order to determine if the in vitro addition of vitamin E 
affected the cytokine production profile when the cells were viable. Peptide specific 
IFNγ and IL-5 production was seen in both DR1 and DR4 transgenic mice. However 
in this case neither an increase nor decrease in peptide specific cytokine production 
was observed in the presence of vitamin E. Therefore it was concluded that within 
the time frame of culture the in vitro addition of vitamin E to T cells was beneficial 
for proliferation whilst having no detrimental effects on cytokine production. As a 
result of these early experiments, the in vitro use of vitamin E was extended to the 
process of screening for novel epitopes.  
Candidate HLA-DR1 and HLA-DR4 restricted peptides were predicted from 
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MART-1 and Tyrosinase proteins using the evidence-based computer algorithm 
SYFPEITHI (http://www.syfpeithi.de/home.htm), allowing the rapid identification of 
promiscuous HLA-DR1 and HLA-DR4 binding peptides. Peptides displaying a high 
score for both HLA haplotypes were selected and used to immunise HLA-DR 
transgenic mice (Table 4.1). Several MART-1 and tyrosinase peptide sequences 
predicted to activate DR1 or DR4 restricted T cells were detected. The MART-129-43 
peptide induced T cell proliferation and cytokine production in DR1 mice; however 
no responses were observed in DR4 mice; hence this peptide could be of use in DR1 
positive patients. The MART-1101-115 peptide was only weakly immunogenic in both 
DR1 and DR4 mice; as such this peptide was not considered for further testing as it 
is unlikely to be of use in the clinic. 
A number of Tyrosinase peptides were also investigated in the DR1 and DR4 mice; 
of these only the Tyrosinase147-161 peptide proved to be immunogenic (Table 4.2). 
Strong proliferative responses were observed in both DR1 and DR4 mice; in contrast 
to the DR1 mice, DR4 mice produced IL-5 in response to this peptide indicating a 
bias towards a Th2 immune reaction. Although the generation of a Th2 response may 
not be ideal it should be possible to initiate a Th1 response with the same peptide by 
changing the adjuvant. 
As a result of being immunogenic in both transgenic mouse strains the Tyrosinase147-
161 peptide was subjected to further testing. It was considered important to determine 
whether or not this peptide might be naturally produced by antigen processing 
pathways within tumour cells and dendritic cells in the tumour environment. To 
accomplish this, tumour cell lines were cultured and cell lysates produced; some of 
these were high in tyrosinase and others were low. Western blotting was employed to 
establish the identity of cell lines possessing Tyrosinase at high and low levels in cell 
lysates. These lysates were then “fed” to dendritic cells that were used in T cell 
assays using Tyrosinase147-161 peptide immunised mice. Both DR1 and DR4 mice 
were capable of mounting an immune response against the tyrosinase high lysate; in 
contrast the tyrosinase low lysate elicited no response. This is an important result as 
it indicates that the Tyrosinase protein may be naturally processed into an 
immunogenic peptide that could be employed as a therapeutic agent in a clinical 
trial. 
All cell proliferation assays were conducted using CD8+ depleted splenocytes and 
anti-HLA-DR blocking antibody plus a relevant isotype control, it was therefore 
concluded from the results that proliferative responses were CD4+ T cell dependant 
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and HLA-DR-restricted; the data was confirmed by cytokine assay.  
The use of vitamin E in vitro was critical in improving the efficacy of the screening 
protocol, permitting the identification of class II peptide epitopes that would 
otherwise have been overlooked. In conclusion, using the modified method for 
assessing CD4+ T cell responses, peptide immunisation of HLA-DR transgenic mice 
permitted the identification of one novel immunogenic HLA-DR-restricted peptide 
from both MART-1 and Tyrosinase antigens. Moreover the Tyrosinase147-161 peptide 
was shown to be naturally processed by both DR1 and DR4 BM-DC and could 
therefore be considered as an appropriate candidate class II peptide for future 
melanoma vaccines. 
The use of MHC transgenic mice has shown utility in this and other studies 
(Touloukian et al., 2000) as it conferred a number of important advantages. Probably 
the most critical was that all the priming steps for any immune reaction occurred in 
vivo. As a result of in vivo priming the screening process could be streamlined 
because multiple rounds of stimulation were not required. Most peptides generated a 
peptide specific proliferative response within either the first or second week of in 
vitro stimulation if they were immunogenic; as a result a substantial repertoire of 
potentially immunogenic peptides was screened in a relatively short period of time. 
Importantly, a strong correlation exists between peptides shown to be immunogenic 
in the transgenic mice and in humans (Rojas et al., 2005), providing a rationale for 
using such HLA transgenic mouse models as an initial screen for “human” T cell 
epitopes. 
Besides being important in generating CD8+ CTL responses to class I peptides, CD4+ 
T cells have been shown to be capable of indirectly killing/clearing MHC class II 
negative tumour masses via cytokine production; this could be of great benefit in 
preventing the generation of tumour escape variants as it is rare that a tumour loses 
both its MHC class I and class II molecules (Egilmez et al., 2002). Hence the 
utilisation of novel MHC class II peptides as a component of next generation cancer 
vaccines is likely to prove vital for promoting “long lasting” CD8+ as well as CD4+ T 
cell memory responses. 
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5 Chapter 5: The effect of protein specific class II help on the 
generation of CTL in vitro 
5.1 Introduction 
It is known that CD4+ T cells are critical in the priming of an immune response through 
two proposed molecular pathways. The first hypothesises that CD4+ T cells activate 
CD8+ CTL’s by producing cytokines such as IL-2, which is essential for the 
proliferation of CD8+ CTL’s. T helper cells are thought to activate CD8+ T cells via 
interaction with APC’s, such as dendritic cells, that present cognate peptides to both 
CD4+ and CD8+ T cells which are in close contact although not in direct interaction 
(Keene & Forman, 1982; Mitchison & O'Malley, 1987). The second theory proposes 
that CD4+ T helper cells recognise MHC class II peptides on the surface of DC’s and 
that this interaction activates both T helper cells and dendritic cells. Once this activation 
step has occurred, dendritic cells are then able to prime and activate CTL’s specific for 
peptides presented by tumour cells (Bennett et al., 1998; Ridge et al., 1998; 
Schoenberger et al., 1998). It is not entirely clear which of these two models operates 
but it seems likely that they are not mutually exclusive. Therefore, based on the 
importance of T helper cells in activation of a CTL response it is necessary to 
understand the nature of the antigens recognised by anti-tumour CD4+ and CD8+ T cells 
and how this may relate to “tumour clearance”.  
For some years there has been a debate over the precise nature of T cell help required to 
initiate optimal generation of anti-tumour CTL. Should the helper peptide be derived 
from the same protein as the CTL epitope or would another antigen found within the 
same tumour cells be as or more appropriate (Assudani et al., 2006; Nishikawa et al., 
2001; Wang et al., 2003)? Many of the helper peptides currently available for use in 
murine models and clinical trials such as Hep B, OVA, PADRE and KLH are 
completely unrelated to the antigens of importance present within a tumour; therefore 
could there be potential for increased clinical efficacy? 
A recent study by Wang et al (2003) investigated the role of T helper epitopes in the 
formulation of an effective cancer vaccine. They utilised a HER2 class I peptide in 
conjunction with either HER2 or OVA class II helper peptides to investigate both in 
vitro cytokine production and in vivo tumour challenge and therapy and reported that 
there was little or no difference in helper ability in vitro but there appeared to be a 
significant difference in vivo as measured by tumour clearance. It was concluded that a 
helper peptide originating from within the tumour was necessary otherwise the therapy 
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would fail (Wang et al., 2003). In contrast a study by Casares et al (2001) found that 
endogenous tumour antigens and non-endogenous antigens had similar therapeutic 
impact in vitro and in vivo (Casares et al., 2001). However in both studies the origin of 
the antigens investigated may have influenced the results as they were non-murine. In 
the present study the use of p53, which has a high sequence homology between the 
mouse and human proteins, enabled the investigation of helper peptide influence on 
CTL generation whilst subject to tolerogenic mechanisms. The choices of adjuvants 
may also influence the results as IFA, used in these studies, is not licensed for clinical 
use in the UK.  
An ideal adjuvant should increase the potency of an immune response, whilst being 
non-toxic and safe. Despite the fact that a wide range of adjuvants have been shown to 
be effective in preclinical and clinical studies, only aluminium based salts (Alum) and 
squalene-oil-water emulsion (MF59) have been approved for human use (Mesa & 
Fernandez, 2004). However, adjuvants to be used in cancer vaccines differ from those 
used in conventional vaccines for a number of reasons; patients receiving the vaccine 
are usually immunocompromised; the antigens involved are usually self derived and are 
therefore only weakly immunogenic and tumour escape mechanisms confer further 
immune suppression. As such, adjuvants used in cancer vaccines need to be more potent 
than in prophylactic vaccines and therefore may be more toxic and could induce 
autoimmunity. Therefore the ideal cancer vaccine adjuvant should rescue/boost the 
existing immune response with acceptable levels of toxicity and safety. Thus a number 
of different adjuvants have been tested in this study in order to determine if a more 
clinically relevant adjuvant than IFA could be used to generate CTL. 
Since its original description, complete Freund’s adjuvant (CFA) has been one of the 
most widely used and effective adjuvants available (Freund, 1951). CFA is composed of 
a light mineral oil, mannide monooleate (a surfactant agent) and heat killed, dried 
mycobacterial cells. Incomplete Freund’s adjuvant (IFA) differs from CFA only in the 
fact that it does not contain the killed mycobacterial cells. Immunisations are prepared 
by emulsification of the antigen in an aqueous solution with the oil, to produce a water-
in-oil emulsion. The formation of this emulsion is critical to the effectiveness of both 
IFA and CFA as adjuvants. The oil mediates a number of effects: (1) establishing an 
antigen depot with slow antigen release, (2) providing a vehicle for antigen transport 
throughout the lymphatic system to immune effector cells and (3) interacting with 
antigen presenting cells including phagocytes, macrophages and dendritic cells. Early 
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studies using water-in-mineral oil emulsions revealed that the antigen persisted within 
the emulsion at the injection site for up to 22 wks after administration (Stills, 2005). 
Unfortunately, IFA has been associated with a variety of lesions when injected into 
humans which has restricted its’ use. A variety of additional guidelines aimed at 
reducing the pain and stress of immunised animals has also been implemented.  
Although adjuvants can be used to boost an immune response to an antigen, their very 
nature can lead to toxic side effects. In order to combat this problem an alternative form 
of immunomodulation has been developed that depends on the “size” of a carrier to 
elicit an immune response. In this case an inert carrier molecule is used with the antigen 
of choice either adsorbed or covalently linked to the carrier surface resulting in the 
generation of strong immune responses after a single dose (Fifis et al., 2004a). 
The use of solid inert beads with surface adsorbed antigen to stimulate CD8+ T cells has 
previously been described, with an optimal bead diameter of 1µm (Falo et al., 1995). 
However, other particulate based immunogenic carriers such as immune stimulating 
complexes (ISCOMS) and virus like particles have a size range of 0.03-0.2µm diameter. 
Normally adjuvants are essential to provide the necessary “danger signals” for 
successful induction of an immune response (Gallucci et al., 1999); however the 
advantage of particulate vaccines is that they seem to be able to induce immunity and 
generate both CD4+ and CD8+ T cell responses without the toxicity risks of other 
adjuvants (Allsopp et al., 1996; Fifis et al., 2004b; Plebanski et al., 1998). 
In the absence of adjuvant the likelihood of an adverse immunological reaction is 
minimal; therefore the present study was designed to test nanobeads (0.04-0.05µm), in 
conjunction with a number of p53 peptides, in a murine system as an alternative to 
using IFA.  
Why use p53 class I and class II peptides for this study? Existing MART-1 and 
Tyrosinase class I peptides and class II peptides, identified in chapter 4, were available 
and would have been the ideal choice to investigate the influence of class II helper 
peptides on the generation of CTL. This choice was made was due to lack of double 
transgenic mice expressing human MHC class I and human MHC class II molecules. 
The HHD II mice available were transgenic for human MHC class I (HLA-A2) but 
expressed mouse class II (I-Ab); the MART-1 and Tyrosinase peptides identified in 
chapter 4 are not I-Ab restricted and so could not be used in conjunction with HLA-A2 
restricted MART-1/Tyrosinase peptides in these animals. In contrast I-Ab restricted p53 
peptides have previously been identified which could be used in conjunction with HLA-
A2 restricted peptides in order to test if protein specific helper epitopes could boost a 
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CTL response. P53 is a self antigen, like MART-1 or Tyrosinase, so central and 
peripheral tolerance mechanisms are liable to act in the same manner regardless of the 
antigen employed in these experiments. Murine and human p53 genes are also readily 
available for cloning into a vector of choice, whereas murine MART-1 and Tyrosinase 
are unavailable without lengthy procedures cloning the genes from murine genomic 
DNA. Therefore, because both peptides and murine/human DNA constructs are 
available for p53 and not MART-1 or Tyrosinase, p53 was chosen as a surrogate model 
self antigen for the study of the influence of MHC class II peptides on the generation of 
a CTL response. 
 
5.2 Results 
5.2.1 The effects of specific class II help on the generation of CTL using 
IFA as an adjuvant 
In order to ascertain the influence of T helper cells on the generation of CTL responses 
a panel of p53 peptides was employed. HHD II mice transgenic for human HLA-A2 and 
expressing murine I-Ab class II molecules were used in this study. As such all class II 
peptides were I-Ab restricted in order to bind to mouse MHC class II. The class I 
peptides employed were all derived from p53, while the class II peptides were derived 
from either Hep B or p53, allowing a comparative study to determine which class II 
peptide was able to deliver optimal help for CTL generation (see Table 5.1). 
In order to confirm the functional efficiency of the MHC class II helper peptides, mice 
were immunised twice at weekly intervals with the peptide of interest. T cells were then 
harvested from the spleen, cultured for one week in the presence of peptide followed by 
depletion of CD8+ T cells. Proliferation assays were performed using tritiated thymidine 
to measure cellular proliferation. Both mp53108 and Hep B were able to elicit peptide 
specific proliferative responses (see Figure 5.1). 
 
Peptide Protein of 
origin 
Sequence MHC restriction 
p53217-225 p53 VVPYEPPEV HLA-A2 
p53264-272 p53 LLGRNSFEV HLA-A2 
mp53108-122 Murine p53 LGFLQSGTAKSVMCT I-Ab 
HepB128-140 
Hepatitis B 
core 
TPPAYRPPNAPIL I-Ab 
 
Table  5.1: p53 and Hep B peptides utilised for testing the influence of MHC class II peptides on 
the generation of an MHC class I CTL response. 
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Figure  5.1: Peptide specific proliferative responses to Hep B and mp53108 in HHD II 
transgenic mice. It can be seen that statistically significant proliferation is obtained with 
both helper peptides (significance determied by paired T test and n = 3 for each graph). 
These data are representative of triplicate experiments and were found to be highly 
reproducible.  
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The ability of the helper peptides to generate a peptide specific proliferative response 
was clearly demonstrated by the data shown in Figure 5.1. Having assessed the helper 
ability of the class II peptides, their effects on the generation of a class I CTL response 
could now be determined. Thus a number of different immunisations were performed: 
(1) p53 class I alone in IFA, (2) p53 class I + p53 class II in IFA and (3) p53 class I + 
Hep B class II in IFA. In combination with the above immunisations, two different p53 
class I peptides were used, one with a lower MHC binding affinity (p53217) and another 
with a higher binding affinity (p53264), in order to investigate the possibility of 
differential helper peptide requirements of high/low affinity class I binding peptides. 
HHD II HLA-A2 transgenic mice were immunised as described above; one week later, 
splenic T cells were harvested and restimulated in vitro for a further week with 
irradiated, peptide pulsed blast cells (see materials and methods). This heterologous T 
cell population was then used as effector cells in a standard chromium release assay. 
These data demonstrate that class II help is an absolute requirement for the generation 
of a CTL response in this model since in the absence of class II peptides no CTL 
response was generated to either p53217 or p53264 peptides (Figure 5.2). 
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Figure  5.2: Class II help is required for the generation of a CTL response when using 
either a high (p53264) or low (p53217) affinity class I peptide. In the absence of helper 
peptide no significant CTL response could be seen (significance determined by Mann 
Whitney U). The E:T ratio refers to the number of T cells per target cell (Target cells 
were EL4 HHD II cells); cytotoxicity could be blocked by the addition of an anti HLA-
A2 antibody (data not shown). Data were highly reproducible. 
Subsequently, a comparison between p53 (antigen specific) and Hep B (antigen non-
specific) class II peptides was undertaken in order to establish whether an improved 
class I response was obtained by using an antigen specific class II peptide (Fig 5.3)  
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Figure  5.3: The difference in median cytotoxicity when using protein-specific (mp53108) 
and non protein-specific (Hep B) class II helper peptides. Error bars shown represent the 
interquartile range of the data. Cytotoxicity was higher when mice were immunised 
with protein specific helper peptides, also the number of mice responding is higher. 
Cytotoxicity was blocked by the addition of anti HLA-A2 antibody (data not shown) 
and results were found to be reproducible. Statistical significance was determined using 
the Mann Whitney U test. 
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When the data were examined closely it was observed that different patterns in the 
cytotoxicity were produced by the low and high affinity class I peptides. When p53217 
was used together with p53 MHC class II helper peptides a higher level of cytotoxicity 
was observed when compared with the Hep B class II helper peptide. Although these 
results did not reach statistical significance (P = 0.12 by Mann Whitney U test) there 
was a distinct trend. However there was a definable difference in the number of mice 
that responded to the peptide immunisation; when both p53 class I and class II peptides 
were used for immunisation 100% of mice responded in a peptide specific manner; 
when p53 class I was used with the Hep B class II peptide only 50% of mice responded 
in a peptide specific manner. Therefore in this model it can be seen that using a low 
affinity peptide with protein specific class II help, cytotoxicity was boosted and the 
number of responding animals was also increased (Figure 5.3). 
When the p53264 class I peptide was used with the p53 MHC class II helper peptide 
there was a significant increase in cytotoxicity compared to when Hep B class II helper 
peptides were employed. These results were highly statistically significant (P = 0.026 
by Mann Whitney U test) and occurred at all T cell dilutions. Once again there was a 
clear difference in the number of mice that responded to the peptide immunisation; 
when both p53 class I and class II peptides were used 100% of mice responded in a 
peptide specific manner; when p53 class I was used with a Hep B class II peptide only 
50% of mice responded in a peptide specific manner. Therefore by using a high affinity 
peptide with protein specific class II help in this system, cytotoxicity was significantly 
boosted in conjunction with raising the number of responding animals (Figure 5.3). 
5.2.2 The effects of specific class II help on the generation of memory 
CTL in vitro  
Having established that the use of a protein specific class II helper peptide can boost 
both cytotoxicity and the number of responders in short term experiments, it was 
decided to investigate the possible long term effects of immunisation. A number of 
different immunisations using the high affinity peptide were performed as follows: (1) 
two mice with class I p53 alone in IFA, (2) four mice with class I p53 + class II mp53 in 
IFA and (3) four mice with class I p53 + class II Hep B in IFA. These mice were 
divided into two separate groups; five mice were sacrificed at four months and the 
remaining five mice at six months. Cytotoxicity assays were then performed to 
determine if a memory response could be recalled at these time points (Figures 5.4 and 
5.5). 
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Figure  5.4: Memory cytotoxic response generated four months post immunisation. Both 
immunisations led to highly significant cytotoxicity; however preliminary experiments 
suggested that Hep B generated the better long term response after four months in this 
single experiment (comparing 100: 1 E:T ratio P = 0.007 by Mann Whitney U test). 
Target cells were pulsed with 10µg/ml of peptide overnight and then washed before 
addition to T cells. Cytotoxicity was blocked by the addition of an anti HLA-A2 
antibody (data not shown) demonstrating the class I restriction of the response. 
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Figure  5.5: Memory cytotoxic response generated six months post immunisation. Both 
immunisations led to highly significant cytotoxicity; however this time when averaging 
results out over all the mice Hep B only generated a marginally higher cytotoxic 
response than p53 after six months (comparing 100:1 E:T ratio P = 0.03 by Mann 
Whitney U test) in this single experiment. Target cells were pulsed with 10µg/ml of 
peptide overnight and then washed before addition to T cells. Cytotoxicity was blocked 
by the addition of an anti HLA-A2 antibody (data not shown) demonstrating the class I 
restriction of the response. 
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It can be seen in Figures 5.4 and 5.5 that using Hep B as the class II helper peptide 
consistently resulted in higher memory cytotoxic responses being produced. However at 
longer time intervals between immunisation and assay, less difference between the p53 
class II helper peptide and the Hep B helper peptide could be found; P = 0.007 at four 
months and P = 0.03 at six months (Mann Whitney U) when comparing cytotoxicity 
produced by the 100:1 E:T value. This can be seen more clearly when the data is 
overlaid as in Figure 5.6. 
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Figure  5.6: The cytotoxicity induced by p53 and Hep B helper peptides in conjunction 
with the p53264 class I peptide in a single experiment. Each data set represents the 
average cytotoxicity of two immunised mice; cytotoxicity could be abolished by 
addition of anti HLA-A2 antibody, demonstrating the MHC class I restriction of the 
response. 
 
It is interesting to note that the number of cells recovered from an animal immunised for 
long term experiments was the same as for an animal prepared for a short term 
experiment; this would seem to indicate that a strong memory response had been 
produced. In this instance, the cytotoxicity produced was more consistent for p53 
helped CTL than for Hep B CTL. However it must be stated that this and all data shown 
regarding long term immunisations are only single experiments, which must be repeated 
in order to confirm initial findings. 
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5.2.3 Peptide conjugated nanobeads as an adjuvant for generating a CTL 
response 
Through collaboration with Prof. M Plebanski (Austin Research Institute, Melboune, 
Australia), peptide coated nanobeads were obtained to determine if they could offer a 
viable alternative to IFA as an adjuvant. These nanobeads were coated with either 
p53264, mp53108 or both peptides. Typically 100µg of peptide linked to nanobeads was 
administered in total and T cell assays performed as described previously. As before a 
class I alone immunisation was performed in order to ascertain the requirement for a 
helper epitope to generate CTL (Figure 5.7). 
Once the requirement of a class II helper epitope had been established for nanobead 
immunisation further experiments were performed; HHD II mice were immunised with 
mp53108 nanobeads to determine if they were capable of producing a peptide specific 
CD4+ T cell response. However, this proved unsuccessful and a non specific CD4+ T 
cell response was observed (results not shown). Further, nanobeads with both p53264 
and mp53108 adsorbed onto the surface were used in an attempt to induce a CTL 
response (Figure 5.8). 
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Figure  5.7: Cytotoxicity induced by the use of p53264 nanobeads in the absence of a 
class II helper epitope. The above graph is representative of highly reproducible data. 
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Figure  5.8: Cytotoxicity produced by nanobead immunisation with p53264 and mp53108. 
Cytotoxicity could be abolished by the use of an anti HLA-A2 antibody, indicating the 
MHC class I restriction of the observed response. These data are representative of 
triplicate experiments and were found to be highly reproducible. 
 
Immunisations utilising the nanobeads as a “carrier” generated consistent results, 
however only low levels of cytotoxicity were generated and the killing was non 
specific, both of which would be undesirable in a clinical setting. It must be stated that 
the above data is only preliminary and therefore further nanobead experiments are 
necessary before conclusions can be drawn about their abilities as an adjuvant.  
 
5.3 Discussion 
Throughout the experiments performed, using a range of adjuvants, one point was clear; 
in this system no significant cytotoxicity was generated in the absence of class II helper 
peptides. There could be several reasons for this; Franco et al (2000) stated that the 
requirement for CD4+ T cell help was dependant on the binding affinity of the MHC 
class I restricted peptide (Franco et al., 2000). In other words, if the class I epitope had 
high MHC class I binding affinity then CD4+ T cells were not required for maximal 
CTL priming; if the class I epitope had low MHC class I binding affinity then either 
CD4+ T cells or the addition of anti-CD40 was required to generate significant CTL 
activity (Franco et al., 2000). However in the present study the use of helper peptides, 
regardless of the binding affinity of the class I epitope, always led to an increase in 
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cytotoxicity from around 5% with no help to approximately 50-100% with help (results 
not shown). This could be due to, for example, the concentration of peptide 
administered, the route of administration, the type of adjuvant used and/or the origin of 
the peptides involved (p53 is a self antigen). This leads onto the second possible reason 
for the absolute requirement of helper epitopes in this system; the origin of the peptide, 
which could be a significant factor in determining the requirement for CD4+ T cell help 
for generating a CTL response against a self antigen (Nishikawa et al., 2001). Both 
peripheral and central tolerance mechanisms sculpt the T cell repertoire in order to 
prevent autoimmune responses, therefore regardless of the binding affinity of a peptide 
epitope for MHC class I, the TCR’s that must interact with the peptide/MHC complex, 
would by definition, be of low affinity (Faro et al., 2004; Saito & Germain, 1988). As 
such it is entirely possible that a high affinity epitope derived from a self antigen would 
require CD4+ T cell help to generate a CTL response. 
Although it was observed that CD4+ T cell help was an absolute necessity in this system 
it still remains to be determined what the precise nature of the help should be in order to 
achieve the optimum possible CTL response. Initial experiments showed that in short 
term experiment, a helper epitope derived from the same protein as the class I peptide 
could lead to both an increase in in vitro cytotoxicity and number of responders when 
compared to a helper epitope derived from a different protein. A low affinity class I p53 
peptide together with the p53108 helper peptide demonstrated a small increase in 
cytotoxicity with 100% of immunised mice responding compared to the Hep B helper 
peptide. A higher affinity class I p53 peptide yielded significant benefits when used 
with the p53108 helper peptide compared to the Hep B helper peptide; cytotoxicity was 
boosted four fold and 100% of immunised mice responded. The reason for this is 
unclear and has not been previously reported in the literature. However, many models 
use non endogenous antigens such as OVA, Hep B and other viral and human proteins 
which bear little homology to any murine proteins; as such the immune reactions 
generated in murine models are liable to be far stronger against foreign proteins since 
there has been no tolerogenic “sculpting” of the immune system (Fifis et al., 2004b; 
Wang et al., 2003). Therefore the results achieved in this study using p53 are analogous 
to T cell responses mounted against previously encountered pathogens, which take 3-4 
days to develop. However it will take up to a fortnight to produce a high affinity 
immune response to a novel pathogen. The two helper peptides were derived from Hep 
B (non-self antigen, i.e. novel) and p53 respectively (self antigen, previously 
encountered). Therefore in a short term experiment, when T cells are harvested from the 
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spleen only one week post immunisation, it seems logical that the antigen with a pre-
existing memory T cell pool (p53) will provide better T cell help than a novel antigen 
(Hep B). 
When examining the data from the long term immunisations (four and six months) 
precisely the opposite is true. In this case the Hep B peptide enhanced the CTL response 
compared with p53108 at both four and six months (P = 0.007 and 0.03 respectively). 
The Hep B helper peptide has a high binding affinity for I-Ab and is a viral antigen; 
therefore a high avidity T cell response can be developed that would lead to the 
production of high avidity memory T cells. The p53108 peptide however has a lower 
binding affinity and is a self antigen; therefore the production of high avidity T cells 
would be limited by anti-autoimmune mechanisms whilst allowing the production of 
lower avidity memory T cells. Thus, mice immunised with the p53 class I peptide 
together with either the Hep B or the p53 helper peptide gave different results. It can be 
suggested that p53108 helper peptide immunisation induces a memory response but at a 
lower avidity due to being limited by tolerogenic mechanisms, thus cytotoxicity is 
augmented but to a lesser extent than for Hep B. It is worthy of note that no memory 
CTL response developed when a helper peptide was not employed at the time of 
immunisation. In addition the statistical difference between the p53 and Hep B 
augmented cytotoxicity decreased when the time between immunisation and T cell 
harvesting was extended. This could be due to a decrease in the numbers of available T 
helper cells; at six months (~180 days) the memory T cell pool will have decreased in 
size and lead to a restricted Hep B helper response. This is an important point, because 
memory T cell stimulation in the absence of immunisation can only occur in response to 
endogenous antigen such as p53 and not exogenous Hep B. Therefore it is possible that 
the Hep B memory T cell pool would shrink more than the p53 memory T cell pool 
because of a lack of repeat stimulation. Further experiments are necessary in order to 
confirm this finding. 
During the course of this study a different adjuvant was tested in an attempt to find and 
alternative to IFA, which is not licensed for clinical use in the U.K. Preliminary 
experiments using peptide conjugated nanobeads obtained from M. Plebanski produced 
inconclusive results. In this case some cytotoxicity (around 20%) was consistently 
obtained, however once again it was not peptide specific. The mode of adjuvant action 
of nanobeads is not entirely understood, it seems to be based purely upon the fact that 
nanobeads of a certain size are preferentially taken up by dendritic cells. In a study by 
Fifis et al (2004) a range of beads sizes were tested for immunogenicity when coated 
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with peptides such as SINFEKL or OVA derived epitopes. It was found that nanobeads 
0.04-0.05µm in diameter could elicit efficient cytokine production as measured by 
ELISPOT; these beads were also found in murine lymph nodes 48h after intradermal 
injection (Fifis et al., 2004a). It is possible that the route of injection used in this study 
was not as suitable for nanobead immunisation and therefore lead to a sub-optimal 
immune response. It is also possible that this novel method of nanobead adjuvant action 
merely is not strong enough to elicit an immune response from the peptides used in this 
study. Alternatives to IFA must be found in order for vaccines to progress from murine 
models into clinical trials, unfortunately nanobeads have so far not been found to be a 
viable alternative using this transgenic mouse system. 
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6 Chapter 6: Production of murine and human p53 vectors 
and the generation of stable EL4 HHD II p53 transfected 
cells 
6.1 Introduction 
6.1.1 Gene transfer: transfection techniques 
A wide range of techniques exist for transferring exogenous genetic material into a cell 
nucleus; these can be simply divided into viral and non-viral vectors (Tan et al., 2005b). 
Such vectors carry genetic material in the form of either DNA or RNA, which can be 
engineered for various purposes, across the cell membrane and into the nucleus to 
undergo transcription. Agents such as short interfering RNA (siRNA) and antisense 
oligonucleotides can be employed to interfere with complementary mRNA in the 
cytoplasm, thereby reducing mRNA translation (Ulanova et al., 2006). 
Regardless of the vector employed, these will have to escape from the cellular 
compartment they are contained within and deliver their genetic message. The hostile 
environments of the endolysosomes and cytoplasm are capable of active degradation of 
nucleotides and vectors that manage to avoid degradation still have to cross the nuclear 
envelope to deliver their message; this is achieved either by passive diffusion through 
the nuclear pores or via energy dependant translocation that requires importins 
(Goldfarb et al., 1986). 
Due to their very nature as pathogens, viruses have evolved multiple mechanisms to 
infect targeted host cells efficiently, either by fusion with the cell membrane or by 
receptor mediated endocytosis, followed by nuclear localisation of the viral genome. As 
a direct result, viral vectors generally have a higher transfection rate than non-viral 
systems (Tan et al., 2005b). The vast majority of modern vectors have been rendered 
incapable of replication by deletion of essential genes; therefore there is little risk of 
proliferation or reversion to wild type (Rees et al., 2002). However they tend to be 
immunogenic, which can be either an advantage or a disadvantage depending on the 
circumstances (Rayner et al., 2001). Not only that but the viral vector can lead to 
alterations in cell function post transduction (Tan et al., 2005a). 
In order to counteract some of the problems associated with viral vectors, a number of 
non-viral strategies have been developed (Table 6.1). These rely on mechanical delivery 
or the use of enhancing chemicals. Non-viral vectors are less able to overcome the 
problems of cell-surface binding, escape from endosomes, and transport into the 
nucleus; therefore they possess lower transfection efficiency than their viral 
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counterparts. As a result, new strategies are being developed in order to overcome these 
difficulties and to achieve comparable transfection levels.  
 
Viral vectors Non-viral vectors 
Mechanical: 
Microinjection 
Pressure 
Particle bombardment 
Ultrasound 
Electrical: 
Electroporation (high or low voltage) 
Retroviral superfamily (MMLV and 
lentivirus) 
Adenovirus 
Adeno-associated virus 
Herpes simplex virus 
Sendai virus 
Polio virus 
Vaccinia virus 
Semliki forest virus 
Chemical: 
DEAE 
Calcium phosphate 
Artificial lipids 
Proteins 
Dendrimers 
Other polymers 
 
Table  6.1: Currently available viral and non-viral vectors (taken from (Tan et al., 2005b) 
Two of the most common non-viral transfection procedures in use are electroporation 
and lipofectamine (artificial lipid). Electroporation has high transfection efficiency but 
it can lead to cell death, particularly if high voltages are required. In contrast the 
lipofectamine based method has a lower efficiency but does not tend to cause extensive 
cell death. Therefore preliminary experiments are required in order to determine which 
methods are most appropriate for the cells involved, particularly if the target cells are 
fragile. 
6.1.2 The use of a surrogate antigen 
The MART-1 and Tyrosinase proteins were screened for novel MHC class II peptides 
(see chapter 4); therefore it would be logical to generate vectors containing these genes 
for use in gene gun immunisation as well as tumour challenge and therapy experiments. 
These vectors would then be used to investigate the effects of class II influence on the 
generation of an effective class I response. Both human and murine genes are required 
to determine if xenogenically transfected tumour cells are more easily eradicated than 
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tumour cells transfected with mouse genes; however murine MART-1 and Tyrosinase 
genes are unavailable for direct cloning experiments. In addition, murine class II 
MART-1 and Tyrosinase peptides would also have to be defined as the HHD II mice 
express human class I and mouse class II (I-Ab). It was therefore decided to use a class 
II peptide derived from p53. A wide range of previously defined class I/class II murine 
and human peptides exist for this protein, which would allow for the investigation of 
helper effects on CTL generation via cytotoxicity assays in vitro; these peptides are also 
known to be naturally produced by proteasome processing of the p53 protein. Also, both 
murine and human p53 genes are available and could be directly cloned into a plasmid 
vector of choice. This would allow the transfection of a cell line with p53, which could 
then be injected in vivo in tumour protection/therapy experiments. 
6.1.3 Selection of target cells and vectors 
P53 overexpression is present in over 60% of cancers and is often a consequence of 
increased protein stability due to point mutation of the protein. The human p53 used in 
this study was R273H, i.e. R has been mutated to H at position 273 (generous gift of B. 
Vogelstein); the murine p53 298 was mutated at residues 168 and 234 (generous gift of 
M. Oren). It was decided to clone both genes into the EGFP-N1 vector as this vector 
contains a small portion of the GFP fluorescent protein allowing transfected cells to 
fluoresce at the same wavelength as FITC (Fig 6.1). This should allow FACS sorting of 
transfected cells enabling transgene expressing cells to be rapidly selected for bulk 
culture. 
The cell line chosen for use as a target in cytotoxicity assays and for transfection was 
EL4 HHD II. These cells have the same genetic background and transgene as the 
C57bl/6 HLA-A2 HHD II transgenic mice and can establish tumours in these mice, thus 
allowing the creation of a transgenic mouse tumour model that could be used to 
investigate the influence of class II peptides on the generation of an anti-tumour class I 
response.  
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Figure  6.1: (A) EGFP-N1 is an expression vector containing the cytomegalovirus 
constitutive promoter followed by a multiple cloning site and adjacent GFP gene and 
the neomycin resistance gene under the control of the simian virus 40 promoter. Murine 
p53, human p53 or nothing was inserted into the multiple cloning site (MCS, map 
shown in B) using Hind III and Bam H1 restriction to create EGFP mp53, EGFP hp53 
and EGFP empty respectively. 
 
6.2 Results 
6.2.1 Production of mp53 and hp53 inserts for cloning 
Neither the human nor the murine p53 vectors contained the necessary restriction sites 
to allow direct transfer of the p53 genes into EGFP-N1. Therefore the decision was 
made to design primers that would add Hind III and Bam HI restriction sites onto the 
ends of the p53 genes during the PCR process (Table 6.2). This would then allow the 
direct insertion of the PCR product into the desired EGFP vector. 
PCR was then performed as detailed in section 2.2.25 to add the restriction sites onto 
the required p53 inserts. PCR products were then run on a gel in order to confirm that 
the correct insert sizes has been obtained (Fig 6.2). 
 
 
 
A 
B 
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Forward 5’-TCTAAAGCTTATGACTGCCATGGAGGAGTCA-3’ 
M
u
rin
e 
Reverse 5’-TCTAGGATCCGACTGAGTCAGGCCCCAC-3’ 
Forward 5’-TCTAAAGCTTATGGAGGAGCCGCAGTCA-3’ 
H
u
m
an
 
Reverse 5’-TCTAGGATCCGTCTGAGTCAGGCCCTTC-3’ 
 
Table  6.2: Forward and reverse primers to generate murine and human p53 inserts 
flanked by Hind III (in red) and Bam HI (in green) restriction sites.  
 
 
 
 
 
 
 
Figure  6.2: Production of murine and human p53 inserts with flanking Hind III and 
Bam HI restriction sites. Lane 1: DNA ladder, lane 2: empty lane, lanes 3 + 4: murine 
PCR product, lane 5: empty lane, lane 6: no DNA control. The PCR product for both 
murine and human p53 was expected to be 1200bp in size.  
 
 
1200bp 
1650bp 
1000bp 
1    2    3    4    5    6 
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6.2.2 Production of mp53 EGFP and hp53 EGFP 
The murine and human PCR inserts generated were band extracted, ligated into EGFP 
and used for cloning into XL-1B competent cells (see sections 2.2.26-31). The EGFP 
vector contains a kanamycin resistance cassette, therefore transfected bacteria could be 
selected by culture on kanamycin containing agar plates (30µg/ml). After 16 hours of 
culture on these selective agar plates, individual bacterial colonies were visible; these 
were picked and cultured in LB broth + kanamycin (30µg/ml) for a further 16 hours 
after which time plasmid DNA was isolated from the bacterial clones. A Bam H1/Hind 
III digest was then performed on each sample of plasmid DNA from the clones in order 
to determine if the insert was present; if so a 1200 bp fragment was expected (Fig 6.3).  
 
Murine Human 
 
 
 
Figure  6.3: Plasmid DNA digestion from murine and human p53 transfected bacterial 
clones. For murine clones lanes 1+12 are DNA ladder, lane 2 is uncut plasmid, lanes 3-
11 are all positive clones. For human clones lanes 1+12 are DNA ladder, lane 2 is uncut 
plasmid, lanes 3-11 are all positive clones.  
 
For murine studies clone 5 was used and for human studies clone 9 was selected. Both 
of these genes were sequenced, all of which were found not to have acquired additional 
mutations when compared to the original vector (results not shown). Following 
successful construction of the murine and human p53 vectors, cellular transfection was 
performed in order to confirm protein expression by fluorescence. 
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1.6Kb 
1.6Kb 
1Kb 
1Kb 
Chapter 6: Vector production and transfection 
 158 
6.2.3 Transient transfection of EL4 HHD II cells 
EL4 HHD II HLA-A2 cells were chosen for transfection as these are capable of growing 
in C57bl/6 HHD II transgenic mice and therefore be used to create a tumour model. 
Transient transfections were done using lipofectamine in order to determine whether all 
the constructs read through the p53 genes into eGFP to produce fluorescence. Three 
different transfections were done: eGFP empty, eGFP murine p53 and eGFP human p53 
as well as a just cells control for comparison. It can be seen that all vectors were able to 
produce fluorescence except for the non-transfected controls (Figure 6.4). 
 
 
 
  
 
Figure  6.4: Untransfected EL4 HHD II cells (A) and cells transfected with eGFP-N1 
empty vector, eGFP-N1 murine p53 and eGFP-N1 human p53 (B, C and D 
respectively). This fluorescence showed that read through the transfected genes was 
occurring and was demonstrated to be reproducible. 
A B 
C D 
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6.2.4 Stable transfection of EL4 HHD II cells 
In order to generate stable transfectants of the three required cell types, EL4-empty 
vector, EL4-mp53 and EL4-hp53, transfection using lipofectamine was undertaken as 
before. Unfortunately EL4 HHD II cells were already transfected with HLA-A2 and the 
antibiotic resistance vector was G418, which was the same resistance cassette as 
encoded within the p53 containing eGFP-N1 vectors. As a result it was proposed to 
transfect cells with the fluorescent vectors and select for positive clones by FACS 
sorting in order to enrich the transfected cell population. However when transfectants 
were sorted for a second time the cells were found to have lost the vector; it was thought 
that this could be due to the prolonged culture period required to expand transfected 
cells in culture for a second round of FACS sorting (results not shown). In consequence, 
stably transfected cell lines could not be produced for use in an in vivo tumour model. 
 
6.3 Discussion 
Ideally MART-1 and Tyrosinase vectors would have been constructed to assess the 
effects of protein specific class II help on the generation of CTL. However this proved 
to be impractical within the time scale as it would have been necessary to produce both 
murine and human MART-1 and Tyrosinase vectors and define a range of I-Ab 
restricted MART-1 and Tyrosinase peptides for use in the C57bl/6 HHD II mice, which 
are transgenic for human HLA-A2 but not for any human MHC class II alleles. As such 
it was decided to use p53 DNA vectors and peptides in their place as a surrogate 
antigen; a number of murine and human p53 peptides and vectors already exist, 
allowing the transfer of the gene into the vector of choice (Friedman et al., 1990; 
Ginsberg et al., 1991; Offringa et al., 2000).  
The p53 protein is overexpressed and/or mutated in approximately 50% of human 
malignancies and is an endogenous protein; as such the murine immune system would 
have “seen” murine p53 previously so tolerance will exist (Offringa et al., 2000). 
Therefore a tumour model utilising this gene should be able to closely mimic the 
tolerogenic processes occurring within a cancer patient allowing detailed investigation 
into the effects of CD4+ T cell help in breaking tolerance and maximising the generation 
of CTL. Murine and human p53 were cloned from their existing vectors (generous gifts 
of M. Oren and B. Vogelstein respectively) into the eGFP-N1 fluorescent vector; 
cloning was achieved without the accumulation of any further mutations (results not 
shown). 
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Having produced both murine and human vectors, these needed to be transfected into a 
cell line to establish a tumour model. EL4 HHD II cells, stably transfected with HLA-
A2, were chosen as a suitable candidate cell line which were previously shown to form 
a tumour when injected subcutaneously into C57bl/6 HHD II HLA-A2 transgenic mice 
(results not shown) (Firat et al., 1999; Machlenkin et al., 2005). EL4 HHD II cells were 
then transfected for a second time with either murine or human p53 contained within the 
eGFP N1 vector; this vector has previously been used in a number of immunological 
models without causing a GFP specific immune reaction (Glinka et al., 2006; Yin et al., 
2004). Transient transfection of EL4 HHD II cells was performed initially in order to 
optimise the process; cells transfected with empty vector, murine p53 and human p53 
all produced high levels of fluorescence, which was clearly observed using confocal 
microscopy (Figure 6.4). 
Stable double transfection of the EL4 HHD II HLA-A2 cell line presented more of a 
problem as both vectors encoded a resistance cassette for the same antibiotic (G418); 
therefore negative selection of untransfected cells would not be possible. It was 
reasoned that FACS sorting at the GFP wavelength should allow for the enrichment of 
transfected cells; it was thought that repeated rounds of sorting would allow for the 
creation of a stably transfected cell line. However, after the first round of FACS sorting, 
transfected cells “lost” the vector before they could be expanded in culture to high 
enough numbers to allow a second round of sorting. This meant that only transient 
transfections were possible. Further optimisation of the transfection procedure may have 
enabled enrichment by FACS sorting.  
Recently a new vector containing eGFP has been produced; this vector however 
encodes a resistance cassette for zeocin, which has a completely different mode of 
action. Using this vector, an EL4 HHD II cell line could be created that expressed both 
HLA-A2 and mutant p53 genes. Therefore in future studies this vector could be used to 
create a tumour model in order to study the antitumour effects of CD4+ T helper cells in 
conjunction with antitumour CTL. This could be done in two ways; mice could be 
immunised with class I and class II peptides and then challenged with tumour cells in a 
protection study or tumour cells could be administered first and class I and class II 
peptides administered as a therapeutic. Not only that but different types of immunisation 
could be tested, such as a prime boost strategy. Prime boost immunisation is when two 
different types of immunogen are employed in an attempt to generate an immune 
reaction; for example mice could be immunised with peptide first, followed by a booster 
immunisation with a DNA construct. There is a wide range of options that could be 
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tested in protection and therapeutic studies such as peptide/lysate pulsed dendritic cells, 
transfected dendritic cells, gene gun immunisation, viral vectors and novel adjuvant 
conjugations; in conjunction with the prime boost strategy, these combinations have the 
potential to create a highly effective immunotherapy. The findings from such a model 
would be invaluable in optimising immunotherapy for clinical application.  
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7 Chapter 7: Discussion 
7.1 CD4+ T cells are central in anti-tumour immunity 
Cytotoxic T lymphocytes (CTL’s) are responsible for the recognition and elimination of 
“altered self” cells such as tumour cells or those infected by a virus. Therefore over the 
last two decades a great deal of attention has focused on activating CTL as an 
immunotherapeutic approach for the treatment of cancer. There is now a wide range of 
well characterised MHC class I epitopes available targeted against tumour associated 
antigens, however studies in both murine models and human studies suggest that CTL 
epitopes alone are unable to generate long lasting immune responses in the majority of 
cancers (Rosenberg & Dudley, 2004; Rosenberg et al., 1998; Wang, 2001). 
The concept of CD4+ T cells being important in providing help for the development and 
maintenance of CTL is not novel (Kern et al., 1986). The lack of CD4+ T cell help may 
be responsible for the failure of adoptively transferred CD8+ CTL to persist for 
prolonged periods in a tumour bearing host. CD4+ T cells are also known to be involved 
in the development of memory CTL, a critical requisite for promoting long lasting 
immunity in order to prevent patient relapse (Gao et al., 2002; Janssen et al., 2005; 
Janssen et al., 2003; Shedlock & Shen, 2003). Previous vaccination strategies employed 
potent non-specific helper epitopes/proteins and stimulated the immune system together 
with strong “danger signals” via adjuvants or microbial products (Pardoll, 1998). Under 
certain conditions, these non tumour-specific immune stimulants provide sufficient help 
for the development of antitumour CTL; therefore the identification and use of tumour 
specific MHC class II helper epitopes did not assume a high research priority. 
In recent years however, it has become apparent that CD4+ T cells play a more active 
role in the control of tumour cells (Bourgault Villada et al., 2004; Cohen et al., 2000; 
Egilmez et al., 2002). A small scale clinical trial by Bourgault Villada and colleagues in 
2004 showed that high circulating levels of HPV specific T cells correlated with high 
levels of tumour infiltrating CD4+ T cells and disease regression. The mechanism of 
action of these infiltrating helper cells has been investigated previously and it is thought 
to depend upon cytokine production leading to recruitment of other cell types involved 
in tumour clearance (Bourgault Villada et al., 2004; Cohen et al., 2000; Egilmez et al., 
2002). Egilmez and colleagues employed SCID mice in conjunction with PBL from a 
cancer patient; these PBL’s were found to inhibit autologous tumour growth in a dose 
dependant manner over a period of four years. Suppression of the patients’ tumour was 
found to require CD4+ T cells, CD56+ natural killer cells and CD14+ 
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monocytes/macrophages but was completely independent of CD8+ T cells. The 
secretion of IL-12 and IFNγ by the patients’ monocytes and T cells respectively was 
also found to be crucial for tumour suppression (Egilmez et al., 2002). It would seem 
unlikely that CD4+ T cells recognise tumour cells directly as the vast majority of tumour 
cells are MHC class II negative, however it has been shown in pre-clinical and clinical 
studies that tumour infiltration with CD4+ T cells correlated with tumour regression 
(Bourgault Villada et al., 2004; Cohen et al., 2000). It has been suggested that these 
helper cells are able to recognise tumour-specific peptide epitopes due to the presence 
of APC, such as dendritic cells, processing tumour antigens and presenting peptides 
within the tumour microenvironment. These APC would present peptide epitopes to T 
cells on MHC class II molecules thus allowing the development of an anti-tumour CD4+ 
T cell response. These activated T helper cells would then secrete cytokines necessary 
for the activation and proliferation of other cell types involved in clearance of a tumour 
mass and the formation of memory cells (Janssen et al., 2003; Wang et al., 1999). 
Recruitment of such accessory cells, often observed in immunohistochemical staining of 
regressed tumours, is likely to be critical in tumour clearance and complements the lytic 
function of anti-tumour CTL. As such it would seem that the identification of CD4+ T 
cell epitopes is important for the development of more successful immunotherapeutic 
strategies. 
To that end, this study aimed to identify new MHC class II restricted peptides derived 
from melanoma antigens. It was further proposed to combine class I and class II 
peptides in immunogenicity studies using MHC-transgenic mice. A classical reverse 
immunology approach was adopted in order to identify “novel” MHC class II restricted 
epitopes from melanoma associated antigens. DC’s were used as antigen presenting 
cells and optimal conditions to mature DC for antigen presentation were established. 
Studies were also undertaken to optimise the survival of activated T cells in order to 
improve and facilitate peptide discovery. In order to determine whether CD4+ restricted 
peptides influence the generation of CD8+ T cell effectors, experiments were performed 
utilising a panel of known p53 and HepB peptides. The longevity of T cell responses 
generated by immunisation with class I and class II peptide combinations was also 
investigated.  
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7.2 The characterisation of BM-DC as APC for use in proliferation 
assays 
CD4+ T cells are only capable of recognising antigen when presented in the context of 
MHC class II molecules, therefore professional APC represent a logical choice for use 
in proliferation assays designed to screen for novel epitopes. Of these dendritic cells 
(DC’s) are the most potent APC, capable of priming naïve T cells (Banchereau & 
Steinman, 1998). 
For the purposes of this study syngeneic BM-DC’s were used as APC in proliferation 
assays and a previously established method, modified from Inaba et al (1992a), for BM-
DC generation was used to obtain and culture cells from FVB/N DR1, C57bl/6 DR4 and 
C57bl/6 HHD II HLA-A2 transgenic mice. This procedure involved the culture of bone 
marrow progenitor cells in the presence of GM-CSF, which permitted cellular 
differentiation into functional DC’s. It was shown that this method could generate DC 
from all of the transgenic mouse strains as assessed by the expression of costimulatory 
molecules such as CD40, CD80 and transgenic MHC molecules.  
High expression of costimulatory molecules and the production of cytokines such as IL-
12 are critically important for the activation of T cells and studies were undertaken to 
investigate which method for DC maturation resulted in maximal costimulatory 
molecule expression and cytokine production. Immature DC can be matured in a variety 
of ways such as culture with cytokines and/or microbial agents, two of the most 
common being LPS and Poly I.C. (Inaba et al., 1992a; Lutz et al., 2000; Ritter et al., 
2003). These agents act to supply the strong immunological signals necessary to induce 
full maturation of DC, thereby leading to efficient activation of T cell responses in vitro 
(Lutz & Schuler, 2002). It was demonstrated that FVB/N-DR1 and C57bl/6 BM-DC 
responded best when matured in the presence of LPS alone. However the C57bl/6 HHD 
II BM-DC produced maximal IL-1β and co-stimulatory molecule expression in 
response to the combination of LPS and Poly I.C. IL-1β was tested for rather than IL-12 
since IL-1β, in conjunction with ligation of other DC cell surface ligands such as CD40, 
induces the production of IL-12 (Wesa & Galy, 2001). These data confirmed that it was 
necessary to use differing cellular maturation protocols for different transgenic mouse 
strains. 
It should be stated that recent findings suggest that determining the maturation state of 
DC’s solely by examining surface marker expression and cytokine production is not 
entirely reliable (Reis, 2006). It has been shown that functionally immature DC’s can 
express maturation markers and that DC’s expressing maturation markers are not 
Chapter 7: Discussion 
 165 
necessarily functionally mature. All of the DC’s maturation protocols employed in this 
study were able to produce functional DC’s when used in proliferation assays. Given 
these results, future work to characterise dendritic cell status should include assays of 
functionality to confirm trends in surface marker expression and cytokine production.  
As such the strain specific optimisation of DC maturation should be considered as a pre-
requisite for maximising the efficiency of assays for measuring T cell responses. 
7.3 Novel immunogenic HLA-DR restricted peptides from MART-1 and 
Tyrosinase identified using MHC transgenic mice 
 
Using optimised strain specific DC maturation protocols it was demonstrated that HLA-
DR restricted responses could be detected in vitro following immunisation of FVB/N-
DR1 and C57bl/6 DR4 transgenic mice with previously described peptides. It was 
reasoned that immunisation of these transgenic mice with peptides predicted to bind 
promiscuously to both DR1 and DR4 MHC molecules would allow the detection of 
novel immunogenic epitopes. This would permit the screening of a large number of 
epitopes derived from several tumour associated antigens. Therefore, HLA-DR1 and 
DR4 restricted peptides were predicted from the tumour antigens MART-1 and 
Tyrosinase using an evidence-based computer-assisted algorithm, SYFPEITHI 
(Rammensee et al., 1999). From the protein sequence overlapping 15 mer peptides are 
ranked according to their score; the higher the score the more likely it is thought that a 
peptide will bind to a particular MHC molecule. Three 15 mers from MART-1 and three 
from Tyrosinase that displayed a score higher than 20 for both HLA-DRβ1*0101 and 
HLA-DRβ1* 0401 alleles were chosen for further study. A score of 20 is used as a cut 
off point as this represents optimal binding by the two peptide anchor residues; with 
lower scores a peptide is unlikely to bind to the MHC antigen (Rammensee et al., 1999). 
It is entirely possible that this predictive algorithm may fail to identify all immunogenic 
HLA-DR restricted peptides, however in the absence of a reliable HLA-DR binding 
assay the majority of studies have employed such algorithms to predict epitopes. It is 
important to note that this algorithm has been used previously to successfully identify 
immunogenic epitopes (Knights et al., 2002; Rojas et al., 2005).  
DR1 and DR4 transgenic mice were immunised with peptides predicted to bind to the 
respective class II antigens and the responses assessed by proliferation and cytokine 
assays using splenocytes from immunised animals restimulated once in vitro with 
peptide. The results showed that the MART-129-43 peptide was immunogenic in DR1 
mice and Tyrosinase147-161 peptide was immunogenic in both DR1 and DR4 mice. 
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Peptide specific proliferation elicited by both of these peptides was abolished by the 
addition of the anti-HLA-DR L243 antibody, demonstrating the MHC class II 
restriction of the responses. Further investigation revealed that the Tyrosinase147-161 
epitope was produced naturally when transgenic murine BM-DC were fed with a cell 
lysate expressing high levels of the Tyrosinase protein. It is important to note that all in 
vitro restimulations were performed in the presence of vitamin E. It has been reported in 
the literature that antigen specific T cells are particularly sensitive to reactive oxygen 
species; high levels of these oxidising molecules led to T cell death and a consequent 
reduction in antigen specific T cells (Malmberg et al., 2001). A recent clinical trial 
involved the administration of an oral dose of Vitamin E to cancer patients; this resulted 
in an increased CD4:CD8 T cell ratio as well as an increase in Th1 cytokine production 
(Malmberg et al., 2002). Therefore it was hypothesised that the addition of Vitamin E to 
T cell cultures could be beneficial to the epitope identification process. This proved to 
be critical in the identification of the Tyrosinase147-161 peptide; without the use of 
vitamin E this peptide would have been considered non immunogenic and a naturally 
processed epitope could have been overlooked. This data indicates that the Mart-129-43 
and Tyrosinase147-161 peptides are likely to be immunogenic in the context of HLA-DR 
antigens in humans. All peptides described in this study were tested in at least six mice; 
in the absence of responses they were deemed to be non-immunogenic for either DR1 or 
DR4. These peptides can now be studied further using PBMC from healthy donors 
and/or cancer patients in order to confirm their immunogenicity in humans. 
Cytokine production in response to peptide stimulation was also investigated; the 
MART-129-43 peptide was able to induce IFNγ production in the DR1 mice indicating a 
Th1 type response. Tyrosinase147-161 was somewhat different: IFNγ was produced when 
DR1 mice were immunised whereas IL-5 was produced when DR4 mice were 
immunised. This suggests that Tyrosinase147-161 was capable of initiating both Th1 and 
Th2 type responses, however careful adjuvant selection might be capable of skewing the 
response towards a more desirable Th1 immune phenotype. A significant proportion of 
CD4+ T cell effector function is mediated by cytokines, therefore analysis of the 
cytokine profile of immunised T cells is crucial (Cohen et al., 2000; Egilmez et al., 
2002; Pardoll & Topalian, 1998). As such it is important in future studies that accurate 
measurements of the cytokines produced by T cells from immunised mice are 
undertaken.  
Overall the results indicate that immunisation of FVB/N-DR1 and C57bl/6-DR4 
transgenic mice with peptides predicted to bind to HLA-DR can be used to define novel 
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epitopes from tumour antigens such as MART-1 and Tyrosinase. These epitopes are 
now suitable for further studies to investigate whether or not they are immunogenic in 
humans allowing the determination their clinical utility. 
7.4 MHC-restricted class II help for in vitro CTL generation 
Although the importance of helper epitopes has been recognised there is still some 
debate as to the nature of the T cell help required: are endogenous or exogenous 
antigens more effective at promoting T cell responses and should the helper peptide be 
derived from the same protein as the class I peptide? Currently the answers to these 
questions are unclear as results vary depending upon the system used (Ali et al., 2000; 
Casares et al., 2001; Wang et al., 2003). This study identified class II epitopes for 
MART-1 and Tyrosinase and subsequent studies should construct vectors encoding 
these epitopes to assess the effects of protein specific class II helper peptides on the 
generation of CTLs. However this proved to be impractical within the time scale of this 
study and would have necessitated the production of both murine and human MART-1 
and Tyrosinase vectors and the identification of I-Ab restricted MART-1 and Tyrosinase 
peptides for use in the C57bl/6 HHD II mice, transgenic for human HLA-A2 but not for 
any human MHC class II alleles. P53 offered an alternative model since a number of 
murine and human p53 peptides had been identified and vectors encoding the p53 
cDNA already exist (Friedman et al., 1990; Ginsberg et al., 1991; Offringa et al., 2000). 
In this study, using C57bl/6 HHD II HLA-A2 transgenic mice, it was found that the 
combined use of p53 class I and class II peptides elicited both an increase in 
cytotoxicity and the number of responders when compared to p53 class I peptides used 
with Hep B helper peptides. This helper effect was particularly pronounced when a 
higher affinity class I p53 peptide was used (p53264) together with antigen specific help, 
a result that contrasts with the literature. Recent studies have suggested that the use of a 
higher affinity class I peptide negates the requirement for a helper epitope, which was 
not the case in the present study; if no helper epitope was included in the immunisation 
then cytotoxicity was generally less than 5%  (Assudani et al., 2006; Franco et al., 
2000). 
The increased response observed using p53 class I and class II epitopes may be due to 
antigen re-exposure. Memory T cells specific for murine p53 are likely to exist in the 
periphery, thus when mice are concomitantly immunised with p53 CTL and helper 
epitopes a high avidity secondary response would be generated. Hep B is an exogenous, 
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foreign antigen, therefore memory T cells would not exist in the periphery and so a 
lower avidity primary response would be generated.  
Although initial findings indicate that the use of p53 helper peptides can boost p53 
specific CTL responses, further studies should be undertaken to determine whether or 
not other helper peptides derived from “self” antigens such as Her2/neu or Tyrosinase 
would be capable of promoting more vigorous CTL responses. There currently exists a 
wide range of Her2/neu class I peptides, however class II epitopes for this protein have 
yet to be defined and so epitope screening would be required. This protein has an 
advantage in that it would be subject to the same tolerogenic regulation as p53 and 
would therefore provide a good comparative model. A number of immunisation 
strategies could be used, similar to p53 protocols and analysis of cytokine production by 
T cells upon restimulation with antigen, the results of which would provide further 
insight into the cellular pathways involved. Transgenic mice recently developed to 
express both HLA-DR1 and HHD II HLA-A2 alleles, would allow the investigation of 
human Tyrosinase class I and class II peptides in the same manner. Once again a 
number of Tyrosinase class I peptides already exist and could be used in combination 
with the Tyrosinase147-161 peptide discovered during the course of this study. Therefore 
future work should first focus on attempting to validate early findings by employing 
other self-antigens and secondly determine the effects of long-term immunisation using 
tumour models for tumour challenge and therapy experiments. The results of these 
studies would have implications for the design of future cancer vaccines and the 
necessity to discern the optimum type of help required to generate both primary 
responses and long-term memory. 
7.5 Peptide immunisation can induce a memory response 
 
P53 and Hep B class II epitopes were employed in time course experiments; C57bl/6 
HHD II HLA-A2 transgenic mice were immunised with either p53 class I peptide alone; 
p53 class I + p53 class II or p53 class I + Hep B class II peptides and assays to 
determine CTL activity performed four and six months following injection. As 
previously, T cell help was found to be critical for the generation of a cytotoxic 
response. The results showed that both helper epitopes were able to generate significant 
cytotoxicity, although further in vitro and in vivo studies would be necessary in order to 
establish whether additional benefit results from immunisation with helper epitopes 
associated with tumour antigens and especially whether protective immunity is 
generated. 
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Anti-tumour CD4+ T cells are liable to act via a number of mechanisms such as 
augmenting CTL development and recruiting accessory cells into the tumour 
microenvironment. Therefore in order to clarify the findings arising from this study a 
number of further experiments should be performed, including a repeat of the time 
course as well as in vivo prophylactic and therapeutic immunisations in an appropriate 
model of “tumour rejection”. Such studies on the antitumour effects of helper epitopes 
could be performed utilising “mutated self protein” transfected tumour cells for 
challenge in C57bl/6 HHD II HLA-A2 transgenic mice. Recently a new vector 
containing eGFP has been produced; this vector encodes a resistance cassette for the 
antibiotic zeocin, which has a completely different mode of action to G418, allowing 
double transfection of cell lines, for example the HLA-A2 transfected EL4 HHD II cell 
line, to be performed. This vector would allow for creation of a cell line which could be 
used as a tumour model in order to study the antitumour effects of CD4+ T helper cells 
in vivo and correlation with CTL activity. 
The tumour model could be employed in several ways; mice could be immunised with 
class I and class II peptides and then challenged with tumour cells in a protection study 
or tumour cells could be injected first and peptides administered as a therapeutic 
vaccine. Time course studies to monitor CTL responses at 6-8 week intervals would 
establish whether long term memory responses resulted from immunisations. In addition 
different types of immunisation could also be employed using a prime boost strategy, 
for example mice could first be immunised with peptide, followed by a booster 
immunisation using a cDNA plasmid or viral vector construct. There are a wide range 
of other antigen delivery methods that could be tested in tumour protection and therapy 
studies utilising a prime boost strategy: peptide/lysate pulsed dendritic cells, transfected 
dendritic cells, gene gun immunisation, viral vectors and novel adjuvant conjugations. 
These delivery methods have the potential to create a highly effective 
immunotherapeutic vaccine and the findings arising from a tumour model would be 
invaluable in optimising immunotherapy for clinical application.  
A number of studies of this nature have been performed with several groups reporting 
that tumour antigen specific CD4+ T cells improved the therapeutic outcome (Gao et al., 
2002; Zwaveling et al., 2002). Gao and colleagues (2002) were able to demonstrate, 
using a murine tumour model, that helper peptides derived from antigens expressed by 
the tumour were essential for re-activation of memory CTL and tumour clearance and 
Wang et al (2003) were able to demonstrate the same requirement for tumour antigen 
specific T helper cells facilitated not only an increased tumour clearance but also 
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protection against further tumour challenge. Furthermore Zwaveling et al (2002) were 
able to generate high affinity T helper responses against p53, a self antigen, that were 
crucial for enabling CTLs to control the growth of a p53 overexpressing tumour in vivo; 
these results suggest that the T cell response is unaffected by tolerance at the Th level. 
Due to the benefits conferred during both challenge and therapy experiments; it would 
seem imperative to exploit tumour specific self-antigen induced T helper responses for 
the benefit of cancer immunotherapy. 
7.6 Vaccine strategies and the use of adjuvants to potentiate anti-
tumour immunity 
The purpose of an adjuvant is to modify the intensity or type of immune response 
generated and in conjunction with a cancer vaccine must stimulate an appropriate Th1 
type cellular immune response, induce tumour rejection and engender long-term 
protection against disease recurrence. There are a number of types of adjuvant that can 
be employed such as chemical compounds that act to enhance, prolong and modulate 
immune responses or genetic adjuvants, which are expression vectors that encode 
immune-modulating molecules. These DNA vaccines have the advantage that they 
possess adjuvant activity due to the presence of unmethylated CpG motifs (Ulmer et al., 
1999). 
Vaccine adjuvants can be considered in two different ways; those that act to boost 
immune responses and those that are used to inhibit a regulatory immune reaction 
therefore allowing successful immunotherapy. Many adjuvants act to stimulate the 
immune system, for example aluminium salts, bacterial derived adjuvants, lipid 
particles, emulsifier based adjuvants, synthetic adjuvants, cytokines, costimulatory 
molecules, chemokines, complement, heat shock proteins, apoptosis inducers and 
transcriptional factors, many of which can be delivered either as protein or in DNA 
format (Stills, 2005). Examples of other “adjuvants” that act to suppress regulatory 
immune functions are anti-CTLA-4 antibodies and lymphodepleting regimens (Egen et 
al., 2002; Phan et al., 2003). 
The aluminium salts currently in use comprise aluminium phosphate, aluminium 
hydroxide and calcium gels, which act by adsorbing antigen onto their surfaces. These 
are easy to use, as they only require simple mixing with the vaccine of choice and are 
approved for human use (Lindblad, 2004). Antigen is released slowly as these salts form 
a “depot” at the injection site leading to chronic immune stimulation. As such this type 
of adjuvant could be used to deliver both class I and class II epitopes in order to 
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maximise vaccine efficacy; unfortunately there can be significant associated toxicity 
such as granuloma formation and increased IgE production, which may limit their use in 
some instances. One solution to this problem is to produce inert microparticles and 
adsorb antigen onto their surface; during the course of this study nanobeads coated in 
class I and class II peptides were employed in an attempt to enhance the immune 
response to class I peptides. However initial experiments proved unsuccessful, as 
cytotoxic responses were not antigen specific in nature; further experiments are required 
to confirm that this delivery system could be a viable alternative. 
Bacterially derived molecules have been widely used; oil in water emulsions containing 
fragments of killed mycobacteria, known such as Freunds complete adjuvant is perhaps 
the most widely known. However the severity of the local reactions induced when used 
in humans prevents it clinical use; the less toxic version, incomplete Freunds adjuvant 
(minus the mycobacteria) is more commonly employed although this too is not licensed 
for clinical use in the UK (Stills, 2005).  
Lipid particle based adjuvants such as cationic liposomes and mannan coated cationic 
lipids are available which have far less associated toxicity and can significantly extend 
the half-life of the immunogen in circulation. These are usually employed for the 
delivery of DNA constructs (Toda et al., 1997); however their adjuvant action is also 
weaker than that of IFA or CFA. The advantage of a DNA construct lies in the fact that 
a whole protein can be used for immunisation, resulting in the development of both 
CD4+ and CD8+ antigen specific immune responses, which was shown to be beneficial 
during the course of this study. 
Cytokines are crucial to the regulation of immune responses and have therefore been 
employed as vaccine adjuvants either in combination with other vaccine components, 
such as peptides (Rosenberg et al., 1998), or as part of a DNA construct encoding a 
tumour antigen; examples include GM-CSF, IL-12, IFNγ and IL-2 (Chow et al., 1998; 
Rees et al., 2002). Use of such cytokines in conjunction with other vaccine components 
has been shown to boost both CD4+ and CD8+ T cell responses and could be beneficial 
to a therapeutic strategy aiming to induce tumour specific class I and class II responses 
(Ali et al., 2002). Combinations of cytokines could also be employed in order to effect 
the desired immune response, for example the inclusion of IL-7 or IL-15 could be 
beneficial in the formation and maintenance of antigen specific memory T cells (Gett et 
al., 2003; Huster et al., 2004). Chemokines could be used in much the same way as they 
act to recruit APC to the site of injection. The use of transfected DC’s or local injection 
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of chemokines would be likely to increase the number of contacts between APC and T 
cells leading to a more vigorous immune response (Condon et al., 1996).  
Optimal T and B cell activation requires a number of signals delivered via costimulatory 
molecules such as CD80 and CD86. It is thought that the simultaneous delivery of a 
plasmid containing these molecules together with a vaccine could lead to an 
improvement in immune response (Kim et al., 1997); therefore it may be beneficial to 
include these in a vaccine strategy designed to elicit both class I and class II responses. 
Heat shock proteins represent another possible adjuvant approach; these are highly 
conserved molecules found in eukaryotes, plants and prokaryotes. They function as 
chaperones, aiding protein folding and subunit assembly, as well as stabilising MHC 
class I and class II molecules during peptide transport (Melnick & Argon, 1995; Smith 
et al., 1998). By linking antigens of interest to HSP’s involved in antigen processing, 
increased CTL priming can be achieved with a concomitant increase in tumour 
clearance (Chen et al., 2000; Srivastava et al., 1998). If this approach were to be used in 
conjunction with adjuvants then it might be possible to induce class II responses at the 
same time, potentially leading to further increases in therapeutic efficiency. 
There exists a number of regulatory mechanisms within the immune system which can 
decrease the efficacy of immunotherapy, as such it may be necessary to employ 
inhibitory molecules in order to bypass these controls. One such example is anti-CTLA-
4 antibodies, which act to block the binding of CTLA-4 to CD28, thereby allowing T 
cell activation (Egen et al., 2002; Phan et al., 2003). Lymphodepleting regimens such as 
whole body irradiation followed by administration of chemotherapeutic agents can also 
be used to deplete or decrease regulatory T cells before commencing immunotherapy 
(Rosenberg & Dudley, 2004). The potential disadvantage of such a strategy is the risk 
of inducing toxicity via the induction of autoimmune reactions with potentially fatal 
consequences for the patient. 
As no single vaccine strategy has resulted in total success, future vaccines should 
consist of a combinatorial approach using adjuvants and agents which prevent the 
induction of Treg cells in conjunction with antigen specific class I and class II T cell 
responses in order to maximise therapeutic efficiency.    
7.7 Conclusions and future work 
It is only in recent years that the importance of CD4+ T cells has become fully apparent 
leading to a requirement for protocols to rapidly identify MHC class II epitopes that 
could be used in the clinic. The use of HLA-DR transgenic mice immunised with 
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predicted peptides has provided a means to facilitate the identification of MHC class II 
restricted peptides; immunisation of MHC transgenic mice can provide data rapidly 
whereas human PBMC restimulation experiments are time consuming. Therefore pre-
screening in transgenic mice can reduce the number of peptides for assessment using 
human T-cell cultures. 
In order to allow the efficient screening of peptides it became necessary to fully 
characterise the responses of DC’s, derived from a number of transgenic mouse strains, 
to various maturation stimuli. If DC’s are not fully matured when they encounter naïve 
antigen specific T cells then the likely outcome is tolerance to that antigen; therefore it 
was paramount to maximise the efficiency of the DC maturation process in order to 
optimise peptide screening by proliferation assays (Dhodapkar et al., 2001). The study 
showed that there were indeed differential maturation requirements depending upon the 
mouse strain used to generate the DC’s; thus for new strains of mice full 
characterisation of DC’s should be undertaken in order to ensure optimal efficiency. 
When DC maturation was combined with the use of the antioxidant Vitamin E a number 
of novel peptide epitopes were identified. The use of Vitamin E enabled the discovery 
of the MART-129-43 and Tyrosinase147-161 peptides that may otherwise have been 
overlooked. Vitamin E is thought to improve T cell survival via two mechanisms: (1) 
reduction of reactive oxygen species that damage radicle sensitive antigen specific T 
cells and (2) reducing activation induced cell death (AICD) of T cells by reducing 
cellular expression of CD95L (Malmberg et al., 2001). The use of Vitamin E resulted in 
a higher proportion of antigen specific T cells surviving the in vitro culture process 
leading to lower levels of background proliferation and allowing the identification of 
several immunogenic peptides. As such it would seem prudent to include vitamin E in 
the culture media used for subsequent epitope screening studies.  
MHC class II peptides identified could be used in combination with MHC class I 
peptides for vaccination of cancer patients. A number of recent studies have shown that, 
in a tumour bearing host, adoptive transfer of a heterogeneous T cell population is more 
beneficial than transfer of CD8+ T cells alone (Dudley et al., 2002; Rosenberg & 
Dudley, 2004), indicating that the provision of CD4+ T helper cells is likely to improve 
the efficacy of therapeutic strategies. It was also confirmed in this study, and others, that 
CD4+ T cells were essential for the generation of both effector and memory CTL, 
indicating the essential role of T helper cells (Gao et al., 2002; Janssen et al., 2005; 
Shedlock & Shen, 2003; Sun & Bevan, 2003). 
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Now that the importance of both class I and class II epitopes has been recognised efforts 
should be made to discern precisely which helper peptides would provide the most 
effective anti-tumour response. Results achieved from short-term experiments 
performed within this study would suggest that class I and class II epitopes derived 
from the same protein results in increased CTL activity, although it remains to be 
established whether this generates long lasting immunity. Further work utilising tumour 
models would be required to investigate whether or not these “helped” CTL responses 
are superior at tumour clearance/disease prevention. 
Although the use of pre-clinical models allows valuable information to be obtained 
regarding the requirements for tumour clearance, the vast majority of the adjuvants used 
in these models are not suitable for use in the clinic (Stills, 2005). Therefore it is 
imperative that novel vaccine and pre-clinical evaluation strategies are designed with 
adjuvants that are suitable for clinical use. The ideal vaccine should have low toxicity 
(such as a DNA vector), be able to stimulate tumour antigen specific class I and class II 
T cell responses and include immunomodulatory cytokines such as GM-CSF/IL-12 (for 
DC stimulation), IFNγ (for T cell stimulation) and IL-7/IL-15 (for memory cell 
formation/maintenance); this could then be combined with a lymphodepleting regimen 
to remove Treg lymphocytes. Therefore it is critical that a more combinatorial approach 
to immunotherapy is developed in an attempt to overcome therapeutic barriers. 
When assessed in context, the findings of this study have important implications for the 
formulation of future cancer vaccines, both in terms of epitope screening and the type of 
help that should be delivered in order to maximise vaccine efficiency. Future work 
should aim to build on these findings in order to clarify the vaccine requirements to 
ensure future therapeutic success.   
Future studies should attempt to clarify a number of aspects of this study. Repeat 
experiments testing memory T cell responses against p53 when provided with different 
types of helper epitope must be carried out in order to assess whether the origin of the 
helper peptide needs to be taken into consideration when designing an immunotherapy. 
These experiments should also be expanded to include other self antigens such as 
MART-1, Tyrosinase and Her2/Neu in order to clarify if the effects seen apply to all 
self antigens. In order to further expand the usefulness of this work a tumour model 
should also be established utilising cells transfected with vectors containing these 
proteins. Challenge and therapy experiments could then be set up in order to determine 
if the origin of a helper peptide can make a difference the generation of cytotoxic 
responses in vivo in a disease setting rather than just in an in vitro assay.  
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Due to the arrival of new transgenic mice (HLA-DR1 and HLA-A2) the above work 
could be performed utilising all human peptide sequences and therefore avoid the 
necessity of identifying murine class II restricted peptides for each antigen. Not only 
that but the creation of DNA vectors for each of these antigens would allow testing of 
prime boost strategies in both tumour challenge and therapy experiments in an attempt 
to discern the most effective therapeutic methods. 
More detailed investigation of the cytokine production by T cells is also necessary as 
the prime mode of action for CD4+ T cells is likely to be via cytokines. As such, 
techniques such as ELISPOT should be employed in conjunction with CD8+ depleted T 
cell proliferation assays in order to determine precisely what cells are secreting cytokine 
and when. Sampling from bulk cultures cannot provide this information, as the T cell 
population is heterogeneous and so existing cytokine data could be inaccurate. 
By making these improvements to the existing screening system and creating a 
transgenic tumour model it may be possible to use the results of future experiments to 
define a more efficient mode of cancer vaccination and hence take immunotherapy into 
the clinic more successfully. 
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Cancer 2003, Oxford, U.K. Delivered 20 minute short talk. 
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Germany. Poster. 
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